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The role of affinity reagents in biological research is essential allowing for the identification, 
characterisation and functional assignment of proteins. To date, antibodies are the most 
widely used and studied affinity molecules. The ability for antibodies to bind, with high 
specificity and high affinity, to the targets they were generated against are features that 
have been exploited in biological research. However, despite the accomplishments that 
have been achieved with antibodies, they do possess limitations which have driven the 
need to develop non-antibody based scaffold proteins that have comparable binding 
affinity and specificity to antibodies. In addition, exploration of highly complex proteomes, 
by affinity reagents will enhance our understanding of areas where analytical capabilities 
are currently limiting findings due to large dynamic range and number of proteins within a 
given proteome. Affimers, developed as antibody-alternative affinity reagents, are 
engineered combinatorial proteins possessing three variable interaction sites. This thesis 
describes the use of mass spectrometry in the characterisation of Affimers and their 
development for affinity purification mass spectrometry (APMS) workflows. Chapter 3 
presents immobilisation strategies for Affimer APMS workflows for the identification of 
unknown protein binders of naïve Affimers and highlights the associated challenges of non-
specific background binding of proteins and achieving sufficient target enrichment. Four 
immobilisation methods were assessed and despite the development of an effective 
method for the enrichment of IgG using Affimers via cysteine-mediated immobilisation, the 
method was not successful for naïve Affimer target identification. Chapter 4 describes the 
characterisation of Affimers that target human pepsinogen. Current assays to detect 
pepsinogen rely on antibodies however they lack any clinical use due to inherent problems 
with antibodies such as reproducibility and batch-to-batch variability. Five Affimers were 
expressed, purified and characterised by intact mass spectrometry.  As a novel approach to 
overcome the issue of the large signal of capture reagents in APMS assays, a pepsinogen 
Adhiron resistant to Lys-C proteolysis was generated. Structural stability of the mutant, 
assessed by analysing the rate of proteolysis and collision induced unfolding, revealed the 
mutant exhibits comparable structural stability to the native protein. Chapter 5 presents an 
alternative approach to Affimer APMS methods for the identification of differentially 
expressed proteins in sepsis, by using discovery proteomics. Due to the large dynamic range 
of plasma, an antibody-based spin column depletion method was applied to samples within 
the study prior to LC-MS/MS analysis. Label-free quantification and bioinformatics analyses 




respectively. A panel of five candidate proteins were selected as potential markers of sepsis 
and for subsequent Affimer development: CRP, neutrophil-gelatinase associated protein, 
Protein S100 A8/A9, interleukin-1 receptor-like 1, cathepsin B. Chapter 6 outlines the 
preliminary development of the major urinary protein (MUP), darcin, as a novel protein 
scaffold. The disulfide bond in darcin was shown to be vital for providing the high structural 
stability of the protein, an important feature of protein scaffolds. In addition, preliminary 
findings demonstrated the development of a darcin resistant to proteolysis may be a 
suitable approach to overcome the intense signal of the affinity reagent in APMS assays. In 
summary, this study presents a novel approach to overcome the challenges of APMS with 
the development of non-digestible protein scaffolds and builds on the literature of common 
affinity purification contaminant proteins. In addition, the study provides a contribution to 
sepsis plasma proteome analysis and identifies five proteins implicated in sepsis that 
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1.1 Complexity of the proteome 
The term ‘proteome’ was first used by Wasinger et al. in 19951 and Wilkins et al. in 19962 to 
describe the protein complement of a cell under defined environmental and physiological 
conditions. Proteomics is the large-scale study of the proteome, encompassing the analysis 
of protein abundance, localisation and function as well as protein-protein interactions to 
gain greater understanding of cellular dynamics and systems. It is estimated that the 
human genome encodes 19000 genes3. However, as numerous protein variants exist for a 
single gene due to alternative splicing, the number of human proteins is estimated to be a 
lot higher4. A recent large-scale transcriptomic study investigating alternative splicing 
estimated that approximately 100,000 different protein isoforms can be produced from the 
human genome5. In addition, post-translation modifications (PTMs) and genetic variations 
increase the size of the human proteome adding to the complexity. Variation in genomes 
between individuals is expected to be as high as 106 differences which is likely to have an 
effect on proteome complexity6. Furthermore, in specific pathophysiological states, 
genomic variation is vastly increased. For example, tumour heterogeneity is predominant in 
many cancer types, diversifying the genome7 and thus contributes to proteome complexity.  
Proteomic analysis of an organism or cell is further complicated by the dynamic expression 
of proteins due to responses to stimuli such as different developmental, pathological and 
environmental conditions. In Saccharomyces cerevisiae, environmental stresses are known 
alter the dynamic expression of the transcriptome and proteome, again adding further 
complexity to the proteome8. 
Despite the vast number of proteins within a proteome, only a small portion of these are 
expressed by a particular cell or tissue at a given time. With the process of protein 
production beginning with transcription followed by translation, what determines protein 
expression is ultimately governed by the regulation of gene expression. Regulation occurs 
at many control points along the pathway of gene expression; transcription, RNA 
processing, RNA transport and localisation, translation, mRNA degradation and control of 
the activation of proteins by PTMs9. Transcriptional control plays a critical role in what 
governs the protein complement of a cell as it is the starting point for RNA production and 
is therefore considered the most important regulatory mechanism for many genes. The 
action of transcription factors, by recognising specific regulatory DNA sequences in 




polymerase and chromatin remodelling10. It is through these mechanisms, that the protein 
complement of a cell is regulated. 
Genomic, transcriptomic and proteomic analysis are complementary large-scale 
techniques, providing a comprehensive view of a biological system. However, correlation of 
mRNA expression levels and the resulting protein is usually poor11. As discussed, many 
factors influence the correlation between mRNA and protein expression levels including 
protein degradation12 and an organism’s regulation of translation13. As proteins make up 
the functional element of a cellular system they provide valuable information regarding the 
biological state of a sample, cell or organism. This highlights the importance of proteomic 
research as a complementary method to genomics and transcriptomics in biological 
exploration. 
 
1.2 Challenges in the analysis of complex proteomes 
The challenges in complex proteome analysis can be attributed to two key features, firstly 
the number of proteins and secondly, the dynamic range. As discussed, the number of 
proteins expressed in a proteome at a given time is vast and highly dynamic with PTMs 
increasing the proteomic space. It is estimated that a single human cell line in culture can 
express up to 12,000 proteins requiring huge breaths in analytical capabilities14-16.  
To add further complexity to this challenging environment, the quantitative amount of each 
protein is varied and continually changing. In proteomics, dynamic range is defined as the 
difference in concentration between the most abundant and least abundant protein. The 
dynamic range of proteins in a proteome can span at least seven orders of magnitude, 
ranging from one copy per cell to 10 million copies per cell17. In human plasma, the dynamic 
range of the proteome is much higher at 1012. This poses a major analytical problem as 
current technology cannot achieve this dynamic range. Therefore, when a proteome is 
analysed with discovery based techniques only a fraction of the proteome is able to be 
accurately identified and an even smaller fraction accurately quantified18 (Figure 1.1). In 
mass spectrometry (MS), sample loading is limited by the concentration of the most 
abundant peptides within the sample so that the detector does not become saturated. 
Therefore, low abundance proteins can therefore fall below the limit of detection of the 




Human plasma is a prime example of the challenges in complex proteome analysis, with 
albumin representing 50% of the total plasma concentration and an additional 12 proteins 
representing a further 95% of the total plasma concentration19. A standard S-shaped 
distribution is observed when plotting protein rank against the log abundance (Figure 1. 1). 
This observation is not only seen in blood but also, proteomic analysis of human cell lines 
revealed a large dynamic range spanning seven orders of magnitude, with core histones 
and enzymes representing the most abundant proteins20. Furthermore, the yeast proteome 
can span up to five order of magnitude with proteins detected from one million copies per 











Figure 1.1 | Distribution of proteins in a proteome and dynamic range of the human 
plasma proteome. 
Top: Expression range of a proteome and the different fractions that can be identified and 
quantified. Image taken from Kuster et al (2007)23. Bottom: The dynamic concentration 
range of the plasma proteome spans 12 orders of magnitude. Proteins are split into three 
key categories based on abundance; classical plasma proteins, tissue leakage and 




Methods for proteome analysis at a protein level 
A large range of diverse analytical methods are available for the study of complex 
proteomes. Traditionally, complex proteomic analysis was performed using two-
dimensional polyacrylamide gel electrophoresis (2-DE) where proteins are separated based 
on isoelectric point (pI) and molecular weight (Mr) in the first and second dimension, 
respectively24. The proteins are then visually detected by protein staining. 2-DE has been 
used to resolve more than 5000 individual protein spots25,26 and can detect less than 1 ng of 
protein per spot27. Due to the visual protein map generated, differential analysis between 
samples can be performed.  2-DE is an advantageous technique for complex proteome 
analysis because of the extensive, highly orthogonal protein fractionation and separation 
providing high resolution of proteins27. Furthermore, the technique is particularly useful for 
the separation of different intact proteoforms due to small difference in net charge induced 
with modifications27. An advancement of 2-DE is the technique ‘difference in gel 
electrophoresis’ (DIGE)28. As a limitation of 2-DE is lack of reproducibility, the DIGE 
approach was developed to overcome this by enabling up to three samples to be analysed 
on a single gel by labelling the samples with fluorescent dyes. The samples are mixed 
together in equal ratios and run on a single gel where the differences in samples are easily 
determined. However, 2-DE and DIGE do not provide sample identification. The protein 
spots have to be extracted for subsequent MS analysis or probed with antibodies 
Protein microarrays are another analytical method to explore the proteome allowing for 
the large scale, high throughput analysis of samples29. The methodology exploits protein-
interactions and the inherent nature that many proteins have of affinity for a specific 
ligand. The technique enables the simultaneous analysis of hundreds to thousands of 
samples30. Detection and measurements of binding is achieved through the labelling of the 
proteins with a fluorescent tag. Microarrays are typically available in three different 
formats; binder arrays that present different affinity reagents, functional arrays that 
present different proteins and reverse phase arrays that probe different biological samples 
with selected affinity reagents30. As reverse phase arrays analyse the proteome in a more 
targeted and specific nature, they will be discussed further in section 1.4. In a binder array, 
individual binding reagents (antibodies, recombinant antibodies or alternative affinity 
reagents) are immobilised onto a slide. Samples are then profiled by the array with the goal 
to identify proteins that are differentially expressed between two conditions, typically 
disease and control samples for biomarker studies. An early application of an antibody 




profiled with the sera of patients with either benign pancreatic disease or pancreatic 
cancer31. A total of 142 samples were analysed and protein markers were identified that 
could distinguish the two conditions with high sensitivity and specificity31.  
A different type of array for proteome analysis is a functional protein array and is produced 
by spotting different purified recombinant proteins on the array. Large numbers of proteins 
can be spotted on the array and can contain over 60 % of an organism’s proteome 
immobilised on the array. Proteome arrays are available for a number of different species 
including E.coli32, humans33 and S. cerevisiae34,35. Functional protein arrays have application 
in assessing various interactions including protein-small molecule, protein-glycan, protein-
protein, protein-peptide36 and protein-nucleic acids interactions. The identification of 
serological biomarkers is a common application for function protein arrays typically 
detecting autoantibodies37. Despite the progress in proteome analysis using protein arrays, 
technical limitations have restricted their potential one of which is that the technique relies 
on high quality binding reagents that target many proteins38.  
Another approach to proteome analysis is by using mass spectrometry (MS). MS is most 
often associated with bottom-up methods, where peptides are generated from protein 
digestion. However, the analysis of intact proteins (top-down proteomics) using MS is a 
powerful method that allows the structural features of the proteins to be preserved such as 
PTMs38.  Complete protein sequencing coverage is regularly achieved allowing information 
on different proteoforms to be obtained39. Intact protein analysis is however, subject to 
limitations. Protein identification based on the intact mass of the protein alone requires no 
deviations of the observed experimental mass from that of the predicted mass from the 
DNA derived sequence. However, PTMs such as glycosylation, phosphorylation and 
acetylation, disulfide bond formation, sequence variations, truncations and proteolysis will 
all result in a deviation from the expected mass. Furthermore, it is likely that a single 
protein will carry a variation of the above modifications, vastly increasing the complexity of 
the mass spectrum. To overcome this, top-down approaches involve the fragmentation of 
the intact protein to generate sequencing information. As fragmentation methods such as 
electron transfer dissociation (ETD) can be used, the PTMs are retained. Top-down 
proteomics does have some limitations such as it is not well suited for the analysis of large 
proteins (greater than 70 kDa). This is due to the formation of a large number of isotopic 




Proteome complexity also hinders top-down MS methods as protein fractionation is usually 
necessary in order to separate proteins. Protein fractionation methods that can be coupled 
with top-down mass spectrometry will be reviewed in section 1.3. But briefly, fractionation 
methods prior to top-down MS are very powerful and have enabled the identification of 
3000 intact proteins40. Interestingly, using electrospray ionisation coupled with a 
quadrupole time-of-flight MS, Hayter et al were able to resolve successfully a complex 
mixture of proteins from chicken muscle without the need for pre-fractionation steps or 
protein fragmnetation41. The multiply charged envelopes were suitably resolved and 
deconvoluted to enable the correct assignment of the observed masses with the genome-
predicted indicating that complex mixtures can be analysed without fractionation. 
Methods for proteome analysis at a peptide level 
As an alternative to intact protein analysis, bottom up proteomics is routinely employed for 
discovery proteomic analysis. Bottom up proteomics involves the analysis of peptides 
generated from the digestion of proteins using specific proteases followed by liquid 
chromatography tandem mass spectrometry (LC-MS/MS). The peptides generated from the 
protein digest are separated using liquid chromatography (LC), ionised by electrospray 
ionisation and analysed by MS where the peptides ions are separated by their mass-to-
charge ratio (m/z) and detected. The peptide ions, termed precursor ions are then 
fragmented, routinely by collision induced dissociation (CID) to generate product ions, a 
technique termed tandem mass spectrometry (MS/MS)42.  
The bottom up approach has advantages over intact protein analysis relating to peptide 
analysis instead of intact proteins. Firstly, peptides are significantly smaller than intact 
proteins and therefore are easier to ionise. Additionally, peptides are generally more 
soluble than proteins which mean that they can be readily analysed by ESI-MS without 
having to be concerned about insolubility43. Another advantage of bottom up proteomics 
relate to the proteases used for protein digestion. Typically, the protease used for protein 
digestion is trypsin due to its highly specific and rapid cleavage at the carboxy-terminal of 
lysine and arginine residues (except when followed by a proline)44. This is an important 
feature as it results in a highly basic amino acid residue at the C-terminal of the peptide. 
The general distribution of lysine and arginine residues in proteins typically results in 
peptides that fall within a small, similar mass range that are in the detection limit of a mass 
spectrometer. Furthermore, the generated peptides are in the preferred mass range for 





Despite the advantages of bottom-up proteomics, numerous limitations are associated with 
digesting proteins into peptides. Firstly, the digestion of protein mixtures vastly increases 
sample complexity, a further challenge when analysing already complex proteomes. 
Secondly, by converting proteins into peptides lots of information can be lost. For example, 
only a few peptides per protein may be detected for a given protein resulting in low 
sequence coverage. This means PTMs, protein isoforms and truncations may not be 
mapped back to the associated protein43. Another limitation of peptide analysis is that 
peptides may not be unique to a single protein leading to ambiguity in protein 
identification.  
Various MS modes are available for peptide analysis and method choice is dependent on 
the experimental set-up. In data-dependent acquisition (DDA), a full survey scan is 
performed on the precursor peptide ions (MS1) from which specific precursor ions are 
selected for fragmentation (MS/MS)42. The fragmentation spectra allows for the deduction 
of peptide sequencing information typically performed by database searching for complex 
samples. A top N approach is implemented, where N is a defined number of precursor ions 
with the highest intensity, are selected for fragmentation. The usual MS method for 
discovery proteomics is DDA. However, this approach has limitations which have led to the 
development of other MS methods. Firstly, the analysis and profiling of peptides is 
dependent on the scanning speed of the mass spectrometer46. Instruments with fast 
scanning speeds can sample more ions at a given time, resulting in a greater number of 
MS/MS fragmentation spectra. A study of a complex cell lysate digest analysed the number 
of peptide ions fragmented in a DDA LC-MS/MS experiment and found extensive under-
sampling with only 16 % of the precursor ions selected for fragmentation47. Secondly, as 
mentioned, DDA methods usually select for the most intense precursor ions for 
fragmentation and therefore there is an inherent bias towards the most abundant peptides 
in the sample. As a result, acquiring MS/MS fragmentation spectra for low abundance 
peptides is less likely. Finally, the co-elution of chimeric peptides is highly likely when 
analysing complex mixtures which can lead to MS/MS spectra composed of more than one 
chimeric peptide ion48,49.   
As an alternative to DDA, data-independent acquisition (DIA) methods were developed to 
improve the dynamic range and to remove the bias sampling and selection of abundant 
precursor ions for fragmentation50. DIA methods broadly operate in two ways; either by the 




the mass range or by acquiring all MS1 spectra followed by fragmentation and acquisition 
of all the MS2 ions51. The most frequently cited techniques are sequential window 
acquisition of all theoretical mass spectra (SWATH)52 and MSE53 both of which have been 
used for complex proteome analysis54,55. DIA methods do however, have limitations. As the 
approach generates many MS/MS spectra due to fragmentation of all precursor ions, the 
MS/MS spectra are highly complex which can result in challenging database searching 
which may compromise confidence in peptide identifications56. However, recent 
developments in data processing are working to overcome this57. 
Alternatively, selected reaction monitoring (SRM) is a targeted mass spectrometric 
technique used predominantly for the quantitative analysis of proteins using a triple 
quadrupole (QQQ) mass spectrometer. The method has the largest dynamic range 
capabilities and the lowest limits of detections compared to shotgun proteomic methods58. 
This can be explained by the non-scanning nature of the method allowing for extended 
times spent recording the signal of an individual transition, known as dwell time. Briefly, 
the method operates as follows. The first quadrupole (Q1) acts as a mass filter whereby 
selected pre-defined precursor ions are allowed through to the second quadrupole (Q2). In 
the second quadrupole, fragmentation by collision induced dissociation (CID) occurs and 
then pre-defined fragment ions are passed through to the third quadrupole (Q3) which acts 
as a mass filter59. Analysis of the precursor-fragment ion pair, termed transitions is what 
gives the technique such high selectivity increasing the signal to noise and therefore is able 
to achieve low detection limits. Although the signal from highly abundant peptides does not 
directly cause problems with detection of the transitions, peptides from highly complex 
samples may result in the interference from co-eluting peptides that have similar precursor 
m/z values. Another limiting aspect of the SRM methodology is that pre-defined targets are 
required meaning that the technique is not suitable for discovery of new proteins. Despite 
this, SRM is still not suitable in overcoming the plasma proteome dynamic range. However, 
the SRM approach, when used in combination with other fractionation and enrichment 
strategies to overcome the large dynamic range of proteomes it may be suitable58.  
 
1.3 Methods for proteome fractionation and enrichment  
Numerous approaches have been developed to reduce or overcome dynamic range issues 
to achieve greater depth of proteome coverage. Proteome fractionation entails the 




to simplify the sample mixture. Enrichment methods on the other hand work by increasing 
protein concentration, increasing the likelihood of detection. The methods available can 
either be carried out a protein level or at a peptide level. Typically, both protein and 
peptide fractionation are used in combination to achieve the enhanced proteome 
coverage.  
Protein fractionation and enrichment 
As discussed in section 1.2, 2-DE is an extremely powerful tool for complex proteome 
fractionation enabling high resolution and separation of proteins. However for intact 
protein analysis post fractionation, the sample recovery can be low60. Therefore other 
methods of protein separation are usually used. More recently an approach that is an 
advancement of 2-DE was proposed for intact protein fractionation. Using a computational 
model for proteome fractionation and identification it was hypothesised that proteins could 
be separated by isoelectric point and then by the linear sequence volume61. Although the 
approach was not proven experimentally, proteins are considered to differ enough in 
isoelectric point and linear volume to provide complete fractionation using one dimensional 
gel electrophoresis followed by nanopore separation61. As the experimental values 
obtained can be compared to computationally generated values, protein identification can 
be performed without the need for protein sequencing by MS.  
 
A widely used method for protein separation is liquid chromatography (LC). The method, in 
general, involves the separation of proteins based on their different physiochemical 
properties using a solid stationary phase and a liquid mobile phase. Various types of 
chromatography are available including hydrophobic interaction liquid chromatography 
(HILIC), size exclusion chromatography (SEC), reversed-phase chromatography (RP) and ion 
exchange chromatography (IEX) and have all been applied to complex proteome 
separation38. SEC separates proteins based on their size and uses columns containing a 
porous material as the stationary phase that small proteins can enter, while larger proteins 
cannot enter. Therefore, larger proteins pass through the column earlier while smaller 
proteins take longer to travel through the pores and thus elute later62. A limitation of SEC is 
the low resolution; however the technique has been improved with the development of 
ultra-high pressure (UHP) SEC63. Using UHP SEC, intact proteins with a mass of 6 – 669 kDa 
were separated with high resolution with direct coupling for top down MS.  
Alternatively, IEX separates proteins based on the charge, with two different types used; 




or anion exchange chromatography (AEX) where a positively charged medium is used. By 
increasing the ionic strength of the mobile phase, proteins are eluted from the stationary 
phase by displacement. As charge is what drives protein separation, when used in 
conjunction with other chromatography methods that separate based by hydrophobicity, 
the separation is highly orthogonal38. IEX usually uses mild buffers and therefore the 
proteins are not denatured which can make it suitable for separating proteins whilst 
maintaining protein complex. Numerous intact protein samples including E.coli64, human 
leukocytes65 and yeast have been separated using strong anion exchange.  
A different approach to reduce the dynamic range of biological samples is to employ 
depletion strategies. Immunodepletion columns, first described in 200366, are an effective 
and frequently used approach to deplete highly abundant proteins. Usually 
immunodepletion columns focus on the depletion of plasma and serum proteins for the 
reasons discussed in section 1.2. The columns contain antibodies to the most abundant 
plasma proteins and thus when the columns are incubated with sample; the respective 
proteins are removed from the sample. Various immunodepletion columns are available 
typically removing the top two, top 12 or top 20 most abundant proteins66. However, it is 
important to note that the binding capacity of the antibodies immobilised in the columns 
determine the effectiveness of protein depletion which typically means that a small volume 
of sample is able to be depleted. Furthermore, the technique may result in the loss of low 
abundance proteins such as cytokines67. Also, as there are high costs associated with the 
columns, more cost-effective methods may be more suitable. Using chemical-based 
depletion methods, highly abundant proteins can be precipitated from samples using 
acetonitrile68, ammonium sulphate69 and sodium chloride with ethanol70. As albumin is the 
most abundant plasma/serum protein, these methods tend to focus on the specific 
depletion of albumin.  
An alternative approach from depletion strategies is equalisation of the dynamic range of a 
proteome. This is usually performed using bead-based combinatorial peptide ligand 
libraries71-73. Complex samples with a large dynamic range are incubated with the beads 
and bind to the random peptides immobilised on the beads. The approach equalises 
protein concentrations as once the beads become saturated with their corresponding 
highly abundant protein, no more can bind and thus the protein is not retained for analysis. 
The approach also enriches for low abundance proteins, concentrating and equalising the 




there is enough of the low abundance protein within the sample to begin with. For proteins 
that do not bind to the bead-conjugated peptides, those proteins are not retained for 
analysis and therefore the methods may result in the loss of numerous proteins. 
Equalisation beads have been employed for the analysis of numerous samples including 
skeletal muscle74, HeLa cells75 and E.coli76 and have been particularly successful in enriching 
for low abundance proteins, reducing the dynamic range of samples.  
 
Peptide fractionation and enrichment 
In addition to employing protein fractionation steps, fractionation at a peptide level can 
also be employed to reach deeper into the proteome. High performance liquid 
chromatography (HPLC) and ultra-performance liquid chromatography (UPLC) are common 
separation techniques for peptide mixtures and are routinely couple with electrospray 
ionisation (ESI) and tandem mass spectrometers for bottom-up proteomics. Reverse-phase 
(RP) chromatography is typically employed for peptide separation based on hydrophobicity 
with gradients of low to high organic solvent. This method is particularly popular due to its 
ability to be directly coupled with mass spectrometry. Work published by Hsieh et al found 
that increasing gradient lengths resulted in a greater number of peptide identifications 
when analysing a complex proteomic sample77. However, despite deeper proteome 
profiling, sample throughput is dramatically reduced when long LC gradients are used.  
To further increase peptide separation and resolve complex samples, two dimensional 
liquid chromatography (2D LC) can be used prior to MS/MS analysis. The technique involves 
the separation of peptides using a first dimension that is highly orthogonal to a second 
dimension. As peptides have various different physiochemical properties, by employing 
different chromatography techniques, orthogonal separation is easily achieved78. First 
dimension techniques applied include normal phase, ion exchange and size exclusion 
chromatography. As the separated peptides are usually analysed by MS, the second 
dimension is normal RP chromatography to enable direct coupling to the MS instrument. In 
multidimensional protein identification technology (MudPIT)79, peptides are separated by 
strong cation exchange (SCX) in the first dimension followed by RP chromatography in the 
second dimension80. An early study of the yeast proteome using MudPIT identified 1483 
proteins80 which pioneered further large-scale proteomic studies. Despite improved 
numbers of protein identifications, long MS analysis time is required due to the large 




acquisition rates have enabled the identification of approximately 4000 yeast proteins 
without the need for time-consuming fractionation54,81. 
Another approach to proteome fractionation and enrichment is to focus on specific subsets 
of proteins or peptides, particularly to proteins with PTMs. The fields of 
phosphoproteomics and glycoproteomics, involving the analysis of phosphorylated and 
glycosylated proteins respectively, provide extensive information on biological processes 
and a greater understanding of cellular dynamics. Whilst it is estimated that approximately 
30 % of all proteins are phosphorylated82 and 50 % are glycosylated83, the level of modified 
protein is relatively low and is highly dynamic particularly in response to external stimuli 
and pathophysiological conditions. The phosphoproteome and glycoproteome represent 
the lower dynamic range of a proteome and therefore can be difficult to detect particularly 
when the unmodified peptides are more abundant. Various enrichment strategies for 
phosphorylated peptides have been employed including immobilised metal affinity 
chromatography84, titanium dioxide (TIO2) chromatography
85 and strong cation exchange 
(SCX)84. Glycopeptides can be enriched using lectin affinity purification, HILIC and SPE86. 
Such enrichment strategies have been able to analyse deeper areas of the proteome. For 
example, a method where a series of enrichment strategies were employed for PTMs 
identified a total of 8000 proteins with over 3000, 15000, and 20000 acetylation, 
ubiquitination and phosphorylation sites respectively87.  
Advancements in MS methodology and fractionation technology are allowing deeper 
proteome analysis. Various groups have now published the identification of over 7000 
proteins in a single sample type14,88-90. However, they typically involve fractionation steps 
and long LC gradients, leading to long MS run times. A recent study, aiming to detect the 
entire human proteome has identified over 84 % proteome coverage of protein-coding 
genes using mass spectrometry91,92. Whilst this is impressive, portions of the proteome are 
still hidden from detection and other strategies for complete proteome analysis are 
needed. Affinity proteomics fits hand-in-hand with MS, involving the application of binding 
reagents to detect specific protein targets. Affinity proteomics, to enrich for low abundance 
proteins, is considered the ideal strategy in order to fully analyse complete proteomes.  
 
1.4 Strategies for selective enrichment of proteins and peptides 
Another approach for the exploration of complex proteomes is to use enrichment steps 




abundance of the target protein in relation to the other background proteins. Many ligands 
have been used for specific enrichment of proteins including Cibacron Blue, Blue B, gelatin 
and biotin for albumin, kinases, fibronectin and streptavidin, respectively86. Briefly 
discussed in section 1.3 was the selective enrichment of glycoproteins using lectin. This has 
proven particularly informative for the analysis of cancer cells, due to the associated 
aberrant protein glycosylation in many tumours93. When combined with microarray 
technology, lectin arrays are a high throughput method to explore glycosylation states94,95. 
Another strategy for the selective enrichment of proteins is for antibody purification that 
exploits the interaction between the constant region of antibodies and protein A or protein 
G from Staphylococcus aureus and Streptococcus bacteria, respectively86.  
One of the most common reagents for selective targeting of proteins is the use of 
antibodies. They have been employed in numerous techniques for the enrichment of 
proteins from complex samples, of which mass spectrometric immunoassays (MSIA)96, 
stable isotope standards and capture by anti-peptide antibodies (SISCAPA)97 and reversed 
phase protein arrays (RPPA) will be discussed.  
A MSIA assays involves the immobilisation of antibodies onto a solid support for targeted 
protein enrichment from samples96. Following capture of the target, the protein is eluted 
for analysis by top down LC-MS or by SRM. A recent study has used the MSIA method to 
isolate MIF from human plasma samples98. Subsequent MALDI TOF MS analysis of both the 
intact protein and peptides from a digest was able to distinguish MIF isoforms and protein 
glycation demonstrating the benefits for low abundance protein identification. In addition, 
the high level of automation makes MSIA fairly reproducible and high throughput. 
Targeted enrichment can also be carried out at a peptide level. SRM approaches analyse 
peptides to obtain quantitative values for protein abundances when coupled with 
quantification strategies and therefore the approaches pair well together. A peptide 
enrichment method, termed stable isotope standards and capture by anti-peptide 
antibodies (SISCAPA) was originally used in 2004 by Anderson et al to enrich for four 
specific plasma proteins97. A large enrichment was observed of the targeted peptides 
compared to the non-enriched peptides. 
Reversed Phase Protein Arrays (RPPA), also known as lysate arrays, are an example where 
the specific binding affinity of antibodies have been exploited to explore the proteome. 
They differ from traditional protein arrays as instead of spotting individual proteins onto 




allow a large number of samples from different patients or cell lines to be screened at once 
for a single antigen target with an individual affinity binder. The assay relies on high quality 
binders which require extensive antibody validation steps to ensure no cross reactivity99. 
However, most antibodies that are currently available do not pass the validation steps. 
Despite the limitations, RPPA have demonstrated clinical relevance and have been 
particularly informative for the analysis of cancer cells. A study in 2014 using RPPA showed 
that proteins related with cell survival and growth, cell adhesion and cellular matrix 
remodelling were upregulated in bone metastasis samples compared to healthy control 
samples100. However, a major limitation of these selective enrichment techniques is that 
they are highly reliant on antibodies which can be a problem if the target of interest does 
not have an associated binder.  
 
1.5 Affinity Reagents 
Affinity proteomics relies on the use of binders or affinity reagents that interact with target 
molecules. Whilst antibodies are currently the main affinity reagent used, there has 
recently been a large focus in developing antibody alternative affinity reagents to greatly 
increase the number of affinity tools available. An overview of the affinity reagents 
currently available will be discussed, including antibodies, aptamers and protein scaffolds. 
The timeline of key events in the development of affinity proteomic tools is displayed in 
Figure 1.2 and highlights the rapid development in recent years of antibody alternative 
binding regents. To conclude this overview, the final binder technology discussed will be 







Figure 1.2 | Timeline of the development of affinity reagents. 
Key events in affinity reagent development. Hybridoma technology101, phage display technology102, DNA aptamers103,104, Kunitz domains, Thioredoxin105, 





Antibodies are the most widely used and studied affinity molecules. They are produced as a 
component of the adaptive immune system and have a vital role in defending vertebrates 
against pathogens and antigens that enter the body. The ability for antibodies to bind, with 
high specificity and high affinity, to the targets they were generated against are features 
that have been exploited in biological research allowing antibodies to be utilised in various 
immuno-affinity assays enabling the identification, characterisation and functional 
assignment of proteins.  
Antibodies are highly conserved in mammalian species and can be divided into five major 
antibody classes; IgA, IgM, IgG, IgE and IgD. The distinction of antibody class is due to 
sequence differences in the constant region of the heavy chain of the antibody conferring 
different immunological responses and properties113. A single antibody structural unit is a 
‘Y-shaped’ structure comprised of four polypeptide chains (Figure 1.3); two heavy chains (~ 
55 kDa each) and two light chains (~ 25 kDa each), connected by disulfide bonds114. The ‘V-
shaped’ portion of the antibody molecule is the area associated with antigen binding, 
known as the complementarity determining regions (CDRs). These regions are the most 
variable portion of an antibody molecule conferring diversity and specificity of binding 
partners. The CDRs are part of the ‘fragment, antigen-binding’ (Fab) region, which is made 
of a variable domain comprised of one heavy and one light chain and a constant domain 
also comprised of one heavy and one light chain. The lower portion of the antibody 
molecule is known as the ‘fragment crystallisable’ (Fc) region and is much more constant in 
its structure between the antibody sub-classes consisting of only constant domains113. 
Immunoglobulins have two key structural regions which can be attributed to different 
portions of the antibody structure; the constant region and the variable region. The 
constant region of the antibody is responsible for the effector function of the molecule 
whereas the variable region provides the antibody with the ability to bind an antigen 
through the Fab region. Variability in the VH and VL is located in three specific areas of the 
domains and are known as hypervariable regions. These regions are approximately located 
at residues 28 to 35, 49 to 59 and 92 to 103 in VL and at similar positions in VH
113. The 
antigen-antibody binding interaction occurs through different non-covalent forces including 






Figure 1.3 | Immunoglobulin G antibody structure 
The IgG structure consists of two heavy chains and two lights chains. The antigen binding 
occurs in the variable regions of one heavy and one light chain. The constant domains are 
blue and the variable regions are red. The top portion of the antibody is the ‘fragment, 




Polyclonal and Monoclonal Antibodies 
There are two forms of antibodies used in biological research differing by the methods of 
production: monoclonal (MAbs) and polyclonal (PAbs) antibodies. In an immune response 
to an antigen, B-lymphocytes produce antibodies to target the antigen116. However, a single 
antigen will present numerous different epitopes due to their high complexity and as a 
consequence, a heterogeneous population of B-lymphocytes will produce antibodies that 
recognise a different epitope of the antigen. Therefore the serum will contain antibodies 
that recognise different epitopes of the same antigen, hence termed polyclonal 
antibodies117. To generate polyclonal antibodies for research applications, an animal is 




which are then purified from the serum. The serum may also contain antibodies against 
antigens previously encountered by the immunised animal. It may be advantageous to use 
polyclonal antibodies compared to monoclonal antibodies in certain assays, such as those 
that require the recognition of antigens in multiple orientations or where financial 
restrictions apply due to relatively low cost of production. 
Conversely, monoclonal antibodies are derived from a single B-lymphocyte clone producing 
homogeneous antibodies with a single epitope target. Monoclonal antibody technology 
was first described in 1975 by Kohler and Milstein, for which they were awarded the Nobel 
Prize in 1984101. To generate monoclonal antibodies, lymphocytes are extracted from the 
spleen or lymph nodes of an animal immunised with a single antigen. Due to the short life 
span of B-lymphocytes and the inability to produce suitable quantities of antibodies 
through culture, the lymphocytes are fused with myeloma cells producing hybridomas. The 
hybridomas, an immortalised cell line, can now be grown in culture at a fast rate, producing 
an unlimited supply of antibodies with a single defined epitope target.  As monoclonal 
antibodies recognise a single epitope, they exhibit exquisite specificity to their target and 
therefore typically demonstrate improved performance in immunoassays compared to 
polyclonal antibodies, generally producing less background and cross-reactivity with other 
proteins118.  
The first application of antibodies in life sciences as a research tool was in the 1940s with 
the development of a tube immunodiffusion technique used to measure the antigen-
antibody interactions and later a plate double diffusion technique119. In 1959 the antigen-
antibody interaction was exploited again with the development of the radioimmunoassay 
(RIA) for insulin120. The RIA method was the predominant technique used to measure 
proteins. Another advancement in the applications of antibodies was with the development 
of the enzyme linked immunosorbent assay (ELISA)121,122. The technique detects antigen-
antibody binding with a colour change induced by the enzyme. ELISA is still the current and 
standard assay for protein detection due to its high sensitivity. Since the development of 
monoclonal antibody technology101, the application and routine use of antibodies has 
become widespread, transforming the fields of biotechnology and life sciences. Antibody 
technology has enabled huge advances in many areas including basic research, 
understanding the biological mechanism of diseases, and diagnostic assays. A key example 
of the success and revolutionary impact of antibody technology is in the development of 




approved for the treatment of 37 diseases, predominantly cancer, becoming a key focus for 
pharmaceutical drug development123. 
Whilst there is no dispute that antibodies are an invaluable tool for biological research, they 
do possess some limitations due to their structural properties. Firstly, high throughput 
antibody production can be difficult to achieve in bacterial expression systems due to 
extensive glycosylation and disulfide bond formation, essential to preserve the stability and 
function of the antibody. Secondly, the production of polyclonal antibodies has ethical 
implications as host animals are required. Thirdly, this process can be expensive and time 
consuming. Finally, in clinical research it is often beneficial to explore different protein 
conformations, isoforms and mutated proteins. Despite the vast numbers of antibodies 
used in biological research, there are still cases where antibodies are not available for this 
subgroup of proteins or where current antibodies are of poor quality. 
Furthermore, a key challenge of antibodies is the lack of reproducibility between 
experiments and low specificity for their intended target due to poor validation and high 
variability124. Numerous initiatives have been suggested in order to ensure that published 
antibody data is both reliable and reproducible for example, publishing the full western blot 
gels and including all appropriate controls125-127. Therefore, the development of alternative 
affinity reagents is necessary to overcome the current limitations of antibodies, providing 
complementary reagents to those currently available.  
Recombinant Antibodies 
Recombinant antibodies were first described in 1990 as a development of phage display 
technology when it was discovered that the variable domains of antibodies could be 
expressed on the surface of bacteriophages128. A brief outline of phage display technology 
is described in section 1.5.4.  The technique is very similar for the production of 
recombinant antibodies however, the initial step involves the creation of an antibody gene 
library. The variable regions of recombinant antibodies are either from genetic material 
from human B-cells or are synthesised in vitro. Human B-cell libraries are either immune 
libraries generated from an immunised donor species or naïve libraries, generated from a 
non-immunised human129. Diversity in the libraries is reported to be higher in the naïve 
libraries (1011 clones) compared to the immune libraries (1010 clones) 130. As recombinant 
antibodies can be synthetically engineered, they do not require an immune response and 
therefore have the potential for development to most protein targets. Recombinant 




range to their targets which can sometimes be greater than the affinities of conventional 
antibodies131. Due to the disulfide bonds between the heavy and light chains of antibodies, 
high expression in bacterial systems is difficult to achieve. Therefore, recombinant 
antibodies are usually based on smaller antibody fragments132, a feature which also assists 
phage display technology and also increases their versatility for different applications129.  
1.5.2 Nanobodies 
Another class of immunoaffinity reagents used in biological research are Nanobodies. As 
previously discussed, antibodies are highly conserved across mammalian species, however 
in addition to conventional antibodies, Camelidae species (camels and llamas) also have 
heavy chain antibodies (HCAbs) that are devoid of the light chains and the first constant 
domain in their sera133. Similarly, shark species have two typical antibodies, IgW and IgM, as 
well as simple antibodies known as Ig new antigen receptor (IgNAR), that lack the light 
chain134. The HCAbs have a variable region known as the VHH (nanobody), comparable to 
the Fab region of antibodies, which confer the antigen binding properties of the HCAbs. The 
VHH regions have been isolated and produced by recombinant technology and expressed, 
primarily in E.coli for use as affinity reagents135.  
Compared to conventional antibodies, Nanobodies are extremely small (13 – 14 kDa), a 
characteristic that provides them with many beneficial features.  Studies on the binding 
mechanism of Nanobodies to their respective targets have demonstrated that Nanobodies 
can recognise less common epitopes such as the active site of enzymes due to their small 
size easily accessing ‘hidden’ sites136,137. The binding to cleft regions of proteins is typically 
less common with conventional antibodies as it is the antibodies that typically have cavities, 
clefts and flat surfaces for target interactions138. Additionally, research has also shown that 
certain nanobodies retain their recognition function after incubation at high temperatures 
up to 90 oC139. Despite these benefits, some of the issues relating to conventional 
antibodies also apply to Nanobodies, reinforcing the need for alternative non-
immunoglobulin affinity reagents.  
1.5.3 Aptamers 
DNA or RNA Aptamers are short single stranded oligonucleotides, typically 20 – 100 bases, 
which fold to form tertiary structures capable of binding to target molecules with high 
specificity and high affinity140. The name ‘Apatmer’ is derived from the Latin word aptus, 




molecules of random sequences can fold to form structures with binding sites for small 
organic dyes 104. Simultaneously reported by another group in 1990, was the development 
of a selection method to identify RNA molecules that bind to bacteriophage T4 DNA 
polymerase, termed systematic evolution of ligands by exponential enrichment (SELEX)103. 
Aptamers have comparable binding affinities to antibodies and interact with their targets 
through hydrogen bonding, electrostatic interactions, salt bridges and van der Waals 
forces141. Aptamers have been developed to a wide variety of different targets including 
human VEGF142. Based on the different properties of DNA and RNA, selection for apatmer 
production may vary; RNA has more flexibility in its backbone compared to DNA however 
RNA is more susceptible to degradation compared to DNA. The process of SELEX involves 
incubating a library of randomised DNA sequences with an immobilised target. DNA that 
does not bind is washed away whilst the bound DNA is eluted and amplified by PCR. The 
selection process is then repeated, usually between eight and 15 rounds. The DNA is 
sequenced which usually reveals a pool of different DNA sequences however with a similar 
protein fold143.  
One key advantage of aptamers is the speed and relative ease of production compared to 
antibody production. Large quantities of aptamers can be quickly generated and as aptamer 
production is a chemical synthesis process, batch-to-batch variability is extremely low143. 
Furthermore, production does not rely on the use of animals eliminating the ethical issues 
of animal use in research. The small size of aptamers means that they may be able to access 
different epitopes or portions of their protein target, which would otherwise remain 
inaccessible for antibodies. Additionally, the production of an aptamer does not rely on the 
generation of an immune response and therefore, an aptamer can theoretically be 
developed for any molecular target. Aptamers can readily accommodate modifications such 
as the addition of functional groups and fluorescent dyes usually without altering the 
binding affinity of the molecules141.   
Despite the numerous benefits of Aptamers compared to antibodies as affinity reagents for 
use in biological research, to date, the implementation of Aptamers as research and clinical 
tools is extremely limited. Antibodies have been used as affinity reagents in research 
laboratories for numerous years and are therefore considered the gold-standard due to 
familiarity with the products and well-defined, standardised protocols are in place. 
Substituting antibodies for Aptamers in conventional immunoassays requires extensive, 
time-consuming method development to generate comparable and robust standardised 




that an extremely broad patent portfolio exists, consisting of over 140 individual patents, 
with few companies having the appropriate licenses to develop the technology144. 
1.5.4 Peptide Aptamers 
Peptide aptamers are typically 5 – 20 amino acids long, constrained within a protein 
scaffold and were first described by Brent et al. in 1996145. The work advanced on a 
previous study on the E.coli protein, thioredoxin, where the loop region of the protein was 
identified as a site for combinatorial peptide insertion146.  Brent et al reported the 
development of thioredoxin as a scaffold protein to display combinatorial peptides of 20 
residues, in a loop region of the protein145. Using the two-hybrid system, the combinatorial 
library of thioredoxin proteins that bound to human Cdk2 were selected and were shown to 
bind to different sites of the Cdk2 protein. A protein scaffold is the term used to describe 
the protein structure that holds the peptide fragments that enable binding to specific 
targets147. The flexible nature of peptide fragments means that when inserted into scaffold 
proteins they are limited in the number of conformations they can adopt and hence display 
greater specificity and affinity to their binding target compared to unconstrained peptide 
fragments148. Additionally, peptides constrained within a scaffold are less susceptible to 
degradation from cellular proteases, increasing their stability compared to free peptides148.  
Selection Techniques 
To produce affinity reagents with randomised variable regions with affinities to different 
targets, selection of the mutated variants is necessary. Display technology enables this 
allowing peptide and proteins to be selected that bind to target proteins with high 
affinities. The most frequently used display technique is phage display and is the method 
used to produce the Affimers in this thesis with defined protein targets. Other display 
technology available includes ribosome display, mRNA display and bacterial and yeast cell-
surface display. Phage display is a method used to screen libraries of proteins for binding to 
specific targets102. The process involves the use of a bacteriophage, which expresses the 
library of peptides or proteins on the surface of the phage. The phage selection process, 
termed bio-panning, consists of five main steps; the preparation of a phage peptide library; 
immobilisation of the target, usually onto a micotitre plate by passive adsorption; exposure 
of the immobilised target to the phage display library for binding; washing to remove 
unbound phage; and elution of the target bound phage. Following the final elution step, the 
recovered phages are amplified and the bio-panning is repeated between three and six 




confirm high selectivity for the target they were generated against which is typically 
performed by ELISA. A defining requirement of the method is that recombinant or purified 
endogenous protein is available for the bio-panning process. 
 
1.5.5 Alternative Scaffolds 
Considerable research has been undertaken to develop non-antibody based scaffold 
proteins150,151. The structure of antibodies, consisting of a constant region and variable 
interaction sites for target binding, lead to the concept of developing alternative affinity 
reagents based on this design152. Under natural conditions, the primary roles of a large 
number of the scaffold proteins that have been developed are to form binding interactions 
with other proteins.  Therefore, the pre-existing binding sites of the protein scaffolds can be 
modified allowing peptide insertions to be introduced at these positions forming a region 
similar to an antibody epitope. Proteins selected for scaffold development must possess 
numerous beneficial features in order to be a superior affinity reagent to antibodies.  The 
protein scaffold must be structurally tolerant to modifications such as the addition of 
variable epitope regions of increased lengths, purification tags and functional groups for 
immobilisation. The size of the scaffold should be relatively small to encourage cellular 
uptake and to limit non-specific binding151. Regardless of selection and production 
methods, the protein scaffold should express at high quantities and display low batch-to-
batch variability. When designing the protein scaffold, the final application should be 
considered, as if the scaffold is intended for medical and human in vivo applications, the 
species of origin of the scaffold should be carefully selected so that it does not evoke an 
immune response. 
Currently, there are over 50 synthetic engineered protein scaffolds that allow specific 
peptide fragments to be presented as recognition sites150,151. Table 1.1 provides an 
overview of some of the scaffold proteins currently available. The protein scaffolds 
described are diverse in terms of the size, structure, interaction sites and protein of origin. 
Typically, protein scaffolds are categorised based on the structure; scaffolds with structures 
that mimic the structure of antibodies with a rigid frame and variable loop regions or 
scaffolds with rigid structures with variable regions in the flat surface of the scaffold151. 
Several protein scaffolds most frequently developed and their applications are discussed 






Table 1.1 | Examples of protein scaffolds developed as novel affinity reagents 
Abbreviations: BBP, bilin-binding protein; ApoD, apolipoprotein D; FABP, bovine heart fatty-acid binding protein; BPTI, beef pancreas trypsin inhibitor; LAC-
D1, lipoprotein-associated coagulation inhibitor; ITI-D”, human inter-α-trypsin inhibitor; APPI, Alzheimer’s amyloid-β protein precursor inhibitor domain 
 
Scaffold 








Affimer Stefin A, plant cystatin 
consensus sequence 
11 – 13 kDa α-helix and β-sheet 98 2 loops Avacta Life 
Sciences111,153 
DARPins Ankyrin repeats 14 -18 kDa 2 x α-helix and β-turn 1 unit – 33  3 x (α/β turn) Molecular Partners108 
Anticalins Lipocalins (BBP, ApoD, FABP) Approx. 20 kDa β-barrel 160 - 180 4 loops Pieris 
Pharmaceuticals154 
Adnectins Fibronectin III Approx. 10 kDa β-sandwich 94 2 – 3 loops Adnexus155 
Affibodies Z domain of Protein A Approx. 6 kDa 3 α-helices 58 2 x α-helix Affibody156,157 
Kunitz 
domain 
BPTI, LACI-D1, ITI-D2, APPI Approx. 7 kDa α-helix and β-sheet 58 1 or 2 loops DYAX158 
Affilin Ubiquitin/ γ-B-crystallin Approx. 10/20 kDa α-helix and β-sheet/ 
β-sheet  
76 -176 β-sheet Navigo Proteins159 





Affibodies are modified protein scaffolds based 
on the Z domain of the immunoglobin Fc-
binding region of Protein A from 
Staphylococcus aureues160. The engineered 
proteins are made from a single polypeptide 
chain of 58 amino acids that folds and is highly 
stable despite lacking cysteine residues. Combinatorial library construction was first 
described in 1995 by Nord et al.156 in which 13 residues in two of the three alpha helical 
regions were randomised. Affibodies are extremely small (approximately 6 kDa) and have 
been used in various applications including the targeting of viruses161, affinity 
chromatography of human apolipoprotein A-1 and Taq DNA polymerase156,162, proteome 
depletion163 and imaging of tumours. A labelled Affibody designed to target epidermal 
growth factor receptor 2 (HER2) has been used to visualise tumours in patients with 
metastatic breast cancer164,165. 
DARPins 
Designed ankyrin-repeat proteins (DARPins) 
are based on a consensus sequence of the 
naturally occurring protein group, ankyrin 
repeat proteins. The natural biological 
function of ankyrin-repeat proteins in 
mediating protein-protein interactions166 
has been exploited for the development of 
engineered binding proteins. The proteins are constructed from repeating units, with a 
single unit typically made from 33 amino acid residues comprised of a β-turn and two anti-
parallel α-helices. Typically, DARPins are made of four to six structural units but can consist 
of up to 29 repeat units, forming proteins with a molecular weight of 14 – 22 kDa. Early 
studies developed combinatorial libraries of DARPins with seven randomised positions per 
repeat unit108. Using ribosome display, DARPins for maltose binding protein were selected 
and had low nanomolar binding affinities167. Since then DARPins have been developed to 
various different targets for different applications including imaging168 and as 
therapeutics169. The DARPin scaffold was developed further to generate a DARPin structure 




round of library screening with the Loop DARPins, binders to BCL-2 were generated with 
low picomolar affinities170.    
 
Anticalins 
Anticalins are engineered lipocalins that have been 
modified to bind specific targets171. Lipocalins are 
small proteins, typically 160 -180 amino acids and 
are found in numerous species including plants, 
humans and bacteria and have a highly conserved 
structure across the different species despite 
having low sequence homology172. The proteins 
consist of a β-barrel core made up of eight 
antiparallel β-strands that are connected with four 
loops. It is this region of the lipocalin protein that is involved in interactions with their 
targets and thus the loop regions that are modified in development of anticalins. The 
typical role of lipocalins is involvement in the transportation and storage of small molecules 
such as steroids, lipids and odorants. The molecules bind tightly to the deep pocket of the 
β-barrel core of the lipocalins, a feature that can be exploited in Anticalin design enabling 
the binders to target small molecules for the development of antidotes173. Furthermore, 
Anticalins are highly stable withstanding temperatures of up to 70 oC, they do not contain 
disulfide bonds and are not glycosylated. The lipocalin initially developed as a protein 
scaffold was bilin-binding protein (BBP) from Pieris brassicae. In four of the loops, a total of 
16 amino acid residues were mutated and demonstrated high binding affinities (low 
nanomolar range) with the plant steroid digoxigenin and the dye florescin. However, as a 
protein scaffold of human origin would be more preferable for medical applications, the 
human lipocalins apolipoprotein D, human lipocalins 1 and human lipocalins 2 (Lcn2) were 
identified for scaffold development172. Anticalins have been used in a variety of applications 
and have been developed against clinically relevant targets. The Lcn2 scaffold has been 
used to develop Anticalins targeting cytotoxic T-lympohcyte associated antigen 4174 and 









Adnectins, also termed Monobodies, are 
engineered protein scaffolds based on the 10th 
extracellular domain of human fibronectin III 
(10Fn3) first described in 1998 by the Koide lab106. 
The protein is ideal for development as a protein 
scaffold as the structure of 10Fn3 is similar to the 
variable domain of antibodies possessing three loops for target binding. 10Fn3 lacks 
disulfide bonds but still able to maintain a highly stable structure. Studies have 
demonstrated that the protein is able to maintain its structure at high temperatures (up to 
80 oC)176 and express at high levels in bacterial expression systems177. Initial adnectin library 
design and selection was carried out using phage display for proteins that bound 
ubiquitin106 and mRNA display to select for Adnectin binders of TNF-alpha178. The generated 
Adnectins had low micromolar106 and low nanomolar178 affinities to their targets 
respectively. More recently, various Adnectins have been generated that bind clinically 
relevant targets. For example, Adnectins that target epidermal growth factor receptor 
(EGFR) and interleukin 23 (IL-23) were produced using mRNA display179. EGFR and IL-23 are 
implicated in cancer and inflammatory diseases respectively, and the corresponding 
Adnectins have been shown to block intracellular signalling in cell-based assays and are 
potentially suitable as antibody alternatives when developing therapeutics.  
 
Knottins 
Cysteine-knot miniproteins, also termed knottins are 
a group of small proteins, comprised of 25 to 35 
amino acids residues. The protein group is 
characteristically defined by having a minimum of 
three disulfide bonds180. The arrangement of the 
disulfide bonds, with one disulfide bond between 
cysteine 3 and 6 going through the disulfide bonds 
of cysteine 1 and 3 and cysteine 2 and 4, forming a highly stable ‘knotted’ structure of 
antiparallel β-strands180. This feature makes knottins ideal candidates for affinity scaffold 
development. The connecting loops between the antiparallel β-strands of naturally 
occurring knottins are highly diverse with over 2000 different sequences observed of 




randomisation181,182. Additionally, the small size and high stability of the protein makes 
them suitable for tumour imaging as they demonstrate rapid uptake and clearance from 
tissues183. The protein, trypsin inhibitor II from Ecballium elaterium (EETI-II) was initially 
developed as a knottin protein scaffold by determining the knottin protein tolerated 
mutations into the loop regions of the protein structure184-186. Other proteins belonging to 
the knottin family developed as scaffold include the C-terminal cellulose-binding domain 
from cellobinohydrolase I of the fungus Trichoderma ressei187,188 and the human protein, 
Agouti-related protein189. Further, to generate Knottin binders that target integrins, known 
binding motifs were incorporated into the loops of EETI-II resulting in binders with 
nanomolar affinities to integrin proteins183.  
 
1.6 Affimers 
Affimers are small engineered proteins, based on either one of two proteins; the human 
protein stefin A or a consensus sequence of plant phytocystatins. The development of 
Affimer technology was first reported in 2005 when Ko Ferrigno et al published work 
detailing the initial stages of engineering the human protein, stefin A to constrain peptide 
aptamers109.  The work successfully demonstrated that the stefin A variant possessed the 
desired features of a scaffold protein; it was made biologically neutral by removing the 
natural cysteine protease inhibitor function of the protein153, remained folded and had high 
thermal stability even whilst displaying a peptide insertion and that designed peptides 
constrained within the scaffold interacted with known targets. Additionally, it was found 
that the protein scaffold expressed well in yeast, mammalian and bacterial cells.  
Further advancements to the protein scaffold were made and work published in 2010 
described the development of five new stefin A protein scaffolds based on the STM (stefin 
A triple mutant) design190. Different modifications were made to the loop regions of the 
scaffold and the structure, stability, folding and expression of the proteins assessed. A 
variant, termed SQM, in which epitope tags were inserted into the N-terminus of the 
protein led to a lower yield of protein expression compared to the other variants described. 
However, one major limitation of the SQM scaffold was that when insertions were made 
into loop 1 and the N-terminus, as well as in loop 2, the stability of the scaffold was 





Therefore, further improvements were made to the scaffold and the final development of 
the Stefin A scaffold was reported in 2011153. The study reports the design of a new Stefin A 
variant called, SQT (Stefin A Quadruple Mutant – Tracy) that is highly stable and can 
withstand the addition of three peptide insertions, giving the scaffold enhanced diversity in 
combinatorial libraries. The SQM scaffold variant was re-engineered to form the SQT 
scaffold by changing the position of a restriction site to the beginning of loop 2 instead of 
the β-sheet resulting in two amino acid substitutions; E78A and L80R. Analysis of the 
proteins by CD spectroscopy to determine the thermal stability discovered that SQT had 
comparable stability to STM. The SQT scaffold is thus the Affimer scaffold (Figure 1.4). 
In 2014, another group published their work describing the development of Adhirons 
(Figure 1.4), now commercially termed Affimers, as a protein scaffold111.  The Adhiron 
protein scaffold is based on a consensus sequence of plant phytocystatins, which are small, 
natural cysteine protease inhibitors, of approximately 100 amino acid residues. The protein 
was selected for development due to inherent features desirable for an ideal protein 
scaffold; small, highly stable, contains no disulfide bonds or glycosylation sites. The natural 
interaction regions of the protein that convey the inhibitory function of the protein were 
modified for peptide insertion leading to the insertion of two, randomised nine amino acid 
loop regions. The group demonstrated that a panel of Adhirons, generated through phage 
display technology for the yeast SUMO protein, could be identified to bind to the yeast 
SUMO protein through ELISA studies. The binding affinities were measured by isothermal 
titration calorimetry and the KD values for three of the Adhirons were in the low 
nanomolar range comparable to other antibody alternative affinity reagents111.   
Despite having low sequence homology between the two Affimer protein scaffolds, 
structurally, they are very similar in structure (Figure 1.4). A key advantage of developing 
Affimers from two different species is that depending on the final application of the protein 
scaffold; one of the proteins may be more beneficial compared to the other. For example, a 
protein scaffold that is modified from a human protein would be better suited for 
therapeutic applications as it is less likely to induce an immune response compared to a 
plant protein. The Affimers based on the phytocystatin consensus sequence are ideal for 










Figure 1.4 | Ribbon diagram and sequence alignment of the two different Affimer structures. 
Ribbon diagrams of the two different Affimer scaffolds. The stefin A scaffold was derived from the Protein Data Bank (PDB) 4N6T and the Adhiron scaffold 




Affimers have comparable binding affinity to antibodies, in the low nanomolar region and 
exhibit high stability to various pH ranges and temperatures. They also have the ability to 
bind to a solid surface and retain their recognition functions, proving very useful for Affimer 
microarray development 192. Due to the relatively small size of Affimers (11 -13 kDa) 
chemical modifications with dyes and protein fusions are easily implemented. To date, 
Affimers have shown their versatility with various cellular and molecular applications. They 
have been utilised for cell imaging, affinity histochemistry, western blotting, MRI reagents 
and for the formation of nanoparticles112.  
1.7 Affimers in the discovery of biomarkers 
Biomarkers are defined as molecules that can be detected and measured to define a 
specific biological state, pathology or response to therapy193. Biomarkers are extremely 
important in the clinical setting as they play a role in disease prediction, diagnosis, 
prognosis and management. In 1948, the very first biomarker was discovered for the 
detection of myeloma194. The light chain of immunoglobulins was identified in 70 % of 
patients with the disease. Since then, many other proteins have been established as 
biomarkers however they are not used alone; other diagnostic tests are performed. This is 
predominantly due to the lack of specificity of the biomarker. To be useful in the clinical 
setting, biomarkers must meet certain criteria. This includes involving minimally invasive 
sample collection methods, high specificity, low cost of testing and show significant 
differences between control and disease samples193. In addition, for a biomarker to have 
clinical applications, extensive validation is necessary193. This includes both analytical and 
clinical validation and assessment of the clinical utility of the biomarker in improving 
patient health outcomes and being economically viable.   
Due to the unbiased nature of discovery LC-MS/MS, it is an ideal method for biomarker 
discovery. However, the method does have limitations in that it lacks the sensitivity needed 
for complex proteome analysis. Although biofluids such as plasma and serum are ideal 
samples for biomarker discovery due to their relative ease of collection and the fact they 
sample the pathophysiology of the whole body, they have dynamic ranges spanning 10 to 
12 orders of magnitude19. In addition, although a large number of proteins can be identified 
in a single MS analysis, sample throughput is low especially if long LC gradients are 
employed. Examples of the other methods available for complex proteome analysis were 




The use of Affimer regents for biomarker discovery has great potential to enrich for specific 
protein targets and overcoming proteome complexity. A proof of concept study using 
Affimers containing randomised peptide insertions in their loop regions, termed naïve 
Affimers, was employed for unbiased sample analysis192,195. The method involved the 
immobilisation of Affimers onto the array followed by incubation of a fluorescently labelled 
sample. Affimers that bound a protein target generated a fluorescence signal and therefore 
was identified as displaying affinity for proteins. This strategy can be employed for the 
differential analysis of samples for biomarker discovery. As each array can contain up to 
20000 different Affimer spots, by comparing the fluorescence signals on the Affimer array 
at a set position a comparison can be made between samples regarding protein capture, 
allowing large scale biomarker discovery screening.  The Affimer are naïve and thus contain 
unknown peptide insertions in the loop regions, so the method is a untargeted method for 
biomarker analysis. In addition, as the Affimers could enrich for target, low abundance 
proteins may be brought into the detectable range for identification. The use of bottom-up 





1.8 Aims and Objectives 
The overall aim of this thesis was to investigate and characterise next generation affinity 
reagents, with a focus on Affimer technology. The primary aim of the first chapter was to 
develop an affinity purification workflow coupled with mass spectrometry to identify 
unknown naïve Affimer binding targets. Naïve Affimers were selected from Affimer array 
data that showed differential binding between hospital control and sepsis serum and it was 
hypothesised that identification of proteins bound to the Affimers could reveal protein 
markers of sepsis192. Various methods for affinity purification were investigated including 
His-tag Affimer immobilisation, covalent Affimer immobilisation and mass spectrometric 
immunoassay (MSIA). The challenges and identification of non-specific background proteins 
in affinity purification workflows is also presented. 
The focus of the second chapter was to characterise Affimers with known binding targets. 
Pepsin has been proposed as a protein marker to distinguish patients with reflux aspiration 
from direct aspiration of food and saliva, allowing clinicians to guide surgical 
intervention196. Current assays rely on antibodies as the detection reagent however they 
lack any clinical utility due to inherent problems with antibodies previously discussed. 
Therefore the aims were to generate Adhirons to target human pepsinogen and develop an 
affinity purification workflow for pepsinogen enrichment.  To overcome the issue of the 
large signal of capture reagents in LC-MS analysis of affinity purifications, a pepsinogen 
Adhiron resistant to Lys-C proteolysis was also expressed and stability analysed. 
The third study in this thesis explored an alternative approach to identify protein markers 
of sepsis due to the limitations in the Affimer array and affinity purification approach. Using 
LC-MS/MS, the aim was to undertake a comparative analysis of plasma from sepsis patients 
and hospital controls to identify changes in protein expression. Results from the 
comparative analysis will guide the selection of candidate proteins for phage display 
Affimer production as potential markers of sepsis.  
The aims of the final chapter were to perform preliminary investigations into whether 
darcin was suitable for development as an alternative affinity reagents scaffold. Previously, 
lipocalins structures have been reported as alternative scaffolds171,172. Darcin, a major 
urinary protein (MUP), found in rodents is an example of a lipocalin and structural analysis 




urea197. The aims were to explore various modifications to the protein and determine the 
effect on protein stability. 
The terms Affimer and Adhiron are used throughout this thesis. Affimer is the commercial 
name of both the stefin A scaffold and plant cystatin consensus sequence scaffold. The 
term Adhiron specifically refers to those binders that are based on the plant cystatin 
consensus sequence. In this thesis, various different Affimers were used of which can be 
grouped into three separate categories based on their intended purpose. For the Affimer 
array work, naïve Affimers based on the Stefin A protein scaffold were used.  These 
Affimers consisted of random peptides within the variable loop region of the scaffold and 
their binding partners was unknown. The second set of Affimers had known binder partners 
and were used for method development and optimisation. The Affimer protein scaffold for 
this set was based on the plant cystatin consensus sequence. The third set of Affimers were 
generated to specific target to overcome a distinct biological problem. To address the need 
for alternative affinity reagents that target pepsinogen, a total of five pepsinogen Adhirons 
were generated.  
Workflow 
The typical approach for Affimer characterisation involved a variety of analytical 
techniques. Affimers were either received as pure protein from Avacta Life Sciences or as 
plasmid DNA from the University of Leeds BioScreening Technology Group for E.coli 
expression. Firstly, SDS-PAGE analysis was performed to confirm the Affimers were 
approximately the expected molecular weight and that the protein sample contained no 
contaminant proteins following purification. 
 
To confirm the molecular weight was as expected, intact mass analysis of the proteins was 
carried out using ESI-MS on the Waters Synapt G2. Electro-spray ionisation (ESI) is the most 
commonly used ionisation technique in the field of proteomics and the predominant 
method used within this study. ESI is a soft ionisation technique and is the process of 
transferring charge particles from the liquid to gas phase before MS analysis. The 
development of ESI for protein analysis was first published by Fenn in 1984 and when 
coupled to a mass spectrometer, revolutionised the field of proteomics198. The technique 
was the first to create multiply charged proteins, bringing them into the mass range of the 
mass spectrometer for detection. The process of ESI involves three main steps; the 
production of nebulised droplets at the tip of the emitter, repeated evaporation of solvent 




Further confirmation of the Affimer sequence was achieved by peptide mapping and 
sequencing. Using either a single protease or a combination to achieve improved sequence 
coverage, the Affimers were digested to their resulting peptides. The peptides were 
analysed by LC-MS/MS on the Thermo Scientific QExactive Orbitrap mass spectrometer to 
obtain sequence information. The instrument has high resolution and high mass accuracy 
allowing the accurate assignment of MS/MS spectra. Following characterisation and 
confirmation of the correct protein product, Affimers were suitable for use in downstream 





Chapter 2: Materials and Methods 
2.1 Protein expression 
E.coli cells (BL21 (λDE3) strain) were made competent by calcium chloride and the cells heat 
shocked to allow the DNA to enter the cells. A total of 5 ng of plasmid, solubilised in TE 
buffer (10 mM Tris, 1 mM ethylenediaminetetraacetic acid (EDTA)) were incubated with 
competent cells and heat shocked at 42 oC. Cells were centrifuged (1600 x g), resuspended 
in LB and grown on agar plates containing antibiotic (dependent on plasmid used, further 
details in results sections). Plates were incubated overnight at 37 oC for selective growth of 
transformed cells only. An individual colony was selected to inoculate LB broth (10 mL) 
containing antibiotic and incubated overnight at 37 oC with mixing at 180 rpm. For larger-
scale protein expression, the overnight broth (4 mL) was added to LB broth (200 mL) 
containing antibiotic and incubated at 37 oC with mixing at 180 rpm. Protein expression was 
induced with isopropyl β-D-1-thiogalactopyranoside (1 mM) at an absorbance reading of 
0.6 at OD (600 nm). The protein was left to accumulate for either 4 hours or 16 hours, as 
specified in the results. The cells were harvested by centrifuged at 3500 rpm at 4 oC for 10 
minutes. The LB broth removed and the protein pellets stored in the freezer until required. 
2.2 Cell lysis using sonication 
A cell pellet from 50 mL of culture was re-suspended in 50 mM phosphate buffer pH 8.0 
plus protease inhibitors and benzonase nuclease (25mL buffer made with 1 x complete 
EDTA-free protease inhibitor tablet and 0.1 % (v/v) benzonase nuclease). The suspension 
was sonicated at 30 % amplitude for 10 seconds every minute for a total of 12 minutes. To 
obtain the soluble fraction, the sonicated solution was centrifuged (6000 g for 8 minutes). 
2.3 Purification with Ni-NTA HisTrap column method 
Manual  
The pepsinogen Adhirons, present in the soluble fraction of the bacterial cell lysate, were 
purified using Ni-NTA affinity columns (HisTrap HP, G.E. Healthcare, Buckinghamshire, UK) 
by use of the His-tag following the manufacturer’s guidelines. After loading the samples, 
columns were washed with wash buffer (0.2 M sodium phosphate, 0.5 M sodium chloride, 
10 mM imidazole, 20 % glycerol, pH 7.8) and the protein was eluted from the column using 




glycerol, pH 7.8).  Eluted fractions were analysed by SDS-PAGE with the fractions with the 
highest concentration of protein combined and the Adhirons stored in elution buffer.  
 
ÄKTA™ start purification system 
Darcin and the darcin variants, present in the soluble fraction of the bacterial cell lysate, 
were purified using Ni-NTA affinity columns (HisTrap HP, G.E. Healthcare, Amersham, UK) 
using the ÄKTA™ start purification system (G.E. Healthcare, Buckinghamshire, UK). After 
loading the samples, columns were washed with wash buffer (0.2 M sodium phosphate, 0.5 
M sodium chloride, 10 mM imidazole, pH 8.0) and the protein was eluted from the column 
using elution buffer (0.2 M sodium phosphate, 0.5 M sodium chloride, 0.5 M imidazole, pH 
8.0).  Eluted fractions were analysed by SDS-PAGE with the fractions with the highest 
concentration of protein combined. Darcin proteins were buffer exchanged by three rounds 
of dialysis into 50 mM ammonium bicarbonate. 
 
2.4 Protein assay 
Protein concentration was calculated using the Coomassie Plus protein assay kit (Pierce, 
Rockford, USA). Bovine serum albumin (BSA) was used as a standard and diluted to create a 
standard curve (0 – 50 mg/mL). Samples were diluted with purified water so they were 
within the range of the standard curve. The samples and BSA standards were mixed with 
Coomassie Plus protein assay reagent (2:1, reagent: sample). The absorbance reading was 
measured at 620 nm using a plate reader (Thermo Scientific™ Multiskan™). 
2.5 Tris((2-carboxyethyl)phosphine) (TCEP) reduction 
Protein reduction was performed using Pierce™ immobilised TCEP disulfide reducing gel 
(Thermo Scientific) as described in the manufacturer’s protocol. Briefly, equal volumes of 
TCEP resin and protein sample were incubated for 1 hour at room temperature on a 
shaking block (1300 rpm). To recover the sample, the solution was centrifuged at 1000 x g 
for 1 minute. 
2.6 1D SDS-PAGE  
SDS-PAGE was performed as described by Laemmli199. Samples were incubated with 
reducing (with dithiothreitol (DTT)) or non-reducing (No DTT added) SDS sample buffer as 
stated for 5 minutes at 95 oC and loaded onto 15 % polyacrylamide gels. BioRad Broad 




constant voltage of 180 V until the dye front reached the bottom of the gel. Protein bands 
were visualised using PhastGel® Blue R Coomassie Brilliant blue stain (Sigma-Aldrich, 
Dorset, U.K.) and destained with destain solution (water 80 %, acetic acid 10 % and 
methanol 10 %). 
2.7 Partial plasma depletion 
Albumin was depleted from plasma samples following the protocol described by Liu et al.200 
with 10 % (v/v) TCA in HPLC grade water used.  
2.8 Spin column depletion 
Plasma sample depletion was performed using the Thermo Scientific™ Pierce™ Top 12 
Abundant Protein Depletion Spin columns (Thermo Scientific™ Pierce™). According to the 
manufacturer instructions, 10 µL of plasma sample was added to the spin column and 
incubated at room temperature on a roller mixer for 1 hour. The columns were centrifuged 
at 1000 x g for 2 minutes and the flow-through collected. 
2.9 Vivaspin® sample concentration 
Vivaspin® 500 centrifugal filter units (Sartorius Stedim Biotech, Germany) with a 3 kDa cut-
off were used to concentrate the protein depletion spin column depleted plasma sample as 
described by manufacturer instructions. Briefly, sample was added to the filter and 
centrifuged at 15000 x g for 20 minutes. The sample was removed from the filter using a gel 
loading tip and retained for in-solution digestion.   
2.10 Strataclean™ resin concentration 
For protein concentration, 16 µL of Strataclean™ resin (Agilent Technologies) was added to 
each sample and vortexed for 2 minutes. The samples were centrifuged for 2 minutes at 
430 x g and the supernatant removed. The protein within the sample was bound to the 
beads and extracted by SDS-PAGE or in-solution digestion. 
2.11 TCA precipitation 
The standard TCA precipitation method201 was performed for protein concentration.   
2.12 His-tag affinity purification  
Protein (20 µg per 10 µL bead slurry) was immobilised by the HexaHistidine-tag to Ni-NTA 




mixer. The beads were washed with PBS-T (Tween 20) and the liquid separated from the 
beads using a magnetic rack. The beads were blocked with 1 % casein in PBS-T for 1 hour at 
room temperature on a roller mixer. The block was removed and beads washed with PBS-T. 
Beads were incubated with target (as described in results) for 1 hour at room temperature 
on a roller mixer. The unbound sample was removed from the beads and washed with NPI-
20-T (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole and 0.05 % (v/v) Tween 20). PBS pH 
7.4 was added to the beads until required for analysis. 
2.13 Mass spectrometric immunoassay (MSIA) method 
The forward MSIA streptavidin protocol was followed as manufacturer’s instructions using 
the Thermo Scientific™ MSIA™ streptavidin D.A.R.T.’s®. The tips were loaded onto a 
Finnpipette Novus i Electronic 12-Channel Pipette (Thermo Scientific) and all solutions 
loaded into a 96-well polypropylene low bind plastic microplates (Thermo Scientific). Using 
the parameters in Table 2.1, the affinity purification was performed. Eluted protein was 
dried down in a SpeedVac concentrator until dry and re-suspended in 25 mM ammonium 
bicarbonate. The resin from the tips was removed and the protein extracted by SDS-PAGE 
or in-solution digestion.  
Table 2.1| MSIA workflow Finnpipette Novus i Electronic 12-Channel Pipette settings 






No. of mixing 
cycle iterations 
1 Pre-wash - wash buffer 200 150 10 
2 
Affinity ligand binding - 
Biotinylated Affimer solution 
125 100 500 
3 
Wash – PBS pH 7.2 (Total of 
two washes) 
250 150 20 
4 Target binding 150 125 999 
5 
Wash buffer – as outlined in 
results (Total of three washes) 
250 150 20 
6 Wash - water 250 150 20 
7 
Elution – 33 % ACN, 0.1 % 
(v/v) formic acid in HPLC grade 
water 




2.14 Pyridyl disulfide-activated magnetic beads affinity purification 
Adhirons (10 µg per 10 µL 10 % (v/v) bead suspension) were immobilised onto the 
PureCube thiol-activated MagBeads (Cube Biotech, Germany) that had been re-suspended 
in PBS pH 7.4, for 1 hour at room temperature on a roller mixer. Using a magnetic rack, the 
beads were separated from the unbound Affimer and washed twice with PBS pH 7.4. Beads 
were incubated with target (as described in results) for 1 hour at room temperature on a 
roller mixer. The unbound sample was removed from the beads and washed twice (as 
described in results). Beads were incubated with reducing SDS sample buffer and analysed 
by SDS-PAGE. 
2.15 SulfoLink® coupling resin affinity purification 
Typically, 50 µL of 50 % (v/v) SulfoLink® coupling resin slurry (Thermo Scientific) was used 
for each affinity purification reaction. The resin was centrifuged at 5000 rpm for 2 minutes 
and the storage buffer remove. The resin was washed twice with coupling buffer (50 mM 
Tris, 5 mM EDTA-Na, pH 8.5) by vortexing briefly, centrifuging at 5000 rpm and removing 
the wash. Prior to coupling, proteins were reduced following the TCEP reduction protocol. 
Adhiron/Affimer coupling solution (15 µg protein in 200 µL coupling buffer per 50 µL 50 % 
(v/v) SulfoLink® coupling resin slurry) was incubated with the resin at room temperature for 
45 minutes on a roller mixer. The Adhiron/Affimer coupling solution was removed by 
centrifugation at 5000 rpm for 2minutes and the resin washed twice with four resin 
volumes of coupling buffer. The non-specific binding sites of the resin were blocked with 
one resin volume of 50 mM L-cysteine·HCl in coupling buffer for 45 minutes on a roller 
mixer. The blocking solution was removed by centrifugation at 5000 rpm for 2minutes and 
the resin washed once with four resin volumes of NaCl (1 M) and twice with four resin 
volumes of PBS, pH 7.4. Sample containing target (total volume of four resin volumes of PBS 
pH 7.4) was incubated with the resin at room temperature for 45 minutes on a roller mixer. 
Sample was removed by centrifugation at 5000 rpm for 2minutes and the resin washed as 
described in the results. 
2.16 In-gel proteolysis 
Pieces of gel were excised from the protein bands using a glass Pasteur pipette. Gel pieces 
were destained with a 2:1 solution of 25mM ammonium bicarbonate: acetonitrile (ACN) for 
15 minutes at 37 oC and repeated until destained. The gel pieces were incubated with DTT 




the gel pieces incubated with iodoacetamide (55 mM) for 45 minutes at room temperature 
in the dark. This step prevents the disulfide bonds from reforming by the covalent binding 
of a thiol group to cysteine residues. The solution was aspirated and the gel pieces 
dehydrated with ACN for 15 minutes at 37 oC. Trypsin (0.25 µg) was added to the gel pieces 
and the sample incubated at 37 oC for 16 hours. The digestion was stopped with formic acid 
(final concentration 1 % v/v). 
2.17 In-solution digestion 
Protein samples were incubated with RapiGest SF surfactant (Waters Corporation, Milford 
MA) at a final concentration of 0.05 % (w/v) in 25 mM ammonium bicarbonate for 10 
minutes at 80 oC. Samples were then incubated with DTT (3 mM, final concentration) for 10 
minutes at 60 oC to reduce disulfide bonds followed by alkylation with iodoacetamide (9 
mM, final concentration) for 30 minutes in the dark, at room temperature. The protease, 
trypsin (diluted in 50 mM acetic acid),) Glu-C (diluted in 50 mM ammonium bicarbonate) or 
Lys-C (diluted in 50 mM ammonium bicarbonate) was added to the sample and incubated 
at 37 oC for 16 hours. The digest was treated with trifluoroacetic acid (TFA, final 
concentration 0.5 % v/v) and incubated at 37 oC for 45 minutes to remove the RapiGest™ SF 
Surfactant. The digested samples were centrifuged at 12000 rpm for 15 minutes. 
2.18 Filter-aided sample preparation (FASP) digestion 
Spin filters with a 10 kDa molecular weight cut off (Vivacon® 500, Sartorius Stedim Biotech, 
Germany) were washed with 300 µL 1% (v/v) formic acid by centrifugation for 15 minutes 
at 12500 rpm to remove any contaminants. Samples were loaded onto the filters and 
washed twice by centrifugation at 12500 rpm for 15 minutes using 500 µL of wash solution 
(0.05 % (v/v) RapiGest™(Waters, Manchester) in 25 mM ammonium bicarbonate). The 
samples were concentrated to approximately 50 µL and incubated for 15 minutes at 80 oC. 
DTT was then added to each sample (final concentration of 5 mM) and incubated at 60 oC 
for 15 minutes followed by the addition of iodoacetamide (final concentration of 5.5 mM) 
and incubation at room temperature in the dark for 30 minutes. The samples were then 
centrifuged at 12500 g rpm for 5 minutes to remove the above solutions and the filtrate 
discarded. Samples were digested overnight (approx. 16 h) at 37 oC using 1 µg sequencing 
grade trypsin (Sigma, Poole, UK, proteomics grade). Peptides were collected by 
centrifugation at 12500 g rpm for 10 minutes. The filters were washed twice with 20 µl 
wash solution by centrifugation at 12500 g rpm for 10 min. The samples were acidified with 




2.19 Native protein digestion 
Darcin or darcin [C78S, C171S] v 2.0 and pepsinogen Adhiron A4 or pepsinogen Adhiron 
[A4_K_R] were incubated with trypsin at 37 oC in ammonium bicarbonate or chymotrypsin 
at 25 oC in 100 mM Tris-HCl, 10 mM CaCl2 respectively (ratio 20:1, sample:protease). During 
the reaction, a volume equivalent to 5 µg of starting protein was removed and split in two 
for intact mass and SDS-PAGE analysis. Proteolysis was stopped by the addition of 10 % 
(w/v) TCA and neutralised with ammonium bicarbonate for SDS-PAGE or by 1 % (v/v) formic 
acid for intact mass spectrometry. 
2.20 MALDI-TOF mass spectrometry using Bruker UltrafleXtreme™ 
Peptide mixtures were spotted onto a target plate and mixed with an equal volume of 
MALDI matrix (saturated solution of α-cyano-4-hydroxycinnaminic acid in 50 % (v/v) 
ACN/0.2 % (v/v) TFA) and left to dry. Data was acquired in reflectron mode using a laser 
energy of approximately 32 % of maximum, a laser frequency of 1000 Hz over 800 – 4000 
m/z range. The data was analysed using Bruker FlexAnalysis software and a peak list 
generated for peptide mass fingerprinting.  
2.21 Electrospray ionisation mass spectrometry (ESI-MS) of intact proteins 
Before loading onto the mass spectrometer, samples containing glycerol were desalted 
offline using a C4 desalting trap (Waters, Manchester, UK) and diluted to 1 pmol/µL in 0.1 % 
(v/v) formic acid, 5 % (v/v) ACN in HPLC grade water. The samples were loaded onto a C4 
desalting trap (Waters Mass PREP™ Micro desalting column, 2.1 x 5 mm, 20 µm particle 
size, 1000 Å pore size) (Waters, Manchester, UK) connected to a Waters nano ACQUITY 
Ultra Performance liquid chromatography® (UPLC®) system. The UPLC® system was coupled 
to a Waters SYNAPT™ G2 QTof mass spectrometer fitted with an electrospray source. 
Protein was eluted using solvent A and solvent B over 10 minutes using a gradient of 5 % to 
95 % solvent B at 40 µL/minute (Solvent A was HPLC grade water with 0.1 % (v/v) formic 
acid and solvent B was HPLC grade ACN  with 0.1 % (v/v) formic acid). Data was acquired 
over 500 – 3500 m/z range. Data processing was performing using maximum entropy 
deconvolution (MAX ENT 1, Mass Lynx version 4.1, Waters). Prior to sample analysis, the 






2.22 Liquid chromatography tandem mass spectrometry (LC-MS/MS) 
Q Exactive™ Orbitrap™ mass spectrometer 
Samples were loaded onto a trap column (PepMap 100 C18, Thermo Scientific) for 7 
minutes with loading buffer (98 % water, 2 % acetonitrile and 0.1 % TFA) at a flow rate of 9 
µL/min. Peptides were separated using a reversed-phase C18 analytical column (Easy-Spray 
PepMap C18 column, Thermo Scientific, 75 µm internal diameter, 500 mm length, 2 µm 
particle size) connected to an Ultimate 3000 RSLC™ nano system (Thermo Scientific). The 
initial gradient conditions were 96.7% mobile phase A (0.1 % formic acid) 3.8 % mobile 
phase B (80 % ACN, 20 % water and 0.1 % formic acid) and over 10 minutes went to 50 % 
mobile phase A, 50 % mobile phase B. Modifications to the gradient time are noted in the 
relevant results sections. The column temperature was 25 oC and the gradient was 
operated at a flow rate of 0.3 µL/min.  Eluted peptides were analysed using a QExactive™ 
mass spectrometer (Thermo Scientific) operating in data dependent acquisition (DDA) 
positive ESI mode. The capillary voltage was set to 2.2 eV with a capillary temperature of 
250 oC. A MS full scan range of 300 to 2000 m/z was selected with a resolution of 70,000, a 
maximum fill time of 200 ms and an AGC value of 1e6. The top 10 most abundant peaks 
were selected for MS/MS fragmentation by collision induced dissociation (CID) with a 
normalised collision energy of 28 %. The MS/MS scans were performed at a resolution of 
35,000, a maximum fill time of 100 ms, an AGC value of 1e5 and an isolation window of 3 
m/z.  
 
Q Exactive™  HFHybrid Quadrupole-Orbitrap™ mass spectrometer 
Samples were loaded onto a trap column (PepMap 100 C18, Thermo Scientific) for 7 
minutes with loading buffer (98 % water, 2 % acetonitrile and 0.1 % TFA) at a flow rate of 9 
µL/min. Peptides were separated using a reversed-phase C18 analytical column (Easy-Spray 
PepMap C18 column, Thermo Scientific, 75 µm internal diameter, 500 mm length, 2 µm 
particle size) connected to an Ultimate 3000 RSLC™ nano system (Thermo Scientific). The 
initial gradient conditions were 96.7 % mobile phase A (0.1 % formic acid) 3.8 % mobile 
phase B (80 % ACN, 20 % water and 0.1 % formic acid) and over 10 minutes went to 50 % 
mobile phase A, 50 % mobile phase B. Modifications to the gradient time are noted in the 
relevant results sections. The column temperature was 25 oC and the gradient was 
operated at a flow rate of 0.3 µL/min.  Eluted peptides were analysed using a QExactive™ 




positive ESI mode. The capillary voltage was set to 2.2 eV with a capillary temperature of 
250 oC. A MS full scan range of 350 to 2000 m/z was selected with a resolution of 60,000, a 
maximum fill time of 100 ms and an AGC value of 3e6. The top 16 most abundant peaks 
were selected for MS/MS fragmentation by collision induced dissociation (CID) with a 
normalised collision energy of 30 %. The MS/MS scans were performed at a resolution of 
30,000, a maximum fill time of 45 ms, an AGC value of 1e5 and an isolation window of 2 
m/z.  
2.23 Ion mobility-MS (IM-MS) and collision induced unfolding (CIU) 
IM-MS analysis was carried out using a Waters Synapt G2-Si mass spectrometer (Waters, 
Manchester). Prior to analysis, proteins were buffer exchanged into 500 mM ammonium 
acetate using Amicon spin filter columns (3 kDa molecular cut-off) and diluted to 5 
pmol/µL. Approximately 1 – 3 µl of sample was analysed. The spray voltage was set at 3 kV 
and the sampling cone 50 V. A single charge state was isolated in the quadrupole and was 
subjected to collisional activation. The activation voltage increased from 10 V to 26 V in 2 V 
increments. The IM wave height was 30 V and the wave velocity was 650 m/s. The data was 
processed using MassLynx v4.1 (Waters, Manchester) and the data exported to generate a 
plot using OriginPro 9.0.  
2.24 Data analysis 
Label-free protein quantification using Progenesis QI 
Protein quantification was performed using Progenesis QI software v2.0 (Waters 
Corporation, Milford, MA). A merged peak list was generated and searched against a 
database as described in the results, using MASCOT search engine. Proteins with similar 
peptides were grouped into families and only unique peptides were used for quantification. 
The criteria used to determine differential expression is outlined in results. 
Proteome Discoverer database searching 
Peak lists were generated by Proteome Discoverer 2.0 (Thermo Scientific) using default 
parameters. The peak lists acquired were searched against a database as stated in the 
results using MASCOT as the search engine (Matrix science, Inc.). The following criteria 
were applied to the database search: carbamidomethylation of cysteine as a fixed 
modification, oxidation of methionine as a variable modification, precursor mass tolerance 





PEAKS database searching 
For identification of Adhiron PTMs, data was searched using PEAKS software 
(Bioinformatics Solutions Inc, Canada) and searched against a custom naive Affimer 
database. The following criteria were applied to the database search: 
carbamidomethylation of cysteine as a fixed modification, oxidation of methionine as a 
variable modification, precursor mass tolerance of 10 ppm, fragment ion mass tolerance of 
0.01 Da, a maximum of one missed cleavages and fragmentation type was set to higher-





Chapter 3: Approaches and Challenges of Affimer Immobilisation for 
Affinity Purification 
3.1 Introduction 
The enrichment or purification of proteins is common practice in biological research with 
immunoaffinity chromatography the most common approach chosen. The general 
principles rely on an affinity reagent immobilised to a solid support (the stationary phase) 
and a solution containing the target molecule (the mobile phase). The solid support is 
necessary in order to isolate the target proteins from the remaining sample following 
capture. Typically, immunoaffinity purification methods rely on the use of antibodies as the 
capture reagent however the principles can be applied to use Affimers as the capture 
reagent. The general approach of an affinity purification workflow involves four main steps. 
1) The immobilisation of the capture reagent onto a solid support through specific 
coupling chemistry. 
2) Incubation of the sample with the affinity reagent for target enrichment. 
3) Removal of non-specific proteins by washing with suitable buffers that still maintain 
the interaction between the affinity reagent and its target. 
4) The elution of target proteins using buffers to disrupt the interaction between the 
affinity reagent and its target. 
The immobilisation of affinity reagents onto solid supports can be performed using various 
methods and chemistries including covalent bonding through different functional groups on 
the protein or through non-covalent interactions. Immobilisation of proteins through the 
primary amine groups is a very common technique, with many solid supports available for 
immobilisation. However, the specific orientation of the molecule cannot be defined. 
Primary amines are located in the side chain of lysine residues and sometimes the N-
terminus of each protein. Immobilisation through lysine residues is not the preferred 
method as it could prevent accessibility to the variable loop regions on the Affimer, 
hindering the capture of protein targets. The engineering of specific regions for coupling 
chemistry into the capture reagent structure is the ideal solution. For purification of 
Affimers following E.coli expression, a His-tag had been included in the protein design 
which facilitates immobilised-metal ion chromatography (IMAC) purification. Another 
functional group that is frequently used for immobilisation of affinity reagents is the 




typical have an important role in protein structure and stability, forming disulfide bonds. 
Characteristically, Affimers do not contain cysteine residues in the scaffold sequence as 
disulfide bonds are not required for the protein to maintain its structure. However, the 
addition of a single cysteine residue into the protein sequence allows for the specific 
orientation of the Affimers. It is essential that the Affimers are in a reduced form to allow 
for immobilisation as when in solution, the Affimers can form disulfide linked dimers. The 
immobilisation techniques, based on his-tag, sulfhydryl chemistry and streptavidin-biotin 
interaction are explored in is chapter. 
His-tag Affinity Purification 
As mentioned above, the addition a His-tag is common in recombinant protein production 
to allow for the relatively simple purification of proteins for other cellular components. A 
His-tag, comprising usually of 6 histidine residues is added to the N- or C- terminus of the 
protein. Due to the relatively small size of the tag, no detrimental effects on protein folding 
or function are usually observed. The interaction between the imidazole group in the side 
chain of histidine residues and transition metal ions (such as Zn2+, Cu2+ and Ni2+) has been 
exploited to allow for the purification of His-tagged proteins IMAC (Figure 3.1). The method 
was first described for protein purification in 1975 using iminodiacetic acid202. In 1987, 
nitilotriacetic acid (NTA) was described as an improved method for the purification of His-
tagged proteins203, by increasing protein yield and improving purity due to the increased 
strength of the interaction between the acid and the metal ions. 
 
Various solid supports are available for His-tag purification but in this study Ni-NTA 
magnetic agarose beads were used. The use of agarose beads for protein purification was 
first described in 1970204 and is commonly used as a solid supports as they are easily 
functionalised for protein binding. Magnetic bead technology allows for small scale affinity 
purifications in tubes by using a magnet to separate the beads from the sample. Elution of 






Figure 3.1 | Interaction between Ni-NTA and histidine residues of the 6XHis-tag. 
A coordination complex is formed between nickel bound to NTA (red) and two adjacent 
histidine residues (blue) of the recombinant protein. The protein bound via the His-tag can 
be removed with imidazole through competitive elution. Image from Qiagen. 
 
Streptavidin-Biotin Interaction and Mass Spectrometic Immunoassay (MSIA) 
The MSIA approach was first described by Nelson et al. in 1995 and involves the 
immobilisation of antibodies to resin contained within a pipette tip96. When attached to an 
automated pipette, the technique enables small scale, reproducible and rapid affinity 
purifications to be undertaken eliminating much of the manual handling steps involved 
when compared to a traditional affinity purification workflow. MSIA affinity pipette tips are 
available from Thermo Scientific and offer various binding chemistry in the tips. The most 
suitable binding chemistry to immobilise the Affimers to the tips is based on streptavidin-
biotin chemistry. The tips are coated with streptavidin and bind the capture protein 
through a biotin molecule. As the Affimers can be engineered to contain a single cysteine 
residue, defined orientation of immobilisation can be achieved through specific cysteine 
biotinylation. Proteins can be readily functionalised with biotin through a simple reaction 
with various functional groups on proteins. Due to the high reactivity of maleimide groups 
with sulfhydryls, biotin functionalised with maleimide will be used in this study (Figure 3.2). 
Streptavidin is a tetramer and has four binding sites for biotin205 (Figure 3.2). The 
interactions between streptavidin and biotin include hydrogen bonding, van der Waals 
forces and hydrophobic interactions206. Although the streptavidin-biotin interaction is non-
covalent, the affinity of streptavidin for biotin is extremely high with a Kd = 10
-14 to 10 -15 M). 
This is an advantage over the his-tag interaction as more stringent washes can be applied 





Figure 3.2 | Reaction for biotinylation of cysteine terminated proteins with maleimide-
PEG11- biotin and the streptavidin-biotin interaction. 
Maleimide groups react with reduced sufhydryl groups forming a thioether bond. 
Biotinylated proteins form strong non-covalent bonds with streptavidin. Image adapted 
from Thermo Scientfic. 
 
Pyridyl disulfide-activated magnetic beads 
Another immobilisation chemistry that utilises the cysteine residue of the Affimer is the 
interaction between pyridyl disulfide and sulfhydryl groups (Figure 3.3). Following the 
reaction, proteins are covalently coupled to the support forming a disulfide bond that can 
be cleaved upon the addition of a reducing agent such as DTT. As the proteins are 
covalently coupled to the beads, stringent wash buffers can be used to remove non-specific 
binding whilst retaining the affinity reagent. 
 
Figure 3.3 | Reaction for the immobilisation of cysteine terminated proteins to pyridyl 
disulfide-activated magnetic beads. 
The pyridyl disulfide functional groups are immobilised onto magnetic agarose beads via a 
12-atom spacer. The reduced sulfhydryl groups of cysteine residues on proteins react with 





The final immobilisation chemistry explored within this chapter again utilise the cysteine 
residue for covalent Affimer immobilisation. Iodoacetyl groups react with sulfhydryl groups 
forming an irreversible covalent thioether bond (Figure 3.4). A commercially available 
product with iodoacetyl groups is the Thermo Scientific SulfoLink® coupling resin. The 
SulfoLink® coupling resin is typically used in a column format where antibodies are bound 
to the resin for affinity purification of specific protein targets. As MS can permit low 
amounts of protein material (low µg), small scale purification can be performed eliminating 
the need to use columns. The functional groups on the resin can be blocked with free 
cysteine which will not interfere with downstream MS analysis. 
 
Figure 3.4 | Reaction for the immobilisation of cysteine terminated proteins to 
Iodoacetyl-activated resin. 
The iodacetyl groups are immobilised onto agarose resin via a 12-atom spacer to help 
reduce steric hindrance. The reduced sulfhydryl groups of cysteine residues in peptides and 
proteins react with the iodoacetyl groups forming an irreversible covalent thioether bond. 
Image from Thermo Scientific.   
 
Naïve Affimer Analysis 
As discussed in Chapter 1, a common approach to protein biomarker discovery involves 
comparative mass spectrometry analysis of patient samples against healthy controls to 
identify differentially expressed proteins. A limitation of MS based approaches is the depth 
of proteome coverage achieved due to the large dynamic range of biological samples, 




affinity reagents to enrich for low abundance proteins whose detection may be masked by 
highly abundant proteins in typical MS methods. Antibody array technology is explained 
further in Chapter 1 and as discussed, is typically a targeted approach to biomarker 
identification due to the immobilisation of antibodies with known protein targets. 
However, non-targeted approaches have been used with combinatorial antibodies as the 
capture reagent providing an unbiased approach to protein enrichment and analysis207. 
Affimer microarray technology has been described for the enrichment of cyclin dependent 
protein kinases208. A naïve Affimer discovery array is similar to antibody array however, 
naïve Affimers containing randomised unknown variable loop regions are immobilised onto 
an array192. Comparative analysis in binding of proteins to Affimers between control and 
disease samples is performed to reveal naïve Affimers that enrich for protein in a particular 
sample type. Identification of the naive Affimer target by mass spectrometry will reveal 
proteins that have an increased expression in either the control or disease samples and 
thus identify a protein biomarker. The naïve Affimer array work was carried out by 
colleagues at Avacta Life Sciences. The need for biomarkers of sepsis is discussed further in 
Chapter 5 and was therefore selected for naive Affimer array interrogation. 
 
3.2 Aims and Objectives 
The work in this chapter will focus on the development of an affinity purification workflow 
to capture, enrich and identify naive Affimer targets. The key aims were to: 
- Optimise the His-tag magnetic bead affinity purification workflow and apply the 
protocol to the analysis of naïve Affimer. 
- Develop the pyridyl disulfide-activated magnetic bead affinity purification.  
- Assess the suitability of the MSIA approach for Affimer affinity purification. 
- Develop the SulfoLink® resin affinity purification workflow and apply the optimised 
method to the analysis of naïve Affimers with subsequent target identification 





3.3 Results and Discussion 
3.3.1 His-tag Experiments 
The work in this chapter was performed in collaboration with Kit-Yee Tan and Vincent 
Puard from Avacta Life Sciences as part of the industrial experience element of CASE. The 
general workflow for a His-tag affinity purification is outlined in Figure 3.5 and indicates the 
various steps that required optimisation.  
The beads selected for use in this study were the Qiagen Ni-NTA magnetic agarose beads. 
Other magnetic beads using nickel ion chromatography were assessed, but greater 
background binding of proteins was observed (data not shown). Based on the 
manufacturers guidelines, the binding capacity of the beads was stated as 20 µg per 10 µL 
bead suspension. However as steric hindrance could interfere with Affimer immobilisation 
by blocking the nickel sites from the His-tag, the binding capacity stated may not be 
accurate. Furthermore, if the full binding capacity of the His-tag beads was not achieved, 
then free sites of the beads may be exposed. This may cause an increase in non-specific 
binding. Therefore, it was vital to confirm that the beads were fully saturated with Affimer.  
To assess the binding capacity of the beads, a titration experiment, increasing the amounts 
of Affimer incubated with the beads was performed following the His-tag immobilisation 
protocol described in Chapter 2.12. The binding titration was performed using 10 µL of 
bead slurry to ensure accuracy in pipetting. Preliminary experiments established that using 
less than 10 µL resulted in bead loss and inconsistencies in the amount of beads retained 
following the washing protocol. As the beads did not bind the Affimer with a covalent bond, 
incubation with sample buffer would release the Afimer from the beads. Therefore, 
samples were analysed by SDS-PAGE by loading the bead-Affimer solution directly into the 
wells of the gel (Figure 3.6). At approximately 14 kDa, the expected molecular weight of the 
Affimer, a band is visible across the gel decreasing in intensity from 20 µg to 1 µg of Affimer 
used in the titration. The amount of Affimer appears to reach a saturation point as no 
difference in band intensity is observed from 20 µg up to 30 µg Affimer. A band is present 
at approximately 6 kDa which is likely to correspond to a degradation product or 
contaminant retained following purification. Based on these findings 20 µg of Affimer per 
10 µL bead slurry was selected as the binding capacity of the beads. 
Due to the large number of optimisation experiments performed, the details of the key 







Figure 3.5 | General approach for a His-tag Affimer affinity purification workflow. 
Affimers are bound to nickel coated magnetic beads through the His-tag. The beads are blocked to reduce non-specific binding and then incubated with 
sample to allow for the Affimers to capture target protein. The beads are then washed to remove non-specific binding. Protein targets can be eluted from 







Figure 3.6 | SDS-PAGE analysis of His-tag magnetic bead binding capacity.  
10 µL Ni-NTA magnetic agarose beads were incubated with different amounts of Affimer (1 
µg to 30 µg) to establish the bead binding capacity. NB corresponds to beads with no 
Affimer bound. Beads were loaded directly onto the gel. Samples were analysed using a 4 – 








Table 3.1 | Summary of His-tag magnetic bead optimisation steps. 
Analysis carried out in collaboration with Avacta Life Sciences. 
Optimisation Step Aim Details Result 
Binding capacity of beads 
To determine the binding capacity of 
10 µL of Ni-NTA magnetic beads for 
Affimer. 
As described above. 20 µg Affimer per 10 µL bead slurry. 
Blocking buffer and time 
To determine if blocking the beads 
with different buffers post Affimer 
incubation reduced the amount of 
non-specific binding for serum 
proteins. 
Comparison of non-specific background from 
serum proteins with beads blocked with casein + 
0.5 %, 1 % or 3 % BSA incubated for 1 hour or 
overnight. 
Casein + 0.5% BSA in PBS-T for 1 
hour. 
Steric hindrance 
To assess if steric hindrance reduced 
the amount of target captured by 
the Affimer. 
Comparison between: 
Chicken IgY Affimer incubated with pure IgY 
target and then immobilised onto His-tag beads 
and; 
Chicken IgY Affimer immobilised onto His-tag 
beads and then incubated with pure IgY target. 
SDS-PAGE analysis revealed more 
target captured when Affimer was 
immobilised onto beads and then 
incubated with target. 
Elution 
To determine a suitable elution for 
removing target and retaining 
Affimer on beads. 
Elution buffer with 250 mM imidazole was used 
to elute the His-tag Affimer from the beads. 
As the elution did not remove all the 
protein from the beads, an on-bead 
digest was carried out. 
Digestion 
To determine the optimal digestion 
method. 
As tween wash added to the wash buffer to 
reduce non-specific binding, a method was 
needed to remove tween before LC-MS/MS 
analysis. In a FASP digest, the beads were loaded 
above the filter and washed extensively to with 
25 mM ammonium bicarbonate to remove 
contaminants. 






His-tag Ni-NTA magnetic bead affinity purification parameters: 
 Beads: Qiagen Ni-NTA magnetic beads. 
 Binding Capacity: 10 µl bead slurry binding 20 µg his-tagged protein (2 mg/mL 
Affimer solution). 
 Blocking solution: Casein + 0.5% BSA in PBS-T. 
 Sample: 10 mg serum incubated for 45 minutes. 
 Wash buffer: PBS-T, 20 mM imidazole, 50 mM NaCl. 
Initially 25 naïve Affimers His-tag affinity purification samples in human serum were 
analysed by SDS-PAGE and LC-MS/MS. On-bead digestion of the Affimer-target complex 
was performed and peptides analysed on the Thermo QExactive mass spectrometer. Both 
SDS-PAGE and LC-MS/MS analysis confirmed the positive control Affimer, CC3, bound its 
target, complement C3. However, due to common background of non-specific proteins, 
identification of naïve Affimer targets was problematic.  
Repeated analysis of the naïve Affimers was performed with each naive Affimer incubated 
with either control or sepsis serum so that a comparative analysis could be performed to 
reveal proteins that bind differentially in the different samples. The beads were divided in 
two and analysed by SDS-PAGE and LC-MS/MS. When comparing control sample and 
disease sample lanes for an individual Affimer by SDS-PAGE, subtle differences between 
protein bands was observed (Figure 3.7). For the positive control CC3 Affimer, bands were 
observed in the control and disease sample at approximately 176 kDa, the expected 
molecular weight of complement C3. The digested affinity purification samples were 
analysed on the Thermo Scientific QExactive mass spectrometer as described in Chapter 
2.22. Peptides for the Affimer were highly abundant and limited the loading of more 
material onto the instrument (Figure 3.7). To investigate quantitative differences in the 
proteins captured in the naïve Affimer affinity purifications, label-free protein 
quantification was performed using Progenesis QI (Waters Corporation). Proteins were 
normalised using the ‘normalise to all proteins method’ and samples grouped by naïve 
Affimer. The data was searched using MASCOT against a human and eSQT database. Due to 
the high sequence homology between the naïve Affimers and eSQT, the database only 
contained eSQT Affimer. A total of 81 proteins were identified and quantified using non-
conflicting peptides with a minimum of 2 peptides per protein. To investigate differences in 
protein abundances between the naïve Affimers, protein abundance values were log 10 




of the heat map represents highly abundant non-specific serum proteins that are 
consistently binding to the naïve Affimers. In addition, keratins were also identified as 
consistent background. Specific enrichment of proteins by the naïve Affimers was not 
observed. 
Extensive optimisation of the His-tag affinity purification approach was carried out as 
outlined in Table 3.1, however various factors prevented the identification of naïve Affimer 
targets. Each naive Affimer affinity purification was only performed in a single replicate. 
Therefore statistical analysis of the identified proteins could not be performed reducing the 









Figure 3.7 |SDS-PAGE analysis of naïve Affimer affinity purifications and representative 
BPI chromatogram of CC3 Affimer on-bead digest of his-tag affinity purification sample. 
Top: Representative SDS-PAGE analysis of 5 of the naïve Affimer comparative affinity 
purifications including the CC3F2 Affimer that targets complement C3. 10 µL of the bead 
slurry was loaded onto a 4 – 12 % gradient polyacrylamide gel and the protein bands were 
visualised using InstantBlue™ Coomassie stain. His-tagged Affimers were immobilised onto 
Ni-NTA magnetic beads B – blocked beads and Affimer, C – blocked beads, Affimer and 
control serum, D – blocked beads, Affimer and sepsis serum. Bottom: Representative BPI 
chromatograms of on-bead digest of CC3F3 affinity purification in control and disease 
serum. Red arrows indicate peaks corresponding to Affimer peptides. Affinity purification 







Figure 3.8 | Heatmap and hierarchical clustering of log 10-transformed protein abundance data for naïve Affimer affinity purifications. 
Protein abundance values were taken from Progenesis QI and log 10—transformed. Samples clustered on protein abundance with highly abundant proteins 
represented in red and less abundant proteins represented in blue. The red portion in the centre of the heatmap represents proteins that are identified as 




3.3.2 MSIA Experiments 
As discussed in Section 3.1, a MSIA affinity purification assay involves using biotinylated 
Affimers that have a high binding affinity to streptavidin which is contained with a tip. The 
MSIA tips are attached to an automated pipette that automatically passes solutions 
through the tips, allowing the reagents to bind to the affinity reagent coupled to the resin. 
The general workflow employed within this study is outlined in Figure 3.9. The MSIA 
method has been frequently used for the enrichment of low abundance proteins captured 
using antibodies from complex biological samples and subsequently detected with SRM 
based assays209 and top down analysis of intact proteins210. However, as the main 
application of this approach is to identify unknown binding partners of naïve Affimers, 
method development is required to determine if the approach can be applied in a discovery 
based format. 
 
Figure 3.9 | Outline of the general MSIA affinity purification workflow. 
The MSIA tips are loaded onto the automated pipette and all samples added to a 96-well 
microtitre plate for automated sample loading. Biotinylated Affimers are bound to the resin 
through streptavidin-biotin chemistry. The sample is then passed through the tip on a 
continuous cycle to allow for the Affimers to capture the target molecules. The tips are 
then washed to remove non-specific binding. The target protein in eluted from the Affimers 
for tryptic digestion and MS analysis. 
3.3.2.1 Analysis of biotinylation efficiency 
The Affimers used in this study were obtained from Avacta Life Sciences. To develop the 
method, Affimers with known, well characterised binding targets were used. In addition, 




protein scaffold that does not contain any peptide insertions within the variable loop 
regions. Although biotinylated Affimers were needed for the MSIA workflow, both 
unbiotinylated and biotinylated Affimers were obtained for confirmation of the correct 
protein product prior to biotinylation. To assess the purity of the proteins, Affimers were 
analysed by SDS-PAGE on a reducing gel (Figure 3.10). At approximately 14 kDa, a band was 
observed for the unbiotinylated version of eSQT Affimer which is the expected molecular 
weight of the protein. For biotinylated eSQT Affimer, a band was observed at approximately 
14 kDa and 16 kDa suggesting a heterogeneous population of Affimer comprised of both 
the biotinylated and non-biotinylated forms. Faint protein bands were observed at 
approximately 30 kDa in both eSQT Affimer samples corresponding to the dimer form of 
the Affimer. A doublet band at approximately 30 kDa and 31 kDa is visible in the 
biotinylated sample. Although the Affimers contain a single cysteine required for 
biotinylation, if the Affimers were biotinylated, the cysteine residues would not be available 
for disulfide linked dimerisation. Therefore, this suggests the Affimer dimers may be 
forming through domain swapped dimerisation211. This is discussed further is Chapter 4. 
Analysis of CC3 Affimer samples revealed similar results. A single band was observed at 
approximately 15 kDa for the unbiotinylated Affimer sample, corresponding to the 
expected molecular weight. For the biotinylated CC3 Affimer sample, two bands were 
observed at approximately 15 kDa and 16 kDa, again suggesting a heterogeneous 
population of both biotinylated and unbiotinylated versions of the Affimer. Protein bands at 
approximately 30 kDa were observed in both CC3 Affimer samples corresponding to the 
dimer form of the Affimer. SDS-PAGE analysis of the Affimer reagents revealed high purity 
and no contaminates (Figure 3.10).  
To confirm the Affimers had the expected molecular weight and to ensure an increased 
mass after biotinylation, the Affimers were analysed by intact mass spectrometry following 
the protocol described in Chapter 2.21. Furthermore, intact mass analysis of the Affimers 
would determine biotinylation efficiency. After deconvolution of the multiply charged 
protein envelope, the average mass of the Affimer was determined (Figure 3.11 and Table 
3.2). The mass adduct following biotinylation was + 922 Da. The predominant species in the 
mass spectrum for unbiotinylated CC3 Affimer was 13793.0 Da which corresponded to the 
theoretical molecular weight. An additional peak of plus 42 Da was also observed which 
was likely to correspond to acetylation. Two main species in the mass spectrum for 
biotinylated CC3 Affimer were observed at 13792.9 Da and 14715.0 Da, corresponding to 




SDS-PAGE analysis confirming that the biotinylation reaction was not 100 % efficient. The 
predominant species within the mass spectrum for unbiotinylated eSQT Affimer has a mass 
of 12000.7 Da which corresponded to the theoretical molecular weight of the Affimer. The 
main species in the biotinylated eSQT Affimer sample had a mass of 12922.7 Da 
corresponding to the expected molecular weight. A peak at 12000 Da was not observed. 
This result differs from SDS-PAGE findings as it suggests almost 100 % biotinylation 
efficiency. In addition, a peak was observed in both of the eSQT Affimer samples of 11869 
Da corresponding to the loss of 103 Da, consistent with the loss of the c-terminal cysteine. 
Biotinylation of this Affimer fraction could not take place which explains why the peak is 
also observed in the biotinylated Affimer sample. Both SDS-PAGE and intact mass results 
confirmed the Affimers are suitable for use in the MSIA workflow; however it was noted 
that it was necessary to use an excess of CC3 Affimer during the immobilisation step due to 
inefficiencies in biotinylation. 
Additional Affimers were also received for the MSIA optimisation. Intact mass analysis 
revealed they were unsuitable for coupling to the MSIA tips due to them lacking a C-
terminal cysteine residue meaning the Affimers could not undergo the biotinylation 
reaction. The Affimers provided would have allowed for recombinant protein to be spiked 
into samples for affinity purification optimisation. Due to the cost of recombinant human 
complement C3 it was not possible to purchase pure protein for optimisation. Therefore, all 
binding studies had to be performed using human plasma or serum which contained 





Figure 3.10 | SDS-PAGE analysis of eSQT and CC3 Affimers, pre and biotinyaltion. 
eSQT and CC3 Affimers (2 µg), pre and post biotinylation were analysed by SDS-PAGE under 
reducing conditions on a 15 % gel and visualised with Coomassie plus stain. A shift in 





Figure 3.11 | ESI-MS analysis of eSQT and CC3 Affimer pre and post biotinylation.  
Protein samples were diluted to 1 pmol/uL in 3% acetonitrile, 0.1% formic acid. A total of 
500 fmol and 4 pmol for eSQT Affimers and CC3 Affimers respectively, was loaded onto a C4 
desalting trapping column. The samples were analysed by ESI-MS on the waters G2 mass 
spectrometer. The multiply charged protein envelope was deconvoluted using Waters 







Table 3.2 | Comparison between theoretical and observed intact mass of Affimers. 
Theoretical mass of biotinylated Affimers corresponds to the addition of biotin (+ 922 Da). 
Affimer Theoretical Mass (Da) Observed Mass (Da) Difference (Da) Interpretation 
CC3 13792.5 13793.0 + 0.5 Expected mass observed 
Biotinylated CC3 14714.5 
13792.9 - 921.6 
Unbiotinylated CC3 Affimer present 
even after biotinylation 
14715.0 +0.5 
Expected mass observed 
~ 50 % biotinylation achieved 
eSQT 12000.5 12000.7 + 0.2 Expected mass observed 
Biotinylated eSQT 12922.5 12922.7 + 0.2 Expected mass observed 







3.3.3.2 Method development 
The method development work in this section was performed in collaboration with 
Kimberley Burrow, an Avacta Life Sciences and University of Liverpool employee. The first 
step in the method development process involved determining the binding capacity of a 
single MSIA tip. Each tip contains a total of 4 µg streptavidin which, based on a molecular 
weight of 57 kDa for streptavidin, is equivalent to 70 pmol per tip. A single streptavidin 
molecule (57 kDa) can bind 4 biotin molecules. Therefore, a maximum of 280 pmol of 
Affimer can bind to each tip which is the equivalent of 3.9 µg (based on an Affimer 
molecular weight of 14 kDa).  However, due to steric hindrance it is unlikely that the full 
binding capacity of 280 pmol of Affimer will be immobilised onto the tips. To assess the 
binding capacity of the tips, samples containing different amounts of Affimer ranging from 
2 µg to 20 µg were incubated with the tips and the unbound Affimer fraction analysed by 
SDS-PAGE to assess for depletion of Affimer (results not shown). The resin inside the tips 
was also removed and analysed by SDS-PAGE. The findings from 2 µg, 3 µg and 4 µg loading 
are evident in Figure 3.12.  A doublet band at approximately 15 kDa was observed for all 
samples of comparable intensity sharing a similar mobility to the control eSQT Affimer also 
analysed on the gel. This result suggested that a sufficient amount of Affimer was loaded 
onto the tips and that little difference was observed when increasing the amount to 4 µg of 
Affimer compared to 2 µg. However, a control tip that had no Affimer bound was also 
analysed and a single band at approximately 15 kDa was observed that matched the lower 
band in the tips where Affimer was bound. Streptavidin is a tetrameric protein and 
incubation with reducing sample buffer would results in the observation of the monomer 
by SDS-PAGE. This band was therefore likely to be streptavidin. Thus the fainter upper band 
in the tips where Affimer was added corresponded to Affimer. Analysis of tips with up to 20 
µg Affimer was added show comparable results to the 2 µg indicating that the binding 
capacity of the tips had been reached. This amount of Affimer was significantly less than 
that used in the His-tag affinity purifications. In addition, results from his-tag affinity 
purifications had demonstrated that the binding of Affimer to target was not a 1:1 ratio and 
therefore it was suggested that the amount of Affimer immobilised onto each tip was not 
enough for an enrichment to be observed. Despite this, enrichment of CC3 using CC3 








Figure 3.12 | SDS-PAGE analysis determining the binding capacity of the MSIA tips. 
After Affimer immobilisation, the resin was removed from the tips and incubated with 
sample buffer at 95 oC for 10 minutes. Each sample was analysed in duplicate as annotated 
by lanes A and B. A tip containing no Affimer, incubated only in PBS, was also analysed.    
Samples were analysed on a 15 % gel and the protein was visualised with Coomassie plus 
stain. SDS-PAGE analysis undertaken in association with collaborators, Kimberley Burrow 






To assess for protein enrichment with the CC3 Affimer and to determine the level of non-
specific background of proteins binding to the tips, the MSIA experiment was performed as 
described in Chapter 2.13 with human plasma and the tips and elution fractions analysed by 
SDS-PAGE. To achieve enrichment of complement c3 with the CC3 Affimer using the His-tag 
approach, 20 mg of serum protein was used for the affinity purification. As the volume of 
the well was limited, 4.5 mg of plasma protein was used for the MSIA purifications. The 
expected concentration of complement c3 in serum was approximately 60 – 150 mg/dL212. 
Included in the analysis were tips with no Affimer bound to assess background binding of 
plasma proteins and tips with only Affimer bound to ensure proteins bands could not be 
attributed to Affimer. After the elution step, the elution fraction was retained for SDS-PAGE 
analysis. To analyse the remaining protein bound to the tips, the resin inside the tips was 
removed and incubated with sample buffer for 10 minutes at 95 OC.  
SDS-PAGE analysis revealed no differences were observed in protein bands in both the 
elution fractions and destroyed tips between the MSIA tips with Affimer bound and those 
without Affimer following exposure to human plasma (Figure 3.13). This would suggest that 
the Affimers are not providing an enrichment of the protein target, complement C3. The 
low amount of Affimer immobilised onto the tips and the high level of background binding 
could explain this result. 
To further assess protein enrichment in plasma using the Affimer MSIA method, 
comparative analysis of the proteins identified with eSQT or CC3 Affimer bound to the tips 
was performed. The MSIA experiment was performed as described in Chapter 2.13 and the 
elution fraction and tips digested for LC-MS/MS analysis. The resin was digested to analyse 
non-specifically bound proteins. Peptides were analysed on the Thermo Scientific QExactive 
mass spectrometer on a 30 minute gradient as described in Chapter 2.22. To investigate 
any enrichment of complement C3 with the CC3 Affimer compared to the eSQT Affimer, 
label-free protein quantification data was obtained using Progenesis QI (Waters 
Corporation). Retention time alignment was performed with sample eSQT Affimer Elution 
replicate 2 selected as the alignment file. Alignment scores achieved 90 % or greater 
indicating similarities in the retention time profiles between the samples. Proteins were 
normalised using the ‘normalise to all proteins method’ and scores for all but one samples 
were with a log factor of 0.3. The data was searched using MASCOT against a human and 
eSQT database. Due to the high sequence homology between eSQT and CC3, the database 
only contained eSQT Affimer. A total of 52 proteins were identified and quantified using 




differences in protein abundances and to asses for enrichment of complement C3 with the 
CC3 Affimer, protein abundance values were log 10 transformed and analysed by 
hierarchical clustering (Figure 3.14). Separation between the tip and elution samples was 
observed with the samples clustering together although within the two groups samples 
from the same Affimers did not cluster together. This suggests little difference in the 
proteins identified and their abundances. The high number of proteins identified 
demonstrates a consistent non-specific background binding to the tips. Abundance values 
for complement C3 were examined further (Figure 5.14) and little difference was observed 
between the CC3 Affimer samples and eSQT Affimer samples.  The high levels of non-
specific binding and the small amount of Affimer bound to the tips could explain this result. 
Various other more stringent wash buffers were tried including PBS (range pH 6.6, 7.2 and 
9.1), ammonium acetate pH4 and Tris-HCl pH 8 however the same level of non-specific 
background was observed. As enrichment of complement C3 was not observed with CC3 
Affimer, the MSIA protocol was not developed further. The CC3 Affimer binds its target 
with high affinity whereas the naïve Affimers bind their target with a weak affinity. Because 
of this, along with the high amount of non-specific background binding it was hypothesised 
that identification of naïve Affimer targets would not be achievable. Although the method 
has numerous benefits due to the high level of automation, the MSIA method may be more 
suitable with capture reagents that have high binding affinities to their target where 







Figure 3.13 | SDS-PAGE analysis of MSIA CC3 Affimer affinity purification. 
The CC3 Affimer that targets complement C3 was bound to tips and incubated with human 
plasma. Bottom: Protein was eluted using 33 % acetonitrile, 0.1 % formic acid. Top: The 
resin was removed from the tips and incubated with sample buffer at 95 oC for 10 minutes 
before SDS-PAGE analysis. Non-specific background from plasma proteins observed. 







Figure 3.14 | Heatmap with hierarchical clustering of log 10-transformed protein 
abundance data for MSIA CC3 Affimer and eSQT affinity purification and abundance data 
for complement C3. 
Top: Protein abundance values were taken from Progenesis QI and log 1—transformed. 
Samples clustered on protein abundance with highly abundant proteins represented in red 
and less abundant proteins represented in blue. Bottom: Normalised abundance data for 





3.3.3 Pyridyl disulfide-activated magnetic beads  
The method development in this section was carried out using pepsinogen Adhirons due to 
the lack of availability of other Affimers containing a single cysteine residue. Further 
information and characterisation of these Adhirons is provided in Chapter 4. A key benefit 
of the pyridyl disulfide based binding chemistry is that the Affimers can be covalently 
immobilised onto the beads and as a disulfide bond is formed, the immobilisation is 
reversible. This would allow for a two-step elution procedure, first by eluting the target 
from the Affimer and then removing the Affimer from the beads by adding a reducing agent 
such as DTT to the buffer. This may be of value if sequencing information of naïve Affimers 
was not available. The general workflow employed for pyridyl disulfide-activated magnetic 
beads is very similar to the His-tag affinity purification approach outlined in Figure 3.5.  
As with the other methods, the first step was to determine the binding capacity of the 
beads. Based on manufacturer’s guidelines, 10 µL of a 10 % bead suspension binds 15 µg of 
protein. However, as the molecular weight of the protein the calculations were based on 
was not stated, then the binding capacity of the beads for the Adhirons could differ.  Thus, 
the binding capacity of the beads was assessed with five different protein amounts ranging 
from 5 µg to 30 µg. Adhirons were immobilised onto the magnetic beads as described in 
Chapter 2.14 and incubated for 1 hour. The unbound fraction was removed from the beads 
and retained for analysis. The beads were washed twice with PBS pH7.4 to remove non-
specific binding and retained for analysis. The beads, unbound fraction and washes were 
analysed by SDS-PAGE (Figure 3.15, Top). As discussed in chapter 4, the pepsinogen 
Adhirons ran on the gel as monomers and dimers and as higher order species. An increase 
in the intensity of the Adhiron bands was not observed after 10 µg suggesting that the 
binding capacity had been reached. However, a large portion of the Adhiron was observed 
in the unbound fraction for all samples regardless of the amount of Affimer used. This may 
have suggested incomplete binding of the Adhiron to the beads. No Adhiron was observed 
in the wash fractions indicating no/low levels of non-specific binding of the Affimer to the 
magnetic beads. Non-specific binding instead of covalent immobilisation of the Adhiron to 
the beads may result in Adhirons in an undesirable orientation for target capture and 
leaching of the Adhiron off the beads during sample incubation and thus this finding was 
preferred. Results for 20 µg and 30 µg Adhiron are not shown as similar results were 
observed to the 15 µg sample. These findings indicated that the binding capacity of the 




To determine the optimal incubation time for Adhiron immobilisation onto the beads, a 
binding time-course was carried out following the method described in Chapter 2.14  The 
beads were incubated with 10 µg Adhiron for either 1 hour, 2 hours, 3 hours or overnight to 
determine if increasing the incubation time resulted in more Affimer immobilised onto the 
beads. Following incubation, the beads were separated from the unbound Affimer fraction 
(labelled UF) using a magnet and washed twice to remove non-specifically bound Affimer. 
Samples were analysed by SDS-PAGE and the beads were loaded directly onto the gel 
(Figure 3.15, Bottom). The sample buffer contained DTT to break the disulfide bond 
between the Affimer and the pyridyl disulfide functional group on the magnetic beads and 
therefore the Adhirons were eluted off the beads and observed by SDS-PAGE. SDS-PAGE 
results indicate that increasing the incubation time did not result in more Adhiron 
immobilised onto the beads as the bands observed representing Adhiron were of similar 
intensity for all incubation times.   
After confirming immobilisation of the Adhiron, enrichment of the Adhirons target was 
assessed following the initial protocol described in Chapter 2.14.  The five different 
pepsinogen Adhirons were immobilised onto beads and incubated with 2 µg of pepsinogen 
in PBS pH 7.4. Beads were washed with wash buffer (0.5 M NaCl, PBS pH 7.4) to remove 
non-specific binding. The bead-Affimer-target complex, unbound pepsinogen fraction and 
washes were analysed by SDS-PAGE to assess for pepsinogen enrichment. Beads with no 
Affimer were also analysed to investigate non-specific binding of pepsinogen to beads. 
Representative SDS-PAGE analysis for pepsinogen Adhiron C2 and beads with no Affimer is 
shown in Figure 3.16. At approximately 14 kDa, a band was observed in the pepsinogen 
Adhiron bead lane confirming the Adhiron was immobilised onto the beads. A band was 
also observed at approximately 47 kDa, the expected molecular weight of pepsinogen 
suggesting capture of the target. However, a band was also observed at 47 kDa for the bead 
only control suggesting pepsinogen had bound non-specifically to the beads. Therefore, it 
could not be confirmed if the Adhirons were enriching for pepsinogen or if the pepsinogen 
was binding non-specifically to the beads.  
Further optimisation was performed to reduce the non-specific binding of pepsinogen to 
the beads. Enrichment of pepsinogen was performed in a phosphate buffer containing 
increasing sodium chloride concentrations (250 mM & 500 mM) to assess whether 
increasing the ionic strength of the buffer would reduce non-specific binding to the resin. 
However, a decrease in non-specific binding was not observed. In addition, various wash 




The buffers investigated included PBS pH 6.8, 7.2 and 8.4 and PBS pH 7.4 with 0.5 M or 0.75 
M sodium chloride. A reduction in non-specific binding of pepsinogen was not observed.  As 
non-specific binding of the Affimer target could not be reduced, further optimisation of this 









Figure 3.15 | SDS-PAGE analysis of pyridyl disulfide-activated magnetic beads binding 
capacity and incubation time. 
Beads, unbound fraction (UF) and washes analysed by SDS-PAGE. Top: 5 µg, 10 µg or 15 µg 
of pepsinogen Adhiron A4 was incubated with 10 µL beads (10% suspension) and incubated 
for 1 hour to immobilise. Binding capacity of the beads was 10 µg Adhiron. Bottom: 10 µg 
of pepsinogen Adhiron A4 were immobilised onto 10 µL beads (10% suspension) and 
incubated for either 1 hour, 2 hours, 3 hours or overnight (O/N). Samples were analysed on 





Figure 3.16 | SDS-PAGE analysis of pepsinogen Adhiron pyridyl disulfide-activated beads 
affinity purification of human pepsinogen. 
Top: Pepsinogen Adhiron C2 (10 µg) was immobilised  on 10 µL of pyridyl disulfide magnetic 
beads (10 % suspension) and incubated with 2 µg pepsinogen in 50 µL PBS pH 7.4. Bottom: 
Bead only control was also analysed to assess non-specific binding of pepsinogen to the 





3.3.4 SulfoLink® resin 
The final immobilisation technique assessed in this chapter is SulfoLink® resin and this work 
was performed in collaboration with Avacta Life Sciences by Kimberley Burrow. As 
discussed in section 3.3.1, the Thermo Scientific SulfoLink® resin is coated with iodoacteyl 
groups to enable binding of proteins through free cysteine residues. Therefore, the 
Affimers required a single free cysteine engineered into their protein structure. The general 
outline of the affinity purification workflow is the same as that described in Figure 3.5. 
However, as the resin is not magnetic, the particles were separated from solution by 
centrifugation. 
3.3.4.1 Quality Control Check of Affimers 
The Affimers used in this study were obtained from Avacta Life Sciences. To assess the 
purity of the Affimer and to confirm full length protein expression samples were analysed 
by SDS-PAGE and by intact mass spectrometry (Figure 3.17). SDS-PAGE results confirm high 
purity of the IgG Affimer with a single band observed at approximately 14 kDa, the 
expected molecular weight of the Affimer. After deconvolution of the multiply charged 
protein envelope, the average mass of the Affimer was determined (Figure 3.17).  The 
predominant species in the mass spectrum for was 12840.6 Da which corresponded to the 
theoretical molecular weight minus the initiating methionine. An additional mass of + 42 Da 
was also observed which is likely to correspond to acetylation (investigated in Figure 3.26). 








Figure 3.17 | SDS-PAGE and ESI-MS analysis of IgG Affimer. 
Left: A total of 2 µg of human IgG Affimer was analysed on a 15 % gel under reducing 
conditions and visualised with Coomassie plus stain. Right: Protein samples were diluted to 
1 pmol/uL in 3 % acetonitrile, 0.1 % formic acid. A total of 4 pmol of Affimer was loaded 
onto a C4 desalting trapping column. The sample was analysed by ESI-MS on the waters G2 
mass spectrometer. The multiply charged protein envelope was deconvoluted using Waters 






3.3.4.2 Method Development 
The SulfoLink® resin is typically used in a column format for affinity purifications of proteins 
in large volumes and therefore the protocol provided by the manufacturers was adapted to 
support use within a 0.5 mL tube due to the smaller volumes analysed in this study. The 
general steps and procedures of the workflow were the same however to separate the 
resin from incubation solutions, the tubes were centrifuged which brought the resin to the 
bottom of the tube and the supernatant to the top (method described in Chapter 2.15). 
Careful pipetting of the supernatant using gel loading tips ensured the resin was not 
disturbed whilst all the liquid was removed successfully. As with the other immobilisation 
techniques, the first step was to determine the binding capacity of the resin. 
Manufacturer’s guidelines state the binding capacity of 1 mL of settled resin at 5 mg for 
human IgG which is equivalent to approximately 33 nmol/mL. As the Affimer is a lot smaller 
(approximately 13 kDa) theoretically 1 mL of settled resin can bind 433 µg Affimer. To 
ensure for complete mixing of the resin with the sample, 50 µL of resin slurry was chosen as 
the volume of resin used for immobilisation which therefore contained 25 µL settled resin. 
Based on the above calculations, 25 µg settled resin could bind 10.8 µg Affimer.  
To assess IgG Affimer immobilisation onto the resin, 15 µg Affimer in 200 µL coupling buffer 
was incubated with the resin for 45 minutes following the protocol described in Chapter 
2.15. To determining the coupling efficiency, unbound fractions, washes and the resin was 
analysed by SDS-PAGE (Figure 3.18). Each fraction had the same volume and thus by 
loading equivalent volumes on the gel it was possible to determine if the Affimer sample 
had been depleted through binding to the resin. The intensity of the protein band in the 
unbound fraction was a lot less than the Affimer band in the starting material lane 
suggesting depletion of the Affimer and sufficient immobilisation of the Affimer to the resin 
(Figure 3.18). A faint band was observed in the first wash lane indicating the removal of 
Affimer non-specifically bound to the resin or to other Affimers. No Affimer band was 
visible in the resin lane. This result was expected as the Affimer was covalently bound to 
the resin and would not elute off during the SDS-PAGE process. LC-MS/MS analysis of resin 
digested using trypsin confirmed the presence of Affimer peptides (data not shown). Both 
these findings confirmed the successful immobilisation of the Affimer and the resin was 
therefore suitable for further affinity purification development. 
The IgG Affimer was selected as the preferred Affimer for method development due to the 




the IgG Affimer, the next step in development was confirming enrichment of the target 
with the Affimer using the SulfoLink® resin protocol. To investigate enrichment of human 
IgG, resin coated with IgG Affimer and resin blocked with cysteine was incubated with 20 µg 
human IgG was analysed by SDS-PAGE (Figure 3.19).  Sample A refers to resin with Affimer 
bound and sample B refers to resin with no Affimer bound but blocked with free cysteine. 
To determine if depletion of IgG could be observed, the unbound sample was also analysed. 
Following removal of the IgG solution, the resin was washed 3 times with PBS pH 7.4 to 
remove non-specific binding. SDS-PAGE analysis of IgG under reducing conditions reveals 
three main bands due to the different antibody fragments at 25 kDa, 50 kDa and 150 kDa 
corresponding to non-reducing IgG. Protein bands corresponding to IgG observed in the 
unbound fraction for the starting material and sample B were slightly more intense 
compared to bands visible in sample A (Figure 3.19). This suggested a small level of 
enrichment of IgG by the resin with Affimer bound. Analysis of resin loaded directly onto 
the gel supported this result with protein bands corresponding to IgG visible in sample A 
lane and not in sample B lanes. This finding demonstrated that the SulfoLink® affinity 
purification method could allow for the enrichment of protein target using the IgG Affimer 
and that the resin was sufficiently blocked to prevent non-specific binding of IgG. 
To assess the level of non-specific binding of proteins, the resin was incubated with one of 
three samples; 20 µg IgG only (sample A), 20 µg IgG and 300 µg  yeast lysate (sample B) or 
300 µg yeast lysate only (sample C).Yeast was selected as the biological sample as no 
endogenous proteins would bind specifically to the Affimer. The resin analysed either had 
IgG Affimer bound or had no Affimer bound. The affinity purification was performed as 
described in Chapter 2.15. The resin for all samples was analysed by SDS-PAGE (Figure 
3.20). As PBS pH 7.4 was sufficient in removing IgG bound non-specifically to the resin, a 
PBS pH 7.4 wash was also assessed on this sample set to determine if it was stringent 
enough to remove non-specific yeast proteins. SDS-PAGE analysis revealed yeast proteins 
remained bound to the resin after 3 washes with PBS pH 7.4 (Figure 3.20). A similar pattern 
was observed for resin containing Affimer and for resin with no Affimer. Enrichment of IgG 
was also observed for samples where IgG was added to the resin with Affimer bound. To 
establish whether increasing the stringency of the wash buffer would reduce non-specific 
binding, the experiment was repeated with two washes with a high pH wash buffer (0.1 M 
Tris-HCl, 0.5 M NaCl, pH 8.0). SDS-PAGE analysis of the resin revealed the non-specific 
background had been eliminated (Figure 3.20). In the yeast lysate only samples no protein 




resin with no Affimer sample but bands were observed in the resin with Affimer bound 
corresponding to IgG. This result indicates that the high pH wash buffer removes non-
specific binding but retains the specific interaction between IgG and the IgG Affimer. The 
high pH wash buffer was used for future experiments. 
A key challenge of the His-tag affinity purification workflow was the highly abundant signal 
from Affimer peptides following the on-bead digestion of the bead-Affimer-target complex. 
It was therefore essential to develop a suitable elution protocol that eluted off the target 
but retained the Affimer on the SulfoLink® resin. The experiment described above was 
repeated however following the final wash step, the resin was incubated with elution 
buffer (0.1 M ammonium acetate, 0.5 M NaCl, pH 4.0). To analyse the effectiveness of the 
elution buffer, both the elution fractions and remaining resin was analysed by SDS-PAGE 
(Figure 3.21). The elution fractions were neutralised with ammonium bicarbonate prior to 
SDS-PAGE analysis. Analysis of elution fractions for samples A and B with the resin 
containing Affimer, revealed bands corresponding to the IgG protein were present 
indicating the elution buffer was suitable for removing the IgG target from the Affimer. No 
IgG bands were observed in the elution fractions for the resin with no Affimer again 
demonstrating no non-specific binding of IgG to the resin. Bands representing yeast 
proteins were not observed in any of the elution samples indicating the wash buffer was 
suitable at removing non-specific binding.  Analysis of the resin revealed no IgG protein 
bands were visible indicating that the elution buffer removed all of the captured IgG (Figure 
3.21).    
To assess the level of non-specific background in human plasma, the SulfoLink® affinity 
purification was repeated using human plasma (300 µg). As with the resin exposed to yeast, 
the resin was washed twice with the high pH buffer followed by a PBS pH 7.4 wash. 
However, SDS-PAGE analysis of the resin revealed the presence of plasma proteins binding 
non-specifically to the resin (data not shown). Therefore, the experiment was repeated and 
the resin was washed four times with the high pH wash buffer and once with PBS pH 7.4. 
Resin with a pepsinogen Adhiron bound was included in the analysis to confirm the IgG 
protein was not binding to the Affimer scaffold. The resin was analysed by SDS-PAGE 
(Figure 3.22). No protein bands were observed in resin samples that had the pepsinogen 
Adhiron bound or the resin with no Affimer bound. For resin samples that had IgG Affimer 
bound, IgG bands were observed in the IgG only, plasma and IgG, and the plasma only 
samples. No other plasma protein bands were observed indicating the wash buffer is 






Figure 3.18 | SDS-PAGE analysis of IgG Affimer immobilisation on SulfoLink resin.  
IgG Affimer (15 µg in 200 µL PBS pH 7.4) was incubated with 50 µL SulfoLink resin (50 % 
suspension) for 45 minutes. The resin was washed in PBS pH 7.4 (200 µL) to remove non-
covalently bound Affimer. Equal volumes of starting material (SM), unbound Affimer 
fraction (UF) and washes were analysed by SDS-PAGE. Depletion of Affimer was observed in 
the unbound fraction indicating immobilisation of Affimer onto the resin. The Affimer was 
irreversibly covalently bound to the resin and was therefore not observed on the gel. 








Figure 3.19 | SDS-PAGE analysis of pure IgG affinity purification with IgG Affimer.  
IgG Affimer (15 µg) was immobilised onto 50 µL SulfoLink resin (50 % suspension), labelled 
A on SDS-PAGE. Resin-Affimer complex was incubated with pure IgG (20 µg in 200 µL in PBS 
pH 7.4) for 1 hour. Resin was washed three times with PBS pH 7.4. A resin control sample 
containing no Affimer, labelled B on SDS-PAGE,  was also analysed to assess for non-specific 
binding of IgG to the resin. Analysis of resin confirms enrichment of IgG with IgG Affimer 
and no non-specific binding of IgG to the resin. Samples were analysed on a 15 % gel and 
the protein visualised with Coomassie plus stain. Affinity purifications and SDS-PAGE 







Figure 3.20 | SDS-PAGE analysis of pure IgG in yeast affinity purification with IgG Affimer 
washing optimisation. 
IgG Affimer (15 µg) was immobilised onto 3 X 50 µL SulfoLink resin (50 % suspension), and 
incubated with either 20 µg IgG (labelled A), 300 µg yeast & 20 µg IgG (labelled B) or 300 µg 
yeast (labelled C) for 1 hour.  Resin with no Affimer bound was also incubated with the 
above samples. Top: Resin washed with PBS pH 7.4. Bottom: Resin washed with Tris-HCl pH 
8. Samples were analysed on a 15 % gel and the protein visualised with Coomassie plus 
stain. Affinity purifications and SDS-PAGE analysis undertaken in association with 






Figure 3.21 | SDS-PAGE analysis elution buffer optimisation of pure IgG in yeast affinity 
purification with IgG Affimer. 
IgG Affimer (15 µg) was immobilised onto 3 X 50 µL SulfoLink resin (50 % suspension), and 
incubated with either 20 µg IgG (labelled A), 300 µg yeast & 20 µg IgG (labelled B) or 300 µg 
yeast (labelled C) for 1 hour.  Resin with no Affimer bound was also incubated with the 
above samples. Resin washed with Tris-HCl pH 8. Top: Protein was eluted off the resin using 
ammonium acetate pH 4 and neutralised with ammonium bicarbonate for SDS-PAGE 
analysis. Bottom: Resin was analysed to confirm elution of IgG. Samples were analysed on a 
15 % gel and the protein visualised with Coomassie plus stain. Affinity purifications and 
SDS-PAGE analysis undertaken in association with collaborators, Kimberley Burrow from 





Figure 3.22 | SDS-PAGE analysis of pure and endogenous IgG in human plasma affinity 
purification. 
IgG Affimer (15 µg) was immobilised onto 3 X 50 µL SulfoLink resin (50 % suspension), and 
incubated with either 20 µg IgG (labelled A), 300 µg plasma & 20 µg IgG (labelled B) or 300 
µg plasma (labelled C) for 1 hour.  Resin with no Affimer bound and pepsinogen Adhiron 
was also incubated with the above samples. Resin washed with ammonium acetate pH 4. 
Samples were analysed on a 15 % gel and the protein visualised with Coomassie plus stain. 
Affinity purifications and SDS-PAGE analysis undertaken in association with collaborators, 




3.3.4.3 Naïve Affimer characterisation and affinity purification 
The final affinity purification SulfoLink® resin protocol discussed in Section 3.3.4.2 
demonstrated the successful enrichment and purification of human IgG using the IgG 
Affimer. Therefore, the affinity purification protocol was tested on naïve Affimers with the 
goal of identification of binding partners using mass spectrometry. It must be noted 
however that the IgG Affimer was based on the cystatin consensus sequence scaffold and 
produced using phage display screens which yields Affimers with much greater binding 
affinities to their target than Affimers based on Stefin A scaffold, those produced for the 
array work. Therefore, the washes applied post sample incubation may be too stringent and 
remove the true interaction partners of the Affimers.  
The Affimer array work was repeated due to inconsistences with the statistical analysis with 
the previous array data set obtained for the naive Affimer his-tag affinity purifications. 
Furthermore, a major issue of the first set of naïve Affimers selected for analysis was that 
they were chosen based on demonstrating the greatest differential signal between control 
and sepsis serum samples regardless of the direction of change. Therefore, the Affimers 
selected were chosen based on preferential binding in the control serum. Patients with 
sepsis experience a systemic immune response in which proteins belonging to the 
inflammatory and immune system such as inflammatory cytokines and complement 
proteins are released213. Therefore, it was thought that the most informative proteins and 
those indicative of sepsis would display an increased expression in the disease cohort. 
Therefore, the naïve Affimers selected for analysis using the SulfoLink® resin protocol had 
displayed increased binding in the sepsis cohort. Furthermore, for reason discussed in 
Chapter 5, plasma is preferred over serum for the identification of sepsis biomarkers.  
A total of 13 naïve Affimers were selected for expression and purification (performed by 
Avacta Life Sciences). All 13 Affimers were chosen as they had the highest signal fold 
change in the disease cohort. Three of the Affimers failed to express and therefore a total 
of 10 naïve Affimers were produced for analysis. To compare the Affimer sequences, a 
multiple sequence alignment was performed (Figure 3. 23). The variable loop regions of the 
Affimers are highlighted at residue positions 50 to 55 and 80 to 91 for loops 1 and loops 2 
respectively. The naïve Affimer sequences were unique. The Adhiron sequences were also 
analysed by generating a phylogenetic tree. Interestingly, the branch lengths are fairly 




the Affimers share the same scaffold sequence, this could explain the low divergence 
observed. 
To assess the purity of the naïve Affimers, samples were analysed by SDS-PAGE under 
reducing and non-reducing conditions (Figure 3.24). Under reducing conditions, a band was 
observed at approximately 14 kDa in all samples which corresponds to the expected 
molecular weight of the Affimers. A faint band was observed at approximately 28 kDa for 6 
of the Affimers which is likely to correspond to an Affimer dimer. This could be due to 
insufficient reduction or domain-swapped dimerisation discussed in Chapter 4211. Under 
non-reducing conditions, a band at approximately 14 kDa and 28 kDa was observed for all 
Affimers representing the monomer and dimer forms. No other protein bands were 
observed by SDS-PAGE indicating high purity of the Affimers. 
To obtain exact mass values and to confirm full length expression of the Affimers, the 
samples were analysed by intact mass spectrometry as described in Chapter 2.21 The 
multiply charged protein envelopes were deconvoluted using MAXENT 1 in Mass Lynx, to 
obtain the average mass of the Affimers (Figure 3.25) and summarised in Table 3.3. For all 
but one Affimer, the observed mass corresponded to the theoretical mass of the Affimer. 
An intact mass value was not obtained for naïve Affimer H8. For naïve Affimer A8, D9 and 
I16 a peak was observed at 103 Da less than the theoretical mass suggesting that a small 
portion of these Affimers had lost the c-terminal cysteine. Although the cysteine is required 
for immobilisation onto the resin, only a small fraction of each Affimer was missing the 
cysteine and therefore it should not have a detrimental effect on Affimer immobilisation.  
A + 42 Da adduct was also observed for 8 of the naïve Affimers. To confirm the modification 
of 42 Da to the naïve Affimers, an in-solution digest was performed on the naïve Affimers 
using either trypsin or GluC as described in Chapter 2.17. The use of two enzymes would 
allow for improved sequence coverage and therefore aid in the identification of the 
modification. Peptides were analysed on the Thermo QExactive mass spectrometer and the 
data searched using PEAKS 7214. The data was searched against a database containing the 
naïve Affimer sequences using the parameters described in Chapter 2.24. Using the PEAKS 
PTM node, modified peptides were identified. A representative peptide map of naïve 
Affimer D9 is shown in Figure 3.26 and identifies the N-terminal peptides as being 
acetylated. The other nine naïve Affimers are also identified as having this modification 









Figure 3.23 | Multiple sequence alignment and phylogenetic analysis of naïve Affimers. 
Protein sequences were aligned and visualised using CLC Viewer. Amino acid residues were coloured using the Rasmol colour scheme. The loop regions of 





Figure 3.24 | SDS-PAGE analysis of naïve Affimers under reducing and non-reducing 
conditions. 
A total of 2 µg of each Affimer sample was analysed by SDS-PAGE. The reducing gel samples 
were incubated with sample buffer containing DTT and non-reducing gel samples were 
incubated in sample buffer than had no DTT added. Affimers L4 and A23 were analysed in 
triplicate and duplicate respectively due to receiving multiple fractions following 
purification. The samples were analysed on a 15 % gel and the protein was visualised with 






Figure 3.25 | ESI-MS analysis of naïve Affimers (Part 1). 
Samples were diluted to 1 pmol/µL in 3 % acetonitrile, 0.1% formic acid. 2 µL of each 
sample was loaded onto a C4 desalting trapping column. Samples were analysed by ESI-MS 
on the Waters G2 mass spectrometer. The multiply charged protein envelope was  
deconvoluted using Waters MAXENT 1 algorithm to determine the average mass of the 






Figure 3.25| ESI-MS analysis of naïve Affimers (Part 2). 
Samples were diluted to 1 pmol/µL in 3 % acetonitrile, 0.1% formic acid. 2 µL of each 
sample was loaded onto a C4 desalting trapping column. Samples were analysed by ESI-MS 
on the Waters G2 mass spectrometer. The multiply charged protein envelope was  
deconvoluted using Waters MAXENT 1 algorithm to determine the average mass of the 







Figure 3.25 | ESI-MS analysis of naïve Affimers (Part 3). 
Samples were diluted to 1 pmol/µL in 3 % acetonitrile, 0.1% formic acid. 2 µL of each 
sample was loaded onto a C4 desalting trapping column. Samples were analysed by ESI-MS 
on the Waters G2 mass spectrometer. The multiply charged protein envelope was  
deconvoluted using Waters MAXENT 1 algorithm to determine the average mass of the 




Table 3.3 | Intact mass summary.  
The observed mass recorded corresponds to the unmodified intact mass.  
Affimer Theoretical Mass 
(Da) 
Observed Mass (Da) Difference (Da) 
I7 14168.1 14168.1 - 0.1 
A8 14023.0 14022.4 - 0.6 
L3 13832.8 13832.2 - 0.6 
H8 13905.9 13843.9 - 62 
D9 13897.8 13897.3 - 0.5 
A23 13841.7 13840.7 - 1.0 
I16 13687.4 13686.7 - 0.7 
K5 13864.9 13864.2 - 0.7 
L4 13953.9 13953.4 - 0.5 











Figure 3.26 | Representative PEAKS PTM peptide map for naïve Affimer D9. 
The naïve Affimers were separately digested with trypsin and Glu-C to obtained sequencing information. Data was searched using PEAKS against a naïve 
Affimer database and over 95 % sequence coverage achieved. Acetylation of the N-terminus is likely to explain the + 42 Da mass discrepancy observed via 




The three Affimers that gave the greatest differential signal between disease and control 
plasma samples on the array were selected for analysis; naïve Affimer D4, E7 and M22. 
Each Affimer sample was analysed in triplicate following the protocol outlined in Chapter 
2.15. Resin with no Affimer bound and a single eSQT sample was included in the analysis as 
negative controls. As the naïve Affimers were identified from array data as having the 
greatest differential signal in disease samples, sepsis plasma was analysed in the affinity 
purification. A pool of 10 patient samples was selected at random and a total of 300 µg 
incubated with each sample. Following the SulfoLink® resin affinity purification workflow, 
protein target was eluted using ammonium acetate pH 4. The elution fraction was 
neutralised with ammonium bicarbonate and along with the remaining resin, digested 
following standard protocol described in Chapter 2.17 for LC/MS-MS analysis on the 
Thermo QExactive mass spectrometer. To investigate quantitative difference in protein 
enrichment, label-free protein quantification was performed using Progenesis QI (Waters 
Corporation). Retention time alignment was performed with naïve Affimer replicate 2 
selected as the alignment file. Alignment scores achieved 66 % or greater. The data was 
searched using MASCOT against a human and naïve Affimer database. A total of 36 proteins 
were identified and quantified using unique peptides with a minimum of two peptides per 
protein. To investigate if the binding partners of the three different naïve Affimers could be 
identified, protein abundance values were log 10 transformed and analysed by hierarchical 
clustering (Figure 3.27).  No clustering of the replicates of each sample was observed 
demonstrating no quantified differences in proteins enriched by the naïve Affimers or by 
the resin and eSQT Affimer. The results demonstrate a consistent level of non-specific 
background binding in the affinity purification. The resin data was also searched using 
Progenesis QI but results are not shown as comparable findings were observed to elution 
data.  
Further analysis of proteins identified from the SulfoLink® naïve Affimer affinity purification 
revealed highly abundant plasma proteins and skin proteins such as keratins (Table 3.4). 
Due to the various sample handle steps involved with the affinity purification workflow, it 
was inevitable that contamination from keratins will occur.  An approach to overcome the 
non-specific binding of highly abundant proteins would be to perform depletion strategies 
on the plasma prior to the affinity purification. However, as the array work that identified 
naïve Affimers was carried out on non-depleted plasma, applying depletion strategies may 




abundance and weak binders then the binding of non-specific background of highly 





Figure 3.27 | Heatmap and hierarchical clustering of log 10-transformed protein 
abundance data for naïve Affimer affinity purifications. 
Protein abundance values were taken from Progenesis QI and log 10—transformed. 
Samples clustered on protein abundance with highly abundant proteins represented in red 
and less abundant proteins represented in blue. The red portion to the left of the heatmap 
represents proteins that are identified as highly abundant consistent non-specific 
background. Affinity purifications undertaken by collaborators, Kimberley Burrow from 




Table 3.4 | Summary of proteins identified from LC-MS/MS analysis of naïve Affimer 
affinity purifications. 
The proteins are ordered based the clustering order in the heatmap in Figure 3.27.  






_D4 GSP00000312_D4 16 6 1086.74 
GSP00000325
_E7 GSP00000325_E7 16 6 1150.87 
GSP00000354
_M22 GSP00000354_M22 14 4 1033.52 
P01011 Alpha-1-antichymotrypsin  3 3 112.61 
P01024 Complement C3  11 11 358.15 
P01591 Immunoglobulin J chain  2 2 59.43 
P01611 Ig kappa chain V-I region Wes  2 2 48.34 
P01834 Ig kappa chain C region  4 4 390.16 
P01857 Ig gamma-1 chain C region  7 2 225.54 
P01859 Ig gamma-2 chain C region  7 3 340.04 
P01871 Ig mu chain C region  18 17 771.51 
P01876 Ig alpha-1 chain C region 3 3 108.4 
P02452 Collagen alpha-1(I) chain 2 2 54.85 
P02533 Keratin, type I cytoskeletal 14 16 4 743.88 
P02647 Apolipoprotein A-I  6 6 176.26 
P02649 Apolipoprotein E  2 2 75.83 
P02671 Fibrinogen alpha chain 6 6 173.9 
P02675 Fibrinogen beta chain  5 4 175.94 
P02679 Fibrinogen gamma chain 2 2 109.11 
P02751 Fibronectin  2 2 100.28 
P02768 Serum albumin 42 42 2303.33 
P02787 Serotransferrin 2 2 43.01 
P04004 Vitronectin 2 2 47.78 
P04264 Keratin, type II cytoskeletal 1 43 35 2543.76 
P08779 Keratin, type I cytoskeletal 16 19 7 794.6 
P0DJI8 Serum amyloid A-1 protein 5 2 285.65 
P0DJI9 Serum amyloid A-2 protein 5 2 293.41 
P13645 Keratin, type I cytoskeletal 10 33 26 2209.02 
P13646 Keratin, type I cytoskeletal 13 12 4 442.98 
P13647 Keratin, type II cytoskeletal 5 20 9 901.96 
P19013 Keratin, type II cytoskeletal 4 8 3 369.96 
P35527 Keratin, type I cytoskeletal 9  33 32 1739.18 
P35908 
Keratin, type II cytoskeletal 2 
epidermal 26 16 1447.11 
P61626 Lysozyme C 2 2 59.88 
P81605 Dermcidin 2 2 98.47 






The primary aim of this chapter was to develop an affinity purification method for the 
identification of naïve Affimer targets using mass spectrometry. A total of four different 
immobilisation chemistries were assessed for suitability in a naïve Affimer affinity 
purification including His-tag, streptavidin-biotin interaction, pyridyl disulfide and 
iodoacetyl chemistry. This work details the challenges of affinity purification and despite 
extensive optimisation, the methods were unsuitable for the analysis of naïve Affimers.  
The SulfoLink resin immobilisation technique based on iodoacteyl chemistry was suitable 
for IgG affinity purification using the IgG Affimer. However, analysis of naïve Affimers with 
this approach failed to result in protein identifications. The optimisation step for all the 
affinity purification methods were performed using a catalogue Affimer which was based 
on the type II cystatin consensus sequence scaffold and generated through phage display. 
Whereas the naïve Affimers are based on the type I Affimer stefin A scaffold and have 
lower binding affinities to their protein target. Therefore, any optimisation steps performed 
using the Type II scaffold could not be directly applied to the analysis of Type I Affimers.  
False positive identification of protein interactions is a common problem with affinity 
purifications. This is primarily due to non-specific background of proteins binding to the 
solid support or the capture reagent scaffold215. Numerous studies have identified bead 
proteomes with different proteins binding non-specifically to different bead types216,217. 
Databases such as the CRAPome215 have been developed in order to establish a repository 
of previously identified proteins from negative controls. The goal is to help identify and 
distinguish true interactions from background contamination. Highly stringent wash buffers 
can be applied in affinity purifications to reduce non-specific interactions however it may 





Chapter 4: Development of Adhirons for Enrichment of Pepsinogen 
4.1 Introduction 
Novel biomarker discovery is a major goal in clinical research to advance disease diagnosis, 
increase the value of prognostic indicators and to provide targeted therapy193. The work 
discussed in Chapter 3 outlines the potential role of Affimer technology in the discovery of 
novel biomarkers.  Although there is a large focus in clinical research to identify novel 
biomarkers, in certain cases, protein biomarkers have already been identified but the 
current assays and technology available prevents the accurate detection of the protein. 
Various diagnostic tests such as ELISAs rely on the use of antibodies which possess various 
limitations as discussed in Chapter 1.5. Due to the ability to generate Affimers to any 
protein target where the recombinant or purified form is available, using phage display 
technology111, Affimers can help to overcome some of the technological issues.  
An example in which a protein has been previously identified for disease diagnosis is 
pepsinogen. Pepsinogen has been implicated in various diseases including gastric 
cancers218,219, duodenal ulcers220, rheumatic disease221 and gastroesophageal reflux 
disease222. More specifically, pepsinogen has been identified as a suitable marker for the 
diagnosis of reflux aspiration (RA) in children with severe neurodisability196. Patients 
present with recurrent respiratory tract infections, which result in regular hospital 
admissions and is the leading cause of premature death in these patients196.  The cause of 
the respiratory problems is multifactorial such as muscle weakness, poor cough function 
and both direct and reflux aspiration. RA is defined as inhalation of the stomach content 
into the airways which differs from direct aspiration (DA) of food and saliva into the 
airways.  Both disorders are common in this set of patients due to lack of motor control of 
both the oral and stomach sphincter. As patients with DA and RA present with similar 
symptoms, treatment and management of the disorders can be difficult. Distinguishing 
between RA and DA would allow clinicians to provide more specialised treatment and to 
select patients suitable for surgical intervention. Patients with proven RA could benefit 
from surgery to tighten the oesophagus, preventing aspiration of the stomach content196.   
Pepsin is an aspartic protease and is the major proteolytic enzyme of the digestive system 
(Figure 4.1), produced as pepsinogen by chief cells that are located in the stomach lining. 
Pepsinogen is a zymogen in that it is produced as an inactive enzyme with no catalytic 




of pepsinogens: pepsinogen A (isozymogens pepsinogen A3, A4 and A5) and progastricsin 
(pepsinogen C) (Figure 4.2). Expression of pepsinogen A is highly specific to the stomach224 
and has not been detected in the oesophagus or lungs225. Therefore the detection of 
pepsinogen in the lungs and oesophagus would identify patients with reflux aspiration196. It 
should be noted that expression of progastricsin has been detected in the lungs. 
The amino acid sequence of pepsinogen is split into three regions from residues 1 -15, 16 – 
65 and 66 – 388 representing the signal peptide, the activation peptide and the active 
pepsin moiety, respectively223 (Figure 4.2). During the synthesis of pepsinogen, the highly 
hydrophobic signal peptide (prepeptide) is removed and therefore the expressed form of 
the pepsinogen protein consists of the activation peptide and the pepsin moiety. The amino 
acid distribution within the two regions of the protein is very distinct; the activation peptide 
is highly basic whereas the pepsin moiety is highly acidic. Pepsinogen is the inactive 
precursor of pepsin and is converted into active pepsin upon exposure to acid conditions226. 
At neutral pH, the binding cleft of the pepsinogen structure is occupied by the activation 
peptide, held in place through hydrophobic, electrostatic and hydrogen bonds, providing 
stability to the protein227. However, at acidic pH the structure is completely different as the 
activation peptide is cleaved from the pepsin moiety223. This cleavage occurs as the carboxyl 
groups in the protein become protonated under acidic conditions which disrupts the 
interactions between the binding cleft and the activation peptide. Thus, conformational 
changes occur which reveal the activation site where the pepsinogen protein cleaves the 
activation peptide through autolysis223. 
As pepsinogen has been identified as the protein of interest, a targeted SRM approach to 
detection could be employed. Typically, the protease of choice for protein digestion is 
trypsin. However, whilst the activation peptide of pepsinogen contains many tryptic 
cleavage sites, the peptide fragments produced would be very small and it is likely that the 
activation peptide may be cleaved from the protein. Pepsin, on the other hand, contains 
four tryptic cleavage sites resulting in extremely large peptide fragments (Figure 4.3). The 
use of alternative proteases, such as endoproteinase Asp-N, could generate suitably sized 
peptide fragments (Figure 4.3). Interestingly, an Asp-N digest of pepsinogen would 
generate a peptide that spans the activation region and the pepsin moiety228. Developing 
SRM transitions that target this peptide could yield valuable information on whether 









Figure 4. 1 | Tertiary structure of human pepsin. 
A ribbon diagram representing the 3D structure of human pepsin 3A (PDB entry: 1PSO). The 
secondary domains are highlighted with the β-sheets shown in yellow and the α-helix 






Figure 4.2 | Multiple sequence alignment of human pepsinogens. 
The pepsinogen A (PGA-3, PGA-4 and PGA-5) and pepsinogen C protein sequences were 
aligned and visualised using CLC Viewer. Amino acid residues were coloured using the 









Figure 4.3 | Theoretical trypsin and endoproteinase Asp-N cleavage sites of pepsinogen A5. 
The signal peptide and the activation peptide are highlighted on the pepsinogen A5 amino acid sequence. Asp-N and trypsin cleavage sites are indicated by 




The current assays for the detection of pepsinogen rely on the use of antibodies for ELISA 
or western blotting. Several commercial ELISA tests are available, including from 
RayBiotech, Thermo Scientific and Sigma-Aldrich, however they are not fully validated for 
the analysis of different biological samples. As previously discussed, antibodies possess 
various limitations such as lack of specificity which may be problematic for pepsinogen 
detection. Due to the nature of reflux aspiration, bronchoalveolar lavage (BAL) and sputum 
are the ideal sample types for pepsin detection196. Both matrixes are fairly complex which 
could cause further problems with antibody specificity. Another key challenge for pepsin 
detection is the low concentration of the protein expected in BAL. Therefore, by enriching 
first for pepsinogen using affinity reagents followed by targeted SRM, sensitivity and 
complexity of the sample would be overcome.  
To overcome the issue of low pepsinogen concentration, an Affimer affinity purification 
strategy could be applied to enrich for the target protein. Previously, a SRM based 
approach was used to detect pepsin with prior enrichment using an anti-peptide antibody 
developed to bind an Asp-N peptide from pepsinogen228. However, despite the method 
detecting pepsinogen, by enriching for a single peptide, valuable information on the rest of 
the protein may be lost. Therefore, Adhirons, designed to target the complete human 
pepsinogen protein, would be the ideal reagent for target enrichment. A major challenge of 
affinity purifications and co-immunoprecipitations coupled with mass spectrometry is the 
identification of genuine interacting proteins215. Typically, the interacting proteins are of 
low abundance and if the elution strategy applied elutes the highly abundant capture 
reagent as well as the interacting proteins, then when digested for MS analysis, peptides 
from proteins of interest may be below the limit of detection. In addition, if an on-bead 
digest of the capture reagent and its interacting partners is performed then the same 
problem arises. Peptides from the capture reagent will limit the amount of sample loaded 
onto the instrument, preventing detection of the specific interacting proteins. Therefore, 
development of a protein scaffold that can withstand proteolysis would be advantageous. It 
would allow for the proteolysis of interacting partners whilst the capture reagent remains 
intact and thus, separation from the peptide mixture. It must be noted that although the 
signal of peptides from the capture reagent would be removed, peptides from non-specific 
proteins binding in the affinity purification would still be present. The appropriate controls 





4.2 Aims and Objectives 
The work in this chapter will focus of the development and characterisation of Adhiron 
binders to capture human pepsinogen. They key objectives of this chapter were to: 
- Express and purify Adhiron binders that target human pepsinogen. 
- Design, express and characterise a pepsinogen Adhiron that is resistant to 
proteolysis. 
- Apply the developed SulfoLink® affinity purification method to capture human 
pepsinogen using the Adhirons. 
 
 
4.3 Results and Discussion 
4.3.1 Expression and purification of pepsinogen Adhirons 
A total of five unique pepsinogen Adhiron plasmids were received from Professor Mike 
McPherson at the University of Leeds in the BioScreening Technology Group where the 
phage display screening and selection process was carried out. A brief description of the 
phage display process can found in Chapter 1.7. The constructs contained a His-Tag 
sequence for purification. The constructs had been sub-cloned into plasmids that allowed 
the introduction of a cysteine residue in the C-terminal portion of the proteins. The 
addition of the cysteine residue is vital for the immobilisation of the Adhirons onto solid 
supports for affinity purification applications. The five Adhiron sequences are shown in 
Figure 4.4 and analysis of the loop regions indicate a high proportion of hydrophobic 
residues. It is therefore likely that the interaction between the Adhirons and pepsinogen is 
mediated through hydrophobic interactions229. 
The plasmids were transformed into BL21 (λDE3) E.coli cells following the transformation 
protocol (Chapter 2.1). The Adhiron plasmids contain the gene for resistance to ampicillin 
and thus cells containing the plasmid were selectively grown. Following overnight growth of 
the transformed E.coli cells, a single colony from the agar cultures for each of the 
pepsinogen Adhirons was selected and used to inoculate a small overnight LB culture. The 




increase the scale of protein production, the overnight cultures were used to inoculate 200 
mL of LB broth, again containing ampicillin, following the protein expression protocol. The 
culture growth rate and protein expression post IPTG induction was monitored by removal 
of culture solution at time points during the growth and analysed by SDS-PAGE (Figure 4.2). 
After 4 hours, the culture was harvested into cell pellets by centrifugation. 
For all five pepsinogen Adhirons, a band at approximately 14 kDa was visible on SDS-PAGE 
after IPTG induction (Figure 4.5). Based on sequence information, this was the approximate 
molecular weight for the Adhirons suggesting full length protein expression. For pepsinogen 
Adhiron A1, a band was also visible pre-induction. In addition, the post-induction band for 
pepsinogen Adhiron A1 was less intense compared to the other pepsinogen Adhirons.   
Before protein purification, the cells were lysed by sonication as outlined in Chapter 2.2. 
Previous work by Tiede et al determined that the Adhiron proteins express in the soluble 
fraction of the lysate111. Therefore following centrifugation, the soluble fraction was taken 
for purification using GE healthcare Ni-NTA affinity columns using a manual elution as 
described in the methods. The sample was loaded onto the column and washed with 10 X 
column volume to remove the non-specific proteins bound to the column. The pepsinogen 
Adhirons were eluted through competitive elution by increasing the concentration of 
imidazole in the elution buffer and fractions analysed by SDS-PAGE (Figure 4.6). For all 
pepsinogen Adhirons, the protein elutes predominately in elution fraction 2. Pepsinogen 
Adhirons A3 and A4 started to form dimers upon purification due to the second band at 
approximate 28 kDa (Figure 4.3). Dimer formation was expected due to the unpaired 
cysteine residues on all of the five pepsinogen Adhirons. This may suggest that the 
concentration of DTT within the sample buffer is not sufficient in reducing the Adhirons 
fully. As the elution buffer was not compatible with LC-MS due to the high salt and glycerol 
concentration, the protein was dialysed into 25 mM ammonium bicarbonate. However, 
upon dialysis, protein precipitation was observed. Therefore, to prevent further loss of 















Figure 4.4 | Amino acid multiple sequence alignment of five pepsinogen Adhirons.  
Protein sequences were aligned and visualised using CLC Viewer. Amino acid residues were coloured using the Rasmol colour scheme. Variable loop regions 











Figure 4.5 | E.coli cultures and expression of pepsinogen Adhirons.  
SDS-PAGE analysis of pre-induction and post-induction time-points and growth curves for five pepsinogen Adhiron expression. Protein expression was 
induced with IPTG at an OD=600 nm and protein left to accumulate for 4 hours. All pepsinogen Adhirons expressed as evident by the band at approx. 14 






Figure 4.6 | Purification of pepsinogen Adhirons.  
His-tag Adhirons were purified using GE Healthcare Ni-NTA affinity columns using a manual 
elution. Adhirons predominantly elute in elution fraction 2. 10 µL of each fraction was ran 
on a 15 % gel and visualised with Coomassie plus stain. SM - starting material, FT- flow 





To confirm the products of protein expression and the absence of contaminant proteins, 
the pepsinogen Adhirons were analysed by intact mass spectrometry as described in 
Chapter 2.21 (Figure 4.7). Due to the Adhirons being stored in the elution buffer, the 
samples were first loaded onto an offline C4 desalting trapping column and washed to 
removed salts and glycerol. After deconvolution of the multiply charged protein envelope, 
the average mass of the intact pepsinogen Adhirons was determined (Table 4.1). The 
predominant species within the mass spectrum for pepsinogen Adhirons A1, A4, C2 and D4 
correspond to the dimer form of the Adhiron minus two methionine residues (Table 4.1). 
The mass resolution was not able to accurately confirm whether there was loss of an 
additional 2 Daltons, corresponding to disulfide bond formation. For pepsinogen Adhiron 
A3, only the monomer form was observed which corresponded to the theoretical mass 
minus the initiating methionine residue. Removal of the N-terminal methionine is expected 
as the residue in position two is alanine230. It is likely that pepsinogen Adhiron A3 was 
observed as a monomer only as it was analysed immediately after purification meaning 
there was no time for dimer formation to occur. As the pepsinogen Adhirons will be used in 
their reduced form, it was necessary to confirm the intact mass of the monomer and to 
confirm effective reduction. 
To reduce the five pepsinogen Adhirons, they were incubated with DTT (final concentration 
5 mM) for 30 minutes at room temperature. Although glycerol was added to the Adhiron 
storage buffer to increase protein stability231, it was incompatible with the mass 
spectrometer. Therefore, using an offline C4 desalting trapping column, the samples were 
cleaned-up to remove salt and glycerol. The pepsinogen Adhirons were then analysed by 
intact mass spectrometry as described in Chapter 2.21. Following deconvolution of the 
multiply charged protein envelope, the average mass of the pepsinogen Adhiron monomers 
was measured (Figure 4.8). All five pepsinogen Adhirons had been fully reduced with none 
of the dimer form of the Adhiron detected. The predominant species within the mass 
spectra for all Adhirons corresponded to the theoretical mass minus the initiating 
methionine (Table 4.1). This result confirmed that for all pepsinogen Adhirons the 
expected, full length protein had expressed and that the Adhirons can be effectively 






Figure 4.7 | ESI-MS intact analysis of pepsinogen Adhirons without reducing agent.  
After offline C4 trap clean-up to remove glycerol and salts, protein samples were diluted to 
1 pmol/µL in 3% acetonitrile, 0.1% formic acid. 2 µL of each sample was loaded onto a C4 
desalting trapping column. Samples were analysed by ESI-MS on the Waters G2 mass 
spectrometer. Multiply charged protein envelope was deconvoluted using Waters MAXENT 
1 algorithm to determine average mass of intact proteins. – 2 Met corresponds to the loss 






Figure 4.8 | ESI-MS analysis of pepsinogen Adhirons incubated with DTT.  
Samples were incubated with DTT to reduce Adhrions. After offline C4 trap clean-up to 
remove glycerol and salts, protein samples were diluted to 1 pmol/µL in 3% acetonitrile, 
0.1% formic acid. 2 µL of each sample was loaded onto a C4 desalting trapping column. 
Samples were analysed by ESI-MS on the Waters G2 mass spectrometer. Multiply charged 
protein envelope was deconvoluted using Waters MAXENT 1 algorithm to determine 
average mass of intact proteins. The observed mass of the pepsinogen Adhiron and the 




Table 4.1 | Comparison between theoretical and observed intact mass of pepsinogen 
Adhrions.  
Theoretical mass (Da) of monomer calculated minus the initiating methionine. The 
theoretical mass (Da) of the dimer is calculated minus initiating methionine residues and -2 





















A1 12348.2 24694.4 12348.0 24696 -0.2 
A3 12256.9 24511.9 12256.5 - -0.4 
A4 12244.9 24487.7 12244.6 24489 -0.3 
C2 12566.3 25130.6 12566.2 25129 -0.1 
D4 12392.0 24782.1 12391.6 24783 -0.4 
 
 
For downstream applications, the addition of DTT to the Adhiron buffer was unsuitable. 
DTT would compete with the cysteine residues on the Adhiron for binding to the sulfhydryl 
groups on the resin and thus reduce the coupling efficiency of the Adhirons. To overcome 
this, the Adhiron solution could be desalted to remove the DTT however due to losses in 
protein with desalting columns, this was not the preferred method. TCEP is an alternative 
reducing agent that efficiently reduces disulfide bonds232. As TCEP is thiol-free then it is not 
necessary to remove it from the sample before coupling the Adhirons to the resin. 
However, TCEP was available in an immobilised form and was therefore used so that the 
sample could be separated from the TCEP by centrifugation preventing the TCEP from 
entering the MS.  
To assess whether immobilised TCEP was suitable for Adhiron reduction and to determine 
the time taken for complete reduction, a reduction time-course experiment was 
undertaken. The immobilised TCEP resin was prepared as described in Chapter 2.5. 
Pepsinogen Adhiron A1 was incubated with the resin and incubated for 60 minutes. During 
the time-course, samples were removed for intact mass analysis (Figure 4.9). After 60 
minutes, the Adhiron was also analysed by SDS-PAGE and compared to unreduced Adhiron 




nearly complete reduction after 5 minutes. After 60 minutes, complete reduction was 
observed with only the monomer form of the Adhiron detectable (Figure 4.9). Conversely, 
SDS-PAGE analysis suggests that the Adhiron has not fully reduced with monomers, dimers 
and higher order species as indicated by the protein bands visible on the gel (Figure 4.9). As 
ESI-MS results indicate complete reduction, this result could suggest that the SDS-PAGE 
process causes protein complexes. Irrespective of TCEP reduction, the lanes for pepsinogen 
Adhiron A1 without and with TCEP reduction look identical. A proposed mechanism for 
dimerisation is through domain swapping. This type of dimerisation does not occur through 
disulfide bond formation but instead by domain swapping of one protein with another, 
resulting in multiple species (two or more) grouping together211. Human cystatin C has 
previously been identified to be involved in domain swapping233. Although the pepsinogen 
Adhirons were based on the plant cystatin consensus sequence, their structure is highly 
homologous to that of the type I Affimer (cystatin A/stefin A sequence) and therefore could 
explain the observation of multimers. The other suggestion is that the bands observed by 
SDS-PAGE with a molecular weight greater than 28 kDa (Adhiron dimer) are from 
contaminating proteins during the purification step.  
To determine the identity of the protein bands from SDS-PAGE analysis of pepsinogen 
Adhiron A1, an in-gel digestion was carried out on specific bands as detailed in Chapter 
2.16.  The samples were analysed by MALDI-TOF MS as described in Chapter 2.20. To 
compare TCEP unreduced and TCEP reduced samples, protein bands from both lanes were 
analysed (Figure 4.10 and Figure 4.11, respectively). Peptides corresponding to pepsinogen 
Adhiron A1 were identified in bands at approximately 14 kDa, 28 kDa, 42 kDa and 56 kDa in 
both samples (Figure 4.10 and Figure 4.11).  As the molecular weight of the protein bands 
increased, the sequence coverage achieved decreased which was probably due to the 
decreasing intensity of the higher molecular weight bands. Despite incomplete sequence 
coverage of pepsinogen Adhiron A1 at the higher mass ranges, the results are sufficient to 









Figure 4.9 | TCEP reduction time-course of pepsinogen Adhiron A1. 
Samples were taken during the time-course for ESI-MS analysis. Rapid reduction of 
pepsinogen Adhiron A1 occurs after the first 5 minutes. SDS-PAGE analysis of pepsinogen 
Adhiron A1 pre and post 1 hour TCEP reduction reveals comparable protein bands 
suggesting SDS-PAGE causes the Adhiron to aggregate or the presence of major 










Figure 4.10 | MALDI spectra of in-gel digest of bands in non-reduced Adhiron A1 sample and peptide maps.  
Main peaks labelled with corresponding peptide number. Confirmation that the Adhiron forms aggregates when analysed by SDS-PAGE. Increasing protein 









Figure 4.11 | MALDI spectra of in-gel digest of bands in TCEP reduced Adhiron A1 sample and peptide maps.  
Main peaks labelled with corresponding peptide number. Confirmation that the Adhiron forms aggregates when analysed by SDS-PAGE. Increasing protein 




4.3.2 Design, expression and purification of ‘non-digestible’ Adhiron 
To generate a protein scaffold resistant to Lys-C proteolysis, the lysine residues within the 
protein would have to be substituted to another residue. The most favoured amino acid 
residue that shares similar properties is arginine; both amino acids are polar, positively 
charged residues. Pepsinogen A4 was selected for modification as the protein contained no 
lysine residues in its variable loop regions. The non-digestible pepsinogen Adhiron A4 was 
termed pepsinogen Adhiron [A4_K_R] (Figure 4.12). 
Pepsinogen Adhiron [A4_K_R] was expressed as described in Chapter 2.1. The gene was 
synthesised by GeneMill at the University of Liverpool and cloned into a pET11a plasmid 
and the plasmid was transformed into BL21 (λDE3) E.coli cells. The pET11a plasmid contains 
a gene for antibiotic resistance to ampicillin and therefore only transformed cells containing 
the plasmid were selectively grown. A single colony was selected from the overnight agar 
plates and used to inoculate a small overnight LB culture. For larger scale production, the 
overnight culture was used to inoculate a 200 mL LB broth containing ampicillin. The 
growth rate was monitored by removal of culture solution at time points during the 
expression. To investigate culture growth and protein expression, the E.coli growth curve 
was analysed and pre- and post- induction times analysed by SDS-PAGE (Figure 4.13). For 
both the pre- and post- lanes on SDS-PAGE, a band is present at approximately 14 kDa, 
although the band did become more intense following IPTG induction. This is the expected 
molecular weight of pepsinogen Adhiron [A4_K_R] suggesting expression of the correct 
protein. As with pepsinogen Adhiron A1, the band observed at 14 kDa pre-induction 
indicated leaky protein expression. The protein was purified as described in Chapter 2.3 
using Ni-NTA affinity chromatography using a manual elution. Elution fractions were 
analysed by SDS-PAGE (Figure 4.13) which determined the protein eluted in elution fraction 
2. The protein concentration was determined by Coomassie plus protein assay and as with 
the other Adhirons, the protein was stored in the elution buffer until needed for 
downstream analysis.  
To confirm expression and purification of the pepsinogen Adhiron [A4_K_R], the protein 
was analysed by intact mass spectrometry as described in Chapter 2.21 (Figure 4.14). Prior 
to MS analysis, pepsinogen Adhiron [A4_K_R] was incubated with DTT for 30 minutes to 
reduce the protein into a monomer followed by sample clean-up using an offline desalting 
C4 trapping column. The main peak within the mass spectrum of 12581.3 Da corresponded 




methionine residue. This result confirmed expression of the correct protein and allowed 
further characterisation studies on the expressed protein to be carried out.  
4.3.3 Characterisation of pepsinogen Adhiron [A4_K_R] 
Although pepsinogen Adhiron [A4_K_R] had the expected molecular weight, to further 
validate and confirm expression of the correct protein with the right substitutions, a 
proteolysis study was undertaken using either trypsin or Lys-C. As pepsinogen Adhiron 
[A4_K_R] contained no lysine residues as they were substituted for arginine residues, the 
protein should be resistant to Lys-C proteolysis. Conversely, pepsinogen Adhiron A4 had 12 
lysine residues and therefore the protein should be amenable to digestion with Lys-C.  
The Adhirons were digested as described in in Chapter 2.17. Following overnight 
incubation, the digestion was stopped with the addition of TFA. As TFA can cause 
undigested protein to form a precipitate, a pre-TFA sample was taken to check for the 
presence of protein. After the addition of TFA and centrifugation, a large white protein 
pellet was visible in the pepsinogen Adhiron [A4_K_R] sample digested with Lys-C. This 
would suggest that the protein has precipitated out of solution and did not undergo 
proteolysis. To evaluate proteolysis, samples were analysed by SDS-PAGE (Figure 4.15). 
Pepsinogen Adhiron A4 undergoes complete proteolysis when digested with either trypsin 
or Lys-C (Figure 4.15). As the protein contains both lysine and arginine residues, this result 
was expected. Pepsinogen Adhiron [A4_K_R] undergoes complete proteolysis with trypsin 
however remains intact following incubation with Lys-C (Figure 4.15). As pepsinogen 
Adhiron [A4_K_R] contained no lysine residues, the cleavage site for Lys-C, the protein was 
resistant to Lys-C proteolysis. This result confirms the successful expression of a pepsinogen 
Adhiron that is resistant to Lys-C proteolysis. 
To further validate the introduction of the arginine mutations and to compare the 
difference in peptides using different proteases, the pepsinogen Adhirons were analysed by 
LC-MS/MS using the Thermo QExactive mass spectrometer. As SDS-PAGE results indicate 
pepsinogen Adhiron [A4_K_R] did not digest with Lys-C, this sample was not analysed by 
LC-MS/MS (Figure 4.15). Peptide map analysis of both pepsinogen Adhiron A4 and 
pepsinogen Adhiron [A4_K_R] demonstrates differences in peptides generated when 
incubated with different proteases. A Lys-C digestion generates larger peptides due to the 
fewer cleavage sites. Analysis of BPI chromatograms reveals differences in peptide elution 













Figure 4.12 | Amino acid sequence alignment of pepsinogen Adhiron A4 and pepsinogen Adhiron [A4_K_R].  
Protein sequences were aligned and visualised using CLC Viewer. Amino acid residues were coloured using the Rasmol colour scheme. Variable loop regions 
of the proteins are evident at positions 39 to 57 and 73 and 81 for loop 1 and loop 2 respectively. The theoretical mass of pepsinogen Adhiron A4 (minus the 





Figure 4.13 | Expression and purification of pepsinogen Adhiron [A4_K_R].  
Top Left: SDS-PAGE analysis of pre-induction and post-induction time-points for pepsinogen 
Adhiron [A4_K_R]. Top Right: Growth curve for pepsinogen Adhiron [A4_K_R] expression. 
Protein expression was induced with IPTG at an OD = 600 nm and protein left to 
accumulate for 4 hours. Bottom: His-tag proteins purified using GE Healthcare Ni-NTA 
affinity columns using a manual elution. Adhirons predominantly elute in elution fraction 2. 
10 µL of each fraction was ran on a 15 % gel and visualised with Coomassie plus stain. SM - 
starting material, FT- flow through and E- elution. Samples ran on a 15 % gel and visualised 













Figure 4.14 | ESI-MS analysis of pepsinogen Adhiron [A4_K_R] incubated with DTT. 
The protein was incubated with DTT to reduce the Adhirons. After offline C4 trap clean-up 
to remove glycerol and salts, protein samples were diluted to 1 pmol/µL in 3% acetonitrile, 
0.1% formic acid. 2 µL of each sample was loaded onto a C4 desalting trapping column. 
Samples were analysed by ESI-MS on the Waters G2 mass spectrometer. Multiply charged 
protein envelope was deconvoluted using Waters MAXENT 1 algorithm to determine 






Figure 4.15 | SDS-PAGE analysis of pepsinogen Adhiron A4 and pepsinogen Adhiron 
[A4_K_R] trypsin and Lys-C proteolysis.  
Top: Pepsinogen Adhiron A4 undergoes complete proteolysis when digested with trypsin 
and Lys-C. Bottom: Pepsinogen Adhiron [A4_K_R] undergoes complete proteolysis when 
digested with trypsin however remains intact when digested with Lys-C. SM – starting 
material. Pre-TFA – Adhiron after overnight digest before TFA addition. Post-TFA – Adhiron 
after overnight digest after TFA addition. The samples were ran on a 15 % gel and visualised 









Figure 4.16 | BPI chromatograms and peptide map for pepsinogen Adhiron A4 and pepsinogen Adhiron [A4_K_R].  
BPI chromatogram with main peaks labelled with corresponding peptide number. Blue peptides identified in mass spectrum with no missed cleavages sites, 
whereas red peptides were identified with one missed cleavage site. Black regions represent unidentified peptides. The peptide maps were generated using 




To investiagte whether the lysine to arginine substitions introduced into pepsinogen 
Adhiron A4 to generated pepsinogen Adhiron [A4_K_R] affects the stability of the protein, a 
proteolysis study was undertaken to examine the rate of proteolysis of the proteins. The 
protease used was chymotrypsin which cleaves at the aromatic amino residues of 
phenylalanine, tyrosine and tryptophan44. A total of 75 µg of both proteins were seperately 
incuabted with 1.5 µg chymotrypsin at 25 oC for 3 hours. Aliquots of sample were taken 
periodically to assess the degree of proteolysis and analysed by SDS-PAGE (Figure 4.17) and 
intact mass spectrometery (Figure 4.18). Proteolysis was stopped by the addition of either 
formic acid for MS analysis or by the addition of TCA for SDS-PAGE analysis followed by 
neutralisation with ammonium bicarbonate. A control sample of each protein was also 
incubated at 25 oC for 3 hours to confirm degredation from the protease and not from the 
temperature. SDS-PAGE analysis reveals that after a 3 hour incubation with chymotrypsin, 
neither pepsinogen Adhiron A4 or pepsinogen Adhiron [A4_K_R] underwent complete 
proteolysis. Lower molecular weight species were observed during the timecourse 
corresponding to an intermediate species forming. After 30 minutes, the protein band for 
the full length version of both proteins is not observed. Intact mass data supports the 
results with identification of fragments of 11421.8 Da and 11284.5 Da in pepsinogen 
Adhiron A4 and 11757.6 Da and 11620.6 Da for pepsinogen Adhiron [A4_K_R] 
corresponding to the loss of six and seven histidine residues (-HHHHHH and -HHHHHHH) in 
both proteins (Figure 4.18). An additional species was observed for pepsinogen Adhiron 
[A4_K_R] with the loss of 2 histidine residues at 2 and 10 minutes. The ratio of starting 
protein to intermediate species is slightly higher for pepsinogen Adhiron A4 compared to 
pepsinogen Adhiron [A4_K_R] at 30 minutes (Figure 4.18), however the rate of proteolysis 
is very comparable. The findings suggest that the mutations introduced into pepsinogen 
Adhiron A4 to form pepsinogen Adhiron [A4_K_R] do not alter the stability of the protein. 
Interestingly, histidine was not a preferential cleavage site of chymotrypsin, although 
histidine cleavage has been found to a less extent235. The free His-tag of the Adhirons 
probably faciliated histidine residue cleavage due to the ease of accessability. Lack of 
proteolysis of both Adhiron structures highlights the robust nature of the protein scaffold. 
To further compare the stability of the two proteins, a collision induced unfolding (CIU) 
experiment was perfomed using ion mobility separation mass spectrometry (IMS- MS) as 
descibed in Chapter 2.23. CIU experiments were performed under native condtions and 
therefore the Adhirons were buffer exchanged into 500 mM ammonium acetate. The 




was observed that when a lower concentration of ammmonium acetate was used, the 
Adhirons would precipitate from solution. The proteins were ionised by electrospray 
ionisation to produced multiple charged species. The number of charged states observed 
for both pepsinogen Adhiron A4 and pepsinogen Adhiron [A4_K_R] were fewer than when 
under denaturing conditions, due to the inaccessibility of the sites of protonation (data not 
shown). Furthermore, as the Adhirons did not undergo reduction prior to analysis, the 
dimer form of the Adhirons was also observed. For the CIU experiment, a single charge 
state was selected and subjected to collisional activation by CID. The activation collison 
energy (CE) was increased from 10 V to 26 V by 2 V increments.  Comparison of the CCS 
distribution and CIU profiles of the two Adhirons revealed differences across the CE range 
(Figure 4.19). At low CE, both proteins adopted a similar cross sectional area of 
approximalty 12 nm2. Both Adhirons required the same CE to induce unfolding  however 
pepsinogen Adhiron [A4_K_R] required higher CE to initiate further unfolding compared to 
pepsinogen Adhiron A4 (22 V compared to 14 V). In addition, at higher CE (26 V) pesinogen 
Adhiron A4 adopted a single elongated conformation at 22 nm2, whereas pepsinogen 
Adhiron [A4_K_R] adopted three distinct conformation at approxiamtely 16 nm2, 19 nm2, 
and 22 nm2 (Figure 4.19). Although arginine and lysine are both positively charged basic 
residues, arginine has a higher pKa which means it generated more stable ionic interactions 
than lysine236. In addition, arginine residues contain a guanidinium group which increases 
the number of electrostatic interactions that can be made compared to lysine237. Therefore, 
the arginine residues may form an increased number of electrostatic interactions which 
may provide the protein with more stabilty. Stability studies on green fluorescent protein 
established that surface lysine to arginine mutations increased protein stabiltiy238. This 
could explain why a higher CE is needed to induce further unfolding of the pepsinogen 








Figure 4.17 | SDS-PAGE analysis pepsinogen Adhiron [A4_K_R] and pepsinogen Adhiron 
A4 proteolysis time-course. 
Top: Pepsinogen Adhiron A4. Bottom: Pepsinogen Adhiron [A4_K_R]. Proteins were 
incubated at 25 oC for 3 hours. Aliquots of samples were taken throughout the time-course 
for analysis. Both proteins incubated with chymotrypsin do not undergo complete 
proteolysis with a stable fragment forming after 3 hours. Control gels with no chymotrypsin 
demonstrate that both pepsinogen Adhiron A4 and pepsinogen Adhiron [A4_K_R] do not 
degrade after 180 minutes at 25 oC. Samples were ran on a 15 % gel and visualised with 











Figure 4.18 | ESI –MS analysis of pepsinogen Adhiron [A4_K_R] and pepsinogen Adhiron A4 proteolysis time-course. 
Proteins were incubated at 25 oC for 3 hours. Aliquots of samples were taken throughout the time-course for analysis. Proteolysis was halted by the addition 
of TCA (5 % final concentration). Both proteins withstood complete proteolysis with intermediate species forming with the loss of six histidine residues and 








          
Figure 4.19 | CIU analysis of pepsinogen Adhiron A4 and pepsinogen Adhiron [A4_K_R] by ESI-IMS-MS. 
Pepsinogen Adhiron A4 and pepsinogen Adhiron [A4_K_R] were analysed by ESI-IMS-MS on the Waters Synapt G2Si in ammonium acetate. CCS distribution 




4.3.4 SulfoLink® Adhiron affinity purification of pepsinogen  
Various immobilisation strategies were described and optimised in Chapter 3. As the 
Adhirons had a His-tag and a cysteine residue, numerous immobilisation techniques were 
available for the affinity purification. Of the immobilisation strategies described, the 
preferred method was the SulfoLink® resin which utilised the cysteine residue from 
covalent immobilisation. Firstly, Adhirons were immobilised to the SulfoLink® resin as 
described in Chapter 2.15. As a quick screen to assess pepsinogen capture by the Adhirons, 
all five Adhirons were analysed. To confirm the successful immobilisation of the Adhirons to 
the SulfoLink® resin, the remaining unbound Adhiron fraction was analysed by SDS-PAGE 
(Figure 4.20). Although the binding conditions and efficiency of Adhirons to the SulfoLink® 
had already been determined in Chapter 3, due to the position of the cysteine residue 
being before the His-tag, binding efficiency was assessed. Equal volumes of the Adhiron 
starting material and unbound fraction were loaded onto the gel and thus depletion of the 
Adhiron could be determined. The initial wash fraction was also analysed by SDS-PAGE to 
assess whether the Adhirons were washed from the resin. A very faint band at 
approximately 14 kDa was observed in the unbound fraction lane for all Adhirons indicating 
sufficient binding of the pepsinogen Adhirons to the SulfoLink® resin. No bands were 
observed in the wash fractions indicating that the Adhirons were not removed from the 
resin during the wash step and the lack of non-specific Adhiron binding. 
After confirming immobilisation of the Adhirons, the resin-Adhiron complexes were blocked 
with free cysteine and then incubated with human pepsinogen.  In total, 5 µg of human 
pepsinogen in PBS was incubated with the pepsinogen Adhirons resin complex. 
Recombinant pepsinogen was purchased from Cell Sciences (USA) and was the same 
recombinant protein that had been used in the phage display screens. As the pepsinogen 
Adhirons had not been validated for use in an affinity purification workflow, it was 
necessary to use recombinant protein from the same supplier as in the phage display 
screens. Pepsinogen Adhiron [A4_K_R] was also included in the analysis despite having the 
same variable regions as pepsinogen Adhiron A4. After incubation, the unbound 
pepsinogen fraction was removed and the resin washed with PBS. A stringent wash buffer 
was not initially used as the strength of the Adhiron-pepsinogen bond was unknown and to 
ensure the interaction was not diminished. After the final wash, PBS and sample buffer was 
added to the resin and then incubated for 5 minutes at 95 oC. The resin was re-suspended 
and analysed by SDS-PAGE (Figure 4.21). A faint band was visible at approximately 14 kDa 




covalently immobilised onto the SulfoLink® resin by a thioester bond and therefore even 
after incubation with reducing sample buffer, the Adhirons could not be eluted off the 
resin. However, it appears that a small amount of Adhiron has been removed from the 
resin. It was likely that the Adhiron removed from the resin was not covalently bound but 
instead non-specifically bound to either the resin or to other Adhirons that were covalently 
immobilised.  At approximately 47 kDa, a faint band representing pepsinogen was observed 
for all pepsinogen Adhirons suggesting that the Adhirons successfully captured pepsinogen. 
However, despite a pepsinogen band present for all Adhirons samples, there is also a 
pepsinogen band present in the resin only lane. This indicates that pepsinogen was binding 
to the resin non-specifically and therefore capture of pepsinogen by the Adhirons couldnot 
be confirmed.  
The wash step in the affinity purification was a PBS buffer which was used so that the 
pepsinogen interaction was not disrupted. As this wash was not sufficient in reducing non-
specific interactions, the affinity purification was repeated with a more stringent wash 
buffer. As before, the resin was analysed by SDS-PAGE (Figure 4.21). Similar results were 
observed with a band at approximately 47 kDa representing pepsinogen observed in the 
Adhiron samples but also in the resin only lane. This again indicated that enrichment of 
pepsinogen could not be confirmed as in the Adhiron containing samples, pepsinogen could 
be binding to the resin instead of the Adhirons. Further analysis was not performed on 
protein bands visible at approximately 25 kDa, 70 kDa and 80 kDa due to time constraints. 
An in-gel digest of the bands to confirm the protein identity of the species would be the 
next step. 
Due to time restrictions, further work developing the Adhiron SulfoLink® affinity 
purification of pepsinogen was not performed. However, various steps, outlined below, 
could be carried out with the aim to achieve a successful affinity purification using the 
SulfoLink® resin. Firstly, wash buffer optimisation is necessary. As it is unlikely that 
pepsinogen was binding covalently to the SulfoLink® resin as it contains no free cysteine 
residues, then increasing the stringency of the wash buffer should reduce the amount of 
non-specific binding of pepsinogen to the resin. However, there is a compromise between 
maintaining the Adhiron-pepsinogen interaction and reducing non-specific interactions. The 
five pepsinogen Adhirons selected as pepsinogen binders, were chosen based on ELISA data 
obtained at the University of Leeds. The Adhiron proteins used within this chapter were 
generated at the University of Liverpool. As the Adhirons were from a different 




Leeds by ELISA would further validate the pepsinogen Adhirons for binding. In addition, 
although all five pepsinogen Adhirons have the correct theoretical molecular weight, the 
proteins may not have adopted the same conformational shape as previously observed.  
Determination of correct protein folding should be carried out to ensure the correct 









Figure 4.20 | SDS-PAGE analysis of unbound Adhiron fractions from affinity purification 
with SulfoLink® resin. 
Equivalent volumes of starting material, unbound fraction and wash 1 loaded analysed by 
SDS-PAGE so depletion of the Adhiron due to immobilisation onto the SulfoLink resin can be 
observed. Faint band observed in the unbound fraction lanes for all Adhirons indicating that 
the majority of the Adhiron is immobilised onto the resin. SM – starting material, UF – 
unbound fraction, W1- wash 1. Samples were ran on a 15 % gel and visualised with 








pH 8 Wash  
 
 
Figure 4.21 | SDS-PAGE analysis of pepsinogen affinity purification with SulfoLink resin. 
Top: Resin washed with PBS only. Bottom: Resin washed with wash buffer pH 8. The resin 
was re-suspended with sample buffer and heated at 95 oC for 5 minutes. The resin-sample 
buffer mix was loaded directly onto the gel for analysis. Small amounts of non-specifically 
bound Adhiron eluting from the resin. Enrichment of pepsinogen observed by all Adhirons 
however, pepsinogen also identified in the negative control lane. Samples were ran on a 15 






A key aim of this chapter was to express and purify Adhiron binders that target human 
pepsinogen. The work undertaken has confirmed the successful expression and purification 
of five pepsinogen Adhirons. In addition, a key aim was develop a mutant Adhiron that was 
resistant to proteolysis. The substitution of all lysine residues to arginine residues within 
the pepsinogen Adhiron A4 sequence generated an Adhiron resistant to Lys-C proteolysis. 
Structural analysis by IMS-MS and a proteolysis time-course established that the mutations 
did not have a detrimental effect on protein stability. An affinity reagent resistant to Lys-C 
proteolysis will be beneficial in affinity purification mass spectrometry assays. The 
preliminary work demonstrates that as a proof of concept, Adhirons are amenable to 
further modification without affecting the structural stability of the protein. 
 The final aim of this chapter was to use pepsinogen Adhirons in a SulfoLink® affinity 
purification assay to capture human pepsinogen. Although the method was successfully 
developed in Chapter 3 using an Affimer designed to capture human IgG, enrichment of 
pepsinogen could not be confirmed due to pepsinogen binding non-specifically to the resin. 
This work demonstrates that a single affinity purification protocol cannot be applied to the 
analysis of all Adhirons. The workflow needs individualisation depending on the capture 







Chapter 5: Comparative Proteomic Analysis of Human Plasma from 
Patients with Sepsis 
5.1 Introduction 
Unbiased biomarker discovery studies are extremely important in clinical research to 
identify novel protein markers to improve disease diagnosis, monitor disease progression 
and to determine the effectiveness of therapeutics. As discussed in Chapter 3, the use of 
naive Affimer arrays in a large scale, multiplexed format provides great promise in 
biomarker discovery. The approach allows for the enrichment of target proteins using 
Affimers that contain randomised variable regions for an unbiased analysis of a proteome. 
Coupled with mass spectrometry for naive Affimer target protein identification, the 
potential of the technique to bring new insights into biomarker discovery is huge. However, 
despite the promise of naive Affimer technology, due to the current limitations outlined in 
Chapter 3, the methodology needs further development and optimisation to truly gain 
definitive identifications of naive Affimer protein targets. Therefore, developing an 
alternative method to identify putative protein markers is vital.  
Figure 5.1 summarises the experimental workflow for both an Affimer- and a proteomics- 
based approach to reach the common goal of the identification of a panel of potential 
protein biomarkers. The outcomes of both approaches will guide the production of Type II 
Affimers, based on the cystatin A consensus sequence, that are the preferred scaffold 
choice due to the higher binding affinities observed to their intended protein target. The 
work described in this chapter will describe the proteomics approach taken to identify a 
panel of potential biomarkers of sepsis.   
Sepsis is a systemic immune response caused by infection and is a major clinical problem 
across the world due to the high mortality rates. The symptoms of sepsis are extremely 
nonspecific as patients present with breathing difficulties, confusion, nausea and vomiting 
and fever. Without rapid therapeutic intervention, severe complications of sepsis can arise 
such as arterial hypotension or organ dysfunction significantly reducing patient survival 
rates239. There is an unprecedented need for an accurate and rapid diagnosis to improve 
patient outcomes. A proposed method for fast disease diagnosis is point-of-care testing 
(POCT). Typically, patient samples are sent to hospital laboratories, imposing a time delay 
on results and requiring highly skilled technicians. In contrast, POCT allows samples to be 




Patients from low income and rural communities, where resources are limited would 
hugely benefit from a POCT kit for sepsis. 
 
Figure 5.1 | Proposed experimental workflows to identify protein markers of sepsis. 
 
Due to the lack of recognised biomarkers to diagnose sepsis, POCT kits are limited. 
Currently, POCT technology is available to measure lactate in the blood of patients with 
suspected sepsis240 and to measure key acute phase proteins such as C-reactive protein241 
and procalcitonin242. Miniaturised multiplexed POCT devices that detect a panel of markers 
of sepsis have been described in the literature243,244, however they are yet to be 
implemented in the clinic. The ability to generate highly stable Affimers to desired protein 
targets make them the ideal reagent for POCT devices. A preliminary study using Affimer 
reagents in a sandwich assay format has been reported195,245 and with further technological 
advances, development and miniaturisation of a POCT device using Affimers is feasible. The 
work in this chapter will contribute to the ultimate goal of developing an Affimer-based 
POCT device for sepsis. 
The first stage in the development of an Affimer-based POCT device is to identify sepsis 
plasma biomarkers. Plasma is the preferred biological matrix over serum246 when studying 




been allowed to clot whereas plasma is obtained from blood that has added anticoagulants. 
During whole blood coagulation, various proteins are secreted by cellular components of 
the process247. In addition, numerous proteins are removed during clot formation due to 
direct involvement in the coagulation or through non-specific interactions.  As activation of 
the coagulation cascade, induced by toxins and the proinflammatory cascade occurs in 
patients with sepsis, to gain a true understanding of the proteomic expression in sepsis248, it 
is vital that proteins involved in coagulation are not removed. Furthermore, plasma is 
considered a more reproducible matrix compared to serum246. The proteomic analysis of 
sepsis plasma by mass spectrometry is not a novel approach, with the methodology 
reported in numerous studies identifying many potential markers of sepsis including 
traditional markers such as C-reactive protein (CRP) 213,249. Although procalcitonin has 
potential as a biomarker of sepsis, its value has been questioned in numerous studies as it 
is unsuccessful at distinguishing sepsis from other inflammatory diseases239,250. To date, an 
individual sepsis protein biomarker had not been discovered that can suitably diagnose and 
manage sepsis due to the lack of specificity of protein markers distinguishing sepsis from 
other inflammatory diseases. A new focus of identifying a panel of sepsis biomarkers is 
considered the best approach to accurately identify patients with sepsis. 
As reviewed in Chapter 1, the complexity and large dynamic range of the human plasma 
proteome is a major challenge for LC-MS/MS discovery proteomics and has hindered 
biomarker discovery studies. The abundance of plasma proteins spans over 10 orders of 
magnitude19 which is much greater than the dynamic range capabilities of current LC-
MS/MS approaches. The peptides from highly abundant proteins can hinder the 
identification of peptides from lower abundance proteins by masking their signal from 
detection. Despite both high and low abundance proteins being clinically informative, it has 
been frequently reported that to gain novel insights into disease diagnosis and to identify 
potential disease biomarkers, the detection of low abundance proteins provides greater 
value. Low abundance plasma proteins are typically associated with disease specific protein 
secretions, leakage from tissues and cytokines making them ideal protein biomarkers19. 
The most abundant protein in plasma is albumin, with a normal clinical reference range of 
35 – 50 mg/mL251, which corresponds to approximately 50 % of the total plasma protein 
content252. Along with albumin, an additional 21 plasma proteins make up approximately   
99 % of the total protein content of plasma2. Therefore, in order to detect and identify the 
remaining 1 % of plasma proteins, depletion strategies for the abundant proteins need to 




In 2003, immunoaffinity depletion columns, containing antibodies to multiple protein 
targets were first described as a method to remove abundant proteins from plasma66. The 
work was a development from antibody-based protein purification methods where a single 
antibody was used per column 253.  The application of immunoaffinity depletion columns 
has become common practice in the analysis of plasma and serum, typically removing the 
top 12 or top 14 most abundant plasma proteins. However, a limitation of the columns is 
the high cost associated with the depletion columns and the risk of non-target protein loss.  
An alternative approach to expensive immunoaffinity depletion methods is the targeted 
removal of albumin. As previously stated, albumin contributes to approximately 50 % of 
total plasma protein and therefore its removal would significantly reduce the dynamic 
range of the plasma proteome. The proposed method is based on a combined approach of 
TCA and organic solvent to precipitate protein200, originally based on the Cohn’s process254 
and later developed with the additional of TCA255. The two depletion strategies are yet to 
be compared. 
5.2 Aims and Objectives 
The work in this chapter focuses on the identification of a panel of candidate proteins 
implicated in sepsis for phage display production of Affimers. The key objectives of this 
chapter were to: 
- Select a suitable method for plasma depletion and sample concentration. 
- Extensively characterise the sepsis plasma proteome to determine changes in 
protein expression induced by sepsis. 





5.3 Results and Discussion 
5.3.1. Selection of depletion method 
As depletion of highly abundant plasma proteins is essential in order to increase proteome 
depth and coverage, two plasma depletion methods were compared to establish the ideal 
method for protein depletion. Human plasma was depleted using either the Thermo 
Scientific Pierce top 12 abundant protein depletion spin columns or the partial plasma 
depletion method as described in the methods section. The proteins depleted by the Pierce 
top 12 abundant protein depletion spin columns are listed in Table 5.1.   
Table 5.1 | Top 12 plasma proteins depleted by Thermo Scientific Pierce Top 12 Abundant 
Depletion Spin Columns and plasma reference ranges. 
α1- Acid 
Glycoprotein 
60 – 120 mg/dL Fibrinogen 200 – 400 mg/dL 
α1-Antitrypsin 78 – 200 mg/dL Haptoglobin 30 – 200 mg/dL 
α2-Macroglobulin 106 – 279 mg/dL IgA 70 – 400 mg/dL 
Albumin 6.4 – 8.3 g/dL IgG 700 – 1600 mg/dL 
Apolipoprotein A-I 101 – 199 mg/dL IgM 40 – 230  mg/dL 
Apolipoprotein A-II 30 – 50 mg/dL Transferrin 212 – 360 mg/dL 
 
The depleted plasma samples, along with non-depleted plasma used to compare standard 
protein abundances, were digested in triplicate following the protocol listed in methods. 
Prior to LC-MS/MS analysis, plasma samples depleted using the depletion spin columns 
were concentrated using Vivaspin® centrifugal concentrators with a 3000 molecular weight 
cut off to reduce the total sample volume from 500 µL to 100 µL. A filter based method was 
selected for concentration so that the salt concentration within the sample did not 
increase. Preliminary LC-MS/MS analysis of the spin column depleted plasma samples 
revealed contamination by PEG. Insufficient washing of the filter concentrators prior to 
sample loading was responsible for the contaminant. To remove the PEG, an additional 
strong cation exchange step was performed, as described in the Chapter 2. Digested 




using Proteome Discoverer and the resultant mgf file searched in MASCOT against a human 
database. The plasma digests were loaded onto the instrument to achieve base peak 
intensity (BPI) chromatograms of similar intensities as opposed to loading a set amount of 
protein. The total ion count (TIC) chromatogram was also assessed as they were more 
representative of the complete sample peptide content and revealed similar findings to the 
BPI chromatograms. The rationale behind this was that typically peptides from albumin 
limit the loading of the digested plasma. In the case of the depleted plasma digests, 
albumin and other highly abundant proteins had been removed allowing for more of the 
plasma digests to be loaded onto the instrument.  
To evaluate the depletion workflows, the total number of proteins, peptides and PSMs 
identified from the digests of the different plasma preparation methods were compared 
(Figure 5.2.). The spin column depleted plasma achieved the best proteome coverage with 
the highest numbers of protein, peptide and PSM identifications. This result was expected 
as the highly abundant proteins have been depleted, more of the sample can be loaded 
onto the instrument resulting in the peptides from less abundant proteins brought into the 
detectable range of the instrument. The performance of TCA precipitation depleted plasma 
and non-depleted plasma have fairly comparable results with an average of 77 and 85 
proteins identified respectively. Comparison of the BPI chromatograms reveal differences in 
the plasma sample complexity depending on depletion method; plasma samples depleted 
using the Pierce spin columns look far more complex than the non-depleted plasma and the 
partial TCA precipitation depleted plasma (Figure 5.3). BPI chromatograms of partial 
depleted and non-depleted plasma appear very similar suggesting inadequate removal of 
the highly abundant proteins from the partial depletion plasma samples. The results of total 
protein identifications further support this. The number of identifications achieved for each 
replicate of the same depletion method was similar as evident from the small standard 
deviations indicating low variability in depletion methods. For all three plasma preparation 









Figure 5.2 | Protein, peptide and PSMs identifications of different depletion methods.  
Bars represent mean number of identifications of the 3 replicates with error bars 
representing standard deviation. Standard deviation is small for all samples indicating high 
reproducibility of the depletion methods. Spin column depleted plasma yielded the highest 
number of protein, peptide and PSM identifications of the methods. The numbers obtained 





Figure 5.3 | Comparison of BPI chromatograms of depletion methods. 
Digests analysed on Thermo Scientific QExactive mass spectrometer on a 2 hour gradient. 
Each sample was analysed in triplicate. Top panel: Non-depleted plasma. Middle panel: TCA 
precipitation partial plasma depletion. Bottom panel: Thermo Scientific Pierce depletion 




To investigate the efficacy of the protein depletion methods at removing the highly 
abundant proteins, abundance values for 4 of the 12 most abundant plasma proteins were 
compared (Figure 5.4.). Due to the differences in sample loading, it was more informative 
to compare label-free protein abundances, calculated from the peak area of the top three 
most abundant peptides for a given protein, expressed as a percentage of total protein 
abundance instead of comparing raw protein abundance values. Albumin represented 2 %, 
51 % and 53.8 % of the total plasma protein for spin column depleted, non-depleted and 
TCA precipitation partial depletion plasma, respectively. Albumin had thus been removed 
successfully from the spin column depleted plasma samples, whereas there has been no 
depletion of albumin from the partial depletion TCA precipitation plasma samples. The 
protein abundance values of haptoglobin, alpha-1 anti-trypsin and apoliporotein A-I for TCA 
precipitation partial depletion plasma and non-depleted plasma are also very similar 
demonstrating the lack of protein depletion.    
As albumin contributed 50 % of the total protein content of plasma, its effective removal 
has a significant impact on the characterisation of plasma as demonstrated in the increase 
in the total proteins identified. The effect is also noted when comparing the protein 
abundance values of abundant plasma proteins that should be depleted (Figure 5.4). 
Albumin accounts for approximately 50 % of the protein abundance19, for the TCA partially 
depleted plasma and the non-depleted plasma; this leaves the other proteins identified (76 
proteins and 84 proteins, respectively) to share the remaining 50 % of the protein 
abundance signal. As a result, the protein abundance (%) of the other highly abundant 
proteins is relatively low compared to the spin column depleted plasma that has had the 
albumin effectively depleted. This is particularly evident with apolipoprotein A-I and alpha-
1-antitrypsin where it appears that the proteins have not been depleted by the depletion 
spin columns when comparing the percentage protein abundance to non-depleted and TCA 
precipitation partial depleted plasma (Figure 5.4). Therefore, it may be more informative to 
compare the rank order of the most abundant proteins quantified in each method.  
To further assess the effectiveness of the depletion methods, protein abundance plots were 
generated to evaluate the dynamic range of the plasma and the rank order of proteins 
quantified using the different depletion methods (Figure 5.5). The dynamic range of the 
TCA partial depleted plasma is very similar to non-depleted plasma with most proteins 
displaying a similar pattern in abundance. Albumin is the most abundant protein in the TCA 
partial depleted and non-depleted plasma, whereas in the spin column depleted plasma it 




plasma is hemopexin whereas in non-depleted and TCA partial depleted plasma it is the 
18th and 13th most abundant protein respectively (Figure 5.5). In addition, the gradient of 
the dynamic range plot for the spin column depleted plasma is less steep at the highly 
abundant protein end of the plot compared to non-depleted plasma indicating effective 
depletion of abundant proteins.  
The spin column depletion method allowed for approximately 120 times more of the 
plasma sample to be loaded onto the instrument than non-depleted plasma compared to 
the TCA partial depleted plasma which allowed for only 1.25 times more samples to be 
loaded. As fewer proteins were identified with this method, it is likely that the increase in 
loading was necessary to account for loss of protein during the depletion protocol. This 
significant increase in sample loading, as well as increase in the number of proteins 
identified can be attributed to protein depletion. Based on the findings from the analysis of 
the different plasma depletion methods, the spin column depletion method was selected as 











Figure 5.4 | Comparison of protein abundance values of four abundant plasma proteins. 
Abundance values of albumin, haptoglobin, alpha-1-antitrypsin and apolipoprotein A-1 expressed as a percentage of total protein abundance. Comparison 






Figure 5.5 | Dynamic range comparison of depleted plasma proteome. 
The mean normalised abundance value of each protein identified in spin column depleted, 
non-depleted and TCA precipitation partial depleted plasma was calculated in Proteome 
Discoverer using the peak area of the top 3 most abundant peptides for a given protein. 
Ordered by control abundance values. Error bars represent standard deviation. Top: 





5.3.2. Selection of concentration method 
5.3.2.1. Assessment of StataClean™ resin for protein concentration 
In the preliminary experiment assessing plasma depletion protocols, a filter based method 
was used to concentrate the plasma sample following spin column depletion. However, 
sample recovery is a major concern when using protein concentrators with semi-permeable 
membranes such as the Vivaspin® filters. Proteins can adhere to the membrane resulting in 
low sample recovery rates. In addition, the membranes within the filtration devices are 
often coated with glycerol and humectants that can introduce contaminates into the 
sample if not washed properly.  
To overcome this, a method to concentrate protein that is frequently used in our laboratory 
is a form of solid phase extraction (SPE) using StataClean™ resin256. StataClean™ resin was 
initially developed as an alternative to phenol based methods for DNA purification to 
remove proteins and enzymes257. The resin is coated with hydroxyl groups to which 
proteins bind, separating the DNA from proteins. The standard method used within our 
laboratory is to bind the proteins within a dilute sample and carry out an in-solution digest 
directly on the StrataClean™ resin. Direct digestion of the resin reduces sample handling 
steps and eliminates the need to elute the proteins from the resin.  
To investigate the suitability of StrataClean™ resin to concentrate protein samples, the 
method was assessed to determine whether the resin binds all protein within a sample. 
Four separate human plasma samples, differing in protein concentration and volume (100 
µg in 1 mL, 100 µg in 250 µL, 50 µg in 1 mL and 50 µg in 250 mL), were processed following 
the StrataClean™ concentration protocol as detailed in the methods.  After the first round 
of sample incubation with Strataclean™ resin (labelled Strataclean 1), the unbound fraction 
was removed and incubated again with Stratclean™ resin (labelled Strataclean 2). TCA 
precipitation was performed on the unbound fraction from Strataclean™ resin 2. The 
Strataclean™ resins and protein pellet from the TCA precipitation were analysed by SDS-
PAGE (Figure 5.6.). Multiple concentrations and volumes were investigated to determine if 
they affected performance of the Strataclean™ resin.  
After the first round of incubating the sample with Strataclean™ resin, a large portion of the 
plasma proteins bound to the resin (Figure 5.6.). However, following the subsequent rounds 
of binding, protein bands were visible in Strataclean 2 and TCA precipitation lanes, 




within the samples did not bind to the resin. Irrespective of the sample concentration and 
volume, similar results were observed with protein bands visible in the Strataclean 1 and 2 
lanes of comparable intensity. In the 250 µL samples, more protein is present in the TCA 
precipitation lanes compared to the 1 mL samples. This may suggest that a larger sample 
volume allows for better mixing of the resin and protein sample, increasing the binding 
efficiency.  
It was noted that the StrataClean™ resin displays similar behaviour to equalising beads, 
reducing difference in protein abundances. This effect is most notable for albumin as the 
resin appears to reach a saturation point for the protein.  The largest band for albumin is in 
the TCA precipitation lane for all sample volumes and concentrations indicating that it 
remains mostly unbound. Despite this being an advantageous feature of potentially 
depleting albumin even further, the results demonstrates the inconsistencies in protein 
binding to StratClean™ resin.  
Although the results from this preliminary investigation into Strataclean™ resin suggest the 
method is unsuitable for protein concentration, the results had not been directly compared 
to other concentration methods. Additionally, the assessment of StrataClean™ resin was 
initially performed on non-depleted plasma. To reproduce conditions more similar to the 
final application of the resin, it was hypothesised that when used to concentrate spin 
column depleted plasma, the StrataClean™ resin would bind protein in a more consistent 
and complete manner. Therefore, the method was investigated further to assess suitability 












Figure 5.6 | SDS-PAGE analysis of human plasma samples concentrated using 
StrataClean™ resin. 
 Sample loading: 25 % of Strataclean 1 and 100 % of Strataclean 2 and TCA precipitation 
pellet. Four different starting concentrations and volumes of plasma were analysed: 100 µg 
n 1 mL, 100 µg in 250 µL, 50 µg in 1 mL and 50 µg in 250 mL. Comparable results were 
observed for all samples. StrataClean™ resin does not bind all protein within a sample. 




5.3.2.2. Comparison of concentration method 
To determine the optimal strategy for sample concentration, three concentration methods 
were compared by assessing the total number of proteins identified by LC-MS/MS. Human 
plasma (10 µL) was depleted using the Thermo Scientific Pierce depletion spin columns as 
described in the methods. The depleted human plasma was separated into three equal 
aliquots to be taken for protein concentration and digestion using StrataClean™ resin, FASP 
or TCA precipitation as detailed in methods section. The digests were analysed by LC-
MS/MS on the Q Exactive Orbitrap mass spectrometer over a 2 hour gradient. To make a 
direct comparison between the methods, the final volume of each digest was made up to 
the same volume and equivalent amounts of each sample loaded onto the instrument. The 
analysis was performed on a single replicate to ensure that variability in the depletion 
method was not taken into account. The data was processed using Proteome Discoverer 
and searched in MASCOT against a human database with a 1 % FDR filter applied.  
The number of protein, peptide, PSMs identified is shown in Table 5.2, where BPI 
chromatogram values were also noted. The FASP concentration method yielded the 
greatest number of proteins, peptide and PSM identifications (263, 3073, 6210 
respectively) compared to the other techniques. In addition, the FASP method also 
achieved the highest BPI chromatogram value (Table 5.2). The StrataClean™ resin method 
produced the least number of protein identifications supporting the findings from the initial 
SDS-PAGE StrataClean™ analysis. Although it has been reported that FASP digestion can 
result in the loss of certain proteins/peptides due to them sticking to the filters, the results 
in this analysis indicate that the method is preferred for total protein identifications. The 
reduced number of sample handling steps in this method compared to StrataClean™ resin 
and TCA precipitation concentration methods may explain the improved number of protein, 
peptide and PSM identifications.   











FASP 263 3073 6210 8.44 E8 
StrataClean™ 173 930 1466 2.78 E8 




The chromatograms were visually compared to assess for similarities and differences in 
sample complexity (Figure 5.7). Overall, the FASP digestion and TCA precipitation 
chromatograms look fairly similar with peaks distributed evenly across the gradient. 
However, the FASP digestion method reached more than double the BPI than the TCA 
precipitation method suggesting better sample recovery for the FASP method. In the latter 
portion of the gradient for the StrataClean™ resin concentrated plasma, the intensity of the 
peptides eluting from the column decreases compared to the initial part of the gradient and 
when compared to the chromatograms from samples concentrated using the other 
methods. In reversed-phased chromatography, hydrophobic peptides are retained on the 
solid phase and elute later in the gradient. As there is a noted reduction in peptide intensity 
in this region of the gradient it may suggest that StrataClean™ resin disfavours binding of 
hydrophobic proteins and displays a preference to hydrophilic proteins.  
Other filtered based concentration methods were not investigated. The FASP based method 
combines both sample concentration and digestion reducing the number of sample 
handling steps. The FASP concentration and digestion method was selected for subsequent 










Figure 5.7 | Comparison of BPI chromatograms of concentration methods.  
FASP, StrataClean™ resin and TCA precipitation method compared. Human plasma digests analysed on Thermo Scientific QExactive mass spectrometer on a 




5.3.3. Comparative proteomic analysis of sepsis plasma – Cohort 1 
To identify a panel of candidate protein markers of sepsis, a comparative proteomics 
analysis of plasma was undertaken. The plasma from six sepsis and six hospital control 
patients were analysed in this study, named Cohort 1. The plasma from sepsis patients had 
been previously analysed for the bacterial diagnosis of sepsis. The control plasma was 
obtained from children admitted to the intensive care unit for elective cardiac surgery with 
no infection and who did not develop infection during their stay on the unit. Cohort 1 
patient information is displayed in Table 3. All patient samples analysed in this chapter 
were obtained by Professor Enitan Carrol from Alder Hey Children’s Hospital. Ethical 
approval was granted by the National Research Ethics Service and patient consent was 
received before sample collection (REC reference: 10/H1014/52). 
Plasma samples were depleted, concentrated and digested using Thermo Scientific Pierce 
depletion spin columns and FASP digestion as described in the methods. Prior to the 2 hour 
LC-MS/MS sample analysis, each sample was analysed on a 30 minute gradient to ensure 
BPI chromatograms were of similar intensity. As each sample achieved similar BPI 
chromatogram intensities and peptides were subsequently analysed by LC-MS/MS on the 
Thermo Scientific QExactive HF on a 2 hour gradient with the same volume of sample 
loaded onto the instrument.  The data was processed using Proteome Discoverer and the 
generated mgf file searched using MASCOT (Matrix Science) against a human database for 
peptide and protein identification. A 1% FDR filter was applied.  
The number of protein, peptide and PSMs identifications for each sample was analysed 
(Figure 5.8.). Box plot analysis comparing the distribution of data between sepsis and 
control plasma revealed the number of protein, peptide and PSMs identified were greater 
in the sepsis plasma group compared to the control plasma group (Figure 5.9). To assess 
whether there was a significant statistical difference between the control and sepsis plasma 
groups in the number of protein, peptide and PSM identifications, a t-test was performed 
(significance level,  P < 0.05). No statistical difference was observed between control and 
sepsis plasma in the number of peptide and PSM identifications. A significant difference (P 
= 0.02657) in the number of proteins identified between the sepsis and control plasma 
samples. As sepsis results in the initiation of an immune response and activation and 
secretion of immune proteins, this may explain the greater number of identifications in the 
sepsis group. Additionally, variability in the number of protein, peptide and PSMs was 




or due to inherent differences in patient samples. BPI chromatograms of sepsis and control 
plasma digests were visually compared (Figure 5.10) and reveal the sepsis plasma 
chromatograms were typically more complex with more peaks of greater intensity along 
the base line compared to control plasma. This would suggest a higher degree of sample 
complexity compared to the control plasma which supports the data from total protein 
identifications.  
To investigate the overlap in protein identification in control and sepsis plasma, a venn 
diagram of proteins identified in at least 2 or more samples of the same condition was 
prepared (Figure 5.8). A total of 154 proteins were identified across all conditions with 105 
proteins identified in both conditions indicating high similarities between the control and 
sepsis plasma on a qualitative level. Six proteins were identified in control plasma only and 
43 proteins were identified in sepsis plasma only. Functional annotation using DAVID of the 
proteins identified in the sepsis plasma only reveals proteins associated with receptor 
mediated endocytosis, positive regulation of B cell activation, innate immune response and 
acute phase responses. This finding was expected due to the systemic immune response 
induced by sepsis. 
Table 5.3 | Patient demographic and clinical data. 
F = female, M = male, Age (Years). 


















43 1.11 F 
22 0.16 M 
7 10.36 M 
24 0.24 F 









Figure 5.8 | Total number of protein, peptide and PSMs identified and overlap of protein identifications. 
Data processed using Proteome Discoverer and searched in MASCOT against a human database with a 1 % FDR filter. Venn diagram: proteins identified in at 






Figure 5.9 | Distribution of the number of protein, peptide and PSMs identified in control 
and sepsis plasma.  
The overall number of protein, peptide and PSM identifications are highest in sepsis 
samples. Line represents median values. Whiskers represent minimum and maximum 
values. The median number of protein, peptide and PSMs identifications was highest in 
sepsis samples. Curve represents distribution. Statistical analysis (t-test) was performed to 








Figure 5.10 | Representative BPI chromatograms of sepsis and control plasma digests 
analysed by LC-MS/MS. 
Depleted patient plasma FASP digests analysed on Thermo QExactive HF on a 2 hour 
gradient. Three BPI chromatograms were selected from sepsis and control samples that 





To investigate quantitative difference in protein expression, label-free protein 
quantification was performed using Progenesis QI (Waters Corporation). Retention time 
alignment was carried out, with sepsis sample 134 selected as the alignment reference file.  
Alignment scores achieved 75% or greater signifying high similarities between retention 
time profiles. The normalisation scores for all samples were within the accepted range 
(Figure 5.11). The dynamic ranges of the sepsis and control plasma proteomes span seven 
orders of magnitude (Figure 5.12.). Typically, the dynamic range with non-depleted plasma 
is ten orders of magnitude19 and the protein index curve has a steeper gradient towards the 
highly abundant proteins compared to the abundance data in this study. This suggests that 
the depletion strategy employed in this analysis has been successful in reducing the 
dynamic range of the plasma proteome. The dynamic range plot was ordered by control 
sample protein abundance and therefore proteins identified in the sepsis group that did not 
follow this trend were highlighted (Figure 5.12). Proteins that were more abundant in the 
sepsis group include haptoglobin, C-reactive protein, lipopolysaccharide binding protein, 
alpha-1-acid glycoprotein 1 and alpha-1-acid glycoprotein 2. As these proteins are involved 
in the acute-phase response, the higher abundance in the sepsis group is expected. The 
greatest variability in protein abundance between the control and sepsis groups was 
observed at the upper and lower ends of the dynamic range (Figure 5.13). Variability of 
protein abundances within the sepsis groups compared to the control group was also 
highest in these portions of the plot as evident by the larger error bars (Figure 5.13). As 
various factors affect protein expression such as stage of infection, age of patients and 
severity of the disease, this observation is expected.  
In total, 297 proteins were quantified by relative quantification using non-conflicting 
peptides with a minimum of two peptides per protein and a protein score ≥ 20. The 
increase in the number of protein identifications with Progenesis compared to MASCOT 
searching only can be attributed to the way Progenesis handles the data. Progenesis works 
by analysing the data at the MS1 level to identify and then quantity peptide ion peaks that 
show differences between experimental conditions. The data is sent for database searching 
for protein identification. During data-dependent acquisition mode, not all peptide ions are 
triggered for fragmentation, especially low abundance peptides ions, which results in the 
loss of a significant amount of data. Additionally, further data is discarded during filtering 
steps due to peptide ions with low quality MS/MS spectra. This approach of merging the 
data is advantageous as peptide ions with no associated MS/MS spectra are not discarded 




between the experimental groups. The result observed in this analysis would suggest that a 
large portion of the data acquired has low quality MS/MS spectra or that a large number of 
peptide ions were not triggered for fragmentation due to the large increase in protein 
identifications between the data searched in MASCOT only and the data searched in 
Progenesis.  
To determine if samples could be separated based on biological differences, the dataset 
was subjected to principal component analysis of protein abundances. Clear separation 
between the two groups was observed with the greatest amount of variation explained by 
principal component 1 (at 35% of total variance compared to 21% for principal component 
2) (Figure 5.14). The control plasma samples (blue dots) cluster closer to each other 
compared to the sepsis plasma samples (purple dots). This may be explained by the higher 
level of variability in the sepsis samples due to the varied bacterial diagnosis. A single sepsis 
plasma sample (sepsis sample 133) is an outlier separating more closely with the control 
samples. Again, this may be because of the high degree of biological variability of the sepsis 
plasma and low sample numbers.  To further investigate separation of samples based on 
biological differences, protein abundance values were log10-transformed and analysed by 
hierarchical clustering (Figure 5.15). Clear discrimination between control and sepsis 
plasma was observed. Again, a single sepsis plasma sample outlier (sepsis sample 133) was 
identified. As this sample shared the same clinical diagnosis of meningococcal sepsis with 
sepsis sample 134, it is expected that these samples would cluster together; however, this 
was not the case. Multiple factors could explain this including patient demographic, stage 
of sepsis and if the patient had any other underlying clinical problems. 
To investigate differentially expressed proteins between control and sepsis plasma, the 
dataset was filtered further; a P value of <0.05 and a q value of <0.05 cut-off was applied. In 
total, 40 proteins were differentially expressed between the two groups with a fold change 
greater than 1.5. Four proteins were quantified as having the highest mean abundances in 
the control group and 37 proteins quantified as having the highest mean abundance in the 
sepsis group (Table 5.4). As with the qualitative analysis of the data searched in MASCOT 
only, quantitative analysis reveals similar biological findings; differentially expressed 











Figure 5.11 | Summary of alignment and normalisation scores of patient samples. 
Top: Progenesis alignment scores. Sepsis sample 134 selected as the alignment reference 
file.  Alignment scores achieved 75% or greater signifying high similarities between 























































Figure 5.12 | Dynamic range of control and sepsis plasma proteome. 
The mean normalised abundance value of each protein expressed in the control and sepsis plasma was calculated using Progenesis QI relative quantification 
using non-conflicting peptides. Ordered by control abundance values. Error bars represent standard error. Blue points correspond to control plasma and red 
points correspond to sepsis plasma. Most abundant and least abundant proteins highlighted in black boxes and examine further in Figure 5.13. Sepsis outlier 





Figure 5.13 | Upper and Lower Dynamic range of control and sepsis plasma proteome. 
Ordered by control abundance values.  Top: Top 25 most abundant proteins. Bottom: 50 











Figure 5.14 | PCA clustering of protein abundance values calculated in Progenesis. 
 Blue points represent control plasma samples and purple points represent sepsis plasma samples. Clear separation between control and sepsis samples 









Figure 5.15 | Heatmap and hierarchical clustering of log10-transformed protein abundance data for comparative proteome analysis of patient cohort 1. 
Normalised protein abundance values taken from Progenesis QI and log10- transformed. Samples clustered on protein abundance with high abundant 








Table 5.4 | Summary of differentially expressed proteins in cohort 1. 
Proteins identified with a minimum of 2 peptides per protein, a protein score ≥ 20, a P value of <0.05, a q value of <0.05 cut-off and a fold change >1.5. 










P02741 C-reactive protein 7 377.9 7.42E-08 1.24E-05 112.60 Sepsis 
P0DJI9 Serum amyloid A-2 protein  2 287.46 0.00018 0.004808 75.40 Sepsis 
Q01638 Interleukin-1 receptor-like 1  3 128.89 0.000659 0.011051 72.64 Sepsis 
Q7RTV2 Glutathione S-transferase A5  2 66.49 0.005098 0.029342 67.20 Sepsis 
P01009 Alpha-1-antitrypsin  36 2654.85 0.000551 0.010272 29.09 Sepsis 
P01258 Calcitonin 2 158.85 0.004085 0.026033 22.49 Sepsis 
P00738 Haptoglobin  16 2189.48 0.010482 0.044308 22.16 Sepsis 
Q92598 Heat shock protein 105 kDa  3 134.82 0.002337 0.020414 21.31 Sepsis 
P18428 Lipopolysaccharide-binding protein  11 716.36 0.000201 0.004808 16.20 Sepsis 
P02763 Alpha-1-acid glycoprotein 1  7 773.92 0.003092 0.02358 13.82 Sepsis 
P19652 Alpha-1-acid glycoprotein 2 8 712.86 0.003686 0.026033 12.05 Sepsis 
P20711 Aromatic-L-amino-acid decarboxylase  2 84.06 3.11E-06 0.000174 11.69 Sepsis 
Q03154 Aminoacylase-1 5 226.94 0.012584 0.046079 9.34 Sepsis 
P01011 Alpha-1-antichymotrypsin  27 2214.44 7.17E-06 0.000301 8.98 Sepsis 
P15144 Aminopeptidase N 5 180.83 0.000878 0.011337 6.14 Sepsis 
P05362 Intercellular adhesion molecule 1  5 187.41 0.00035 0.007334 6.06 Sepsis 
P02750 Leucine-rich alpha-2-glycoprotein  15 1062.94 0.002195 0.020414 5.42 Sepsis 
P08123 Collagen alpha-2(I) chain 5 229.59 0.004593 0.027523 5.34 Control 
Q8N6C8 
Leukocyte immunoglobulin-like receptor subfamily A 








P33908 Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA  6 280 0.000956 0.011452 4.66 Sepsis 
P13796 Plastin-2  18 945.86 0.009294 0.043321 4.48 Sepsis 
P06702 Protein S100-A9  4 189.73 0.008537 0.04213 4.22 Sepsis 
P15151 Poliovirus receptor 3 102.17 0.004189 0.026033 4.06 Sepsis 
P80188 Neutrophil gelatinase-associated lipocalin 4 167.98 0.012632 0.046079 4.05 Sepsis 
Q15582 Transforming growth factor-beta-induced protein ig-h3  13 476.81 0.004058 0.026033 4.03 Sepsis 
P01871 Ig mu chain C region  9 557.79 0.010826 0.044308 3.99 Sepsis 
P06733 Alpha-enolase  8 609.01 0.001991 0.01965 3.88 Sepsis 
Q86UD1 Out at first protein homolog 3 117.6 0.011355 0.045363 3.63 Sepsis 
P01019 Angiotensinogen 16 1198.38 0.002433 0.020414 3.29 Sepsis 
P55058 Phospholipid transfer protein  5 341.01 0.002775 0.02217 3.27 Sepsis 
P24821 Tenascin 8 319.88 0.007839 0.039858 3.21 Sepsis 
P13489 Ribonuclease inhibitor  2 78.36 0.00418 0.026033 3.17 Sepsis 
Q8NBP7 Proprotein convertase subtilisin/kexin type 9  4 192.06 0.006086 0.032943 3.16 Sepsis 
Q9UK55 Protein Z-dependent protease inhibitor  4 198.5 0.007034 0.036883 2.95 Sepsis 
O00391 Sulfhydryl oxidase 1 7 332.16 0.001819 0.019075 2.79 Sepsis 
Q96IY4 Carboxypeptidase B2 8 365.52 0.010787 0.044308 2.66 Control 
P35527 Keratin, type I cytoskeletal 9 19 1143 0.014256 0.049889 2.52 Control 
P12259 Coagulation factor V  20 724.91 0.009814 0.043336 2.29 Sepsis 
P22792 Carboxypeptidase N subunit 2  12 755.14 0.014271 0.049889 2.17 Sepsis 








Of the 40 proteins identified as differentially expressed (fold change of 1.5 or greater), six 
were selected as possible candidate proteins based on previous work implicating their 
involvement in sepsis and immune response239,258. The six proteins were C-reactive protein, 
interleukin-1 receptor-like 1, glutathione S-transferase A5, calcitonin, protein S100A9 and 
neutrophil gelatinase-associated lipocalin. The role these proteins play in sepsis will be 
discussed in section 5.3.4. The normalised protein abundance plots for the candidate 
proteins are displayed Figure 5.16. To assess whether there was a significant statistical 
difference between the control and sepsis plasma groups, a t-test was performed (P < 
0.05). A significant difference between the control and sepsis plasma was observed for all 
proteins (Figure 5.16). While the selected proteins show overall differences in expression 
between control and sepsis plasma, variation of protein abundance within the sepsis 
groups is relatively high. The sepsis samples in this study did not share a common bacterial 
diagnosis as there were three different bacterial causes; Streptococcus empyema, S. 
pyogenes and Meningococcal meningitis. Although the different bacteria all induced sepsis 
in the patients, the immune response may differ due to the different pathogens. 
Consequently, this may be reflected in the plasma proteome of the sepsis patients.  
Although biological variance is expected between patient samples, such noted difference in 
samples may have hindered candidate protein identification as protein expression may vary 
within the sepsis samples, reducing the statistical significance of the identified differentially 
expressed proteins.  
To improve on the study design, selecting patients with a common bacterial diagnosis may 
result in a more robust dataset, potentially reducing the level of variance on protein 
expression and providing improved separation of samples in cluster analysis. In addition, 
increasing the number of samples in the study would provide greater statistical power to 
the analysis. 
As the aims of this analysis were to identify a panel of proteins implicated in sepsis and not 
to identify a single novel sepsis biomarker, the initial findings of this analysis are promising. 
The results from cohort 1 can act as a validation dataset to provide further confidence to 










Figure 5.16 | Log 2 Progenesis QI normalised protein abundance plots of candidate proteins. 
CRP, glutathione S-transferase A5, calcitonin, protein S100-A9, interleukin-1 receptor-like 1 and neutrophil gelatinase-associated lipocalin abundance plots. 
Plots display the log 2 normalised protein abundance values. Black plots represent control plasma samples and red plots represent sepsis plasma samples. 




5.3.4. Comparative proteomic analysis of sepsis plasma – Cohort 2 
As discussed previously, to identify a panel of candidate markers of sepsis with greater 
statistical significance and confidence, a second cohort of 20 patient plasma samples was 
selected for comparative proteomics analysis. The plasma from 10 sepsis and 10 hospital 
control patients were analysed in this study, termed cohort 2. As before, the plasma from 
sepsis patients had been previously analysed for bacterial diagnosis and for this study were 
selected on the basis of meningococcal sepsis diagnosis. The control plasma was obtained 
from children admitted to the intensive care unit for elective cardiac surgery with no 
infection and who did not develop infection during their stay on the unit. Patient sample 
information is displayed in Table 5.5. 
Plasma samples were prepared as discussed in section 5.3.3 and prior to the 2 hour LC-
MS/MS sample analysis, each sample was analysed on a 30 minute gradient to check if the 
BPI chromatograms were of similar intensity. As the BPI chromatograms varied in intensity 
between samples, loading was adjusted to achieve similar intensities and peptides were 
subsequently analysed by LC-MS/MS on the Thermo Scientific QExactive HF on a 2 hour 
gradient with the same volume of sample loaded onto the instrument. The data was 
processed using Proteome Discoverer and the mgf file generated searched using MASCOT 
(Matrix Science) against a human database for peptide and protein identification with a 1% 
FDR filter. The number of proteins, peptides and PSMs identified in each sample were 
examined (Figure 5.17).  When comparing the distribution of the data for the number of 
protein, peptide and PSMs identified between sepsis and control plasma, it was noted that 
sepsis samples generated the highest number of identifications (Figure 5.18) as observed in 
cohort 1. Similarities to cohort 1 were also observed in the spread of data, with high 
variability in the number of protein, peptide and PSMs identifications between samples. 
Variability in protein depletion of highly abundant proteins or inherent differences in 
patient samples could explain this. Due to the low number of protein identifications, sepsis 
sample 41 was identified as an outlier. To assess whether there was a significant statistical 
difference between the control and sepsis plasma groups in the number of protein, peptide 
and PSM identifications, a t-test was performed (significance level,  P < 0.05). No statistical 
difference was observed between control and sepsis plasma in the number of protein, 
peptide and PSM identifications. BPI chromatograms of sepsis and control plasma digests 
were visually compared (Figure 5.19.); the sepsis plasma chromatograms were typically 




To investigate the overlap in protein identification in control and sepsis plasma, a Venn 
diagram of proteins identified in at least 2 or more samples of the same condition were 
examined (Figure 5.17). A total of 209 proteins were identified with 178 proteins identified 
in both conditions demonstrating qualitative similarities between the control and sepsis 
plasma. Twenty-one proteins were identified in sepsis plasma only and 10 proteins were 
identified in control plasma only. Due to the low number of proteins identified in the sepsis 
plasma only, functional annotation was not carried out on this dataset. 
 
Table 5.5 | Patient demographic and clinical data.  
M = male, F = female, Age (Years). 





370 1.78 M 
552 4.18 M 
204 0.67 M 
545 1.16 F 
549 1.2 M 
41 3.92 M 
429 2.63 M 
217 2.44 F 





32 0.24 F 
20 7.43 F 
6 0.87 F 
21 2.7 M 
51 4.37 M 
8 8.51 F 
48 6.05 M 
56 7.42 M 












Figure 5.17 | Total number of protein, peptide and PSMs identified and overlap of protein identifications. 
Data processed using Proteome Discoverer and searched in MASCOT against a human database with a 1 % FDR filter. Venn diagram: proteins identified in at 







Figure 5.18 | Distribution of the number of protein, peptide and PSMs identified in 
control and sepsis plasma. 
The overall number of protein, peptide and PSM identifications are highest in sepsis 
samples. Line represents median values. Whiskers represent minimum and maximum 
values. The median number of protein, peptide and PSMs identifications was highest in 
sepsis samples. Curve represents normal distribution. Statistical analysis (t-test) was 









Figure 5.19 | Representative BPI chromatograms of sepsis and control plasma digests 
analysed by LC-MS/MS.  
Depleted patient plasma FASP digested analysed on Thermo QExactive HF on a 2 hour 
gradient. Three BPI chromatograms were selected from sepsis and control samples that 





To investigate quantitative difference in protein expression, label-free protein 
quantification was performed using Progenesis QI (Waters Corporation). Sepsis sample 545 
was selected as the alignment reference file. The alignment scores achieved 69.6% or 
greater however control sample 56 failed to align (Figure 5.20). Alignment is an important 
feature of the Progenesis workflow to ensure accurate peak picking. Therefore, manual 
alignment of this sample was attempted to align the run correctly, however this also failed. 
When visually comparing the BPI chromatogram of this sample to the other samples in the 
cohort, large differences in peak intensities and distribution were observed (Figure 19). The 
BPI chromatogram for this sample looked more similar to non-depleted plasma suggesting 
a problem with the protein depletion spin column step of the protocol. The low number of 
proteins, peptides and PSMs identified would also support this explanation. The sample 
was therefore excluded from the Progenesis analysis. Apart from this sample, the alignment 
scores of the other samples indicate similar retention time profiles. Normalisation scores 
were also assessed (Figure 5.20), identifying sepsis sample 41 as an outlier with a 
normalisation score of 6.8.  A total of 55 proteins were identified in this sample suggesting 
a technical problem with this sample. This sample was also excluded from the Progenesis 
analysis. A total of 307 proteins were quantified using relative quantification with a 
minimum of 2 unique peptides per protein and a protein score ≥ 20. As with cohort 1, an 
increase in the number of protein identification with Progenesis compared to MASCOT was 
observed.  
The dynamic range of the sepsis and control plasma proteomes spans seven orders of 
magnitude (Figure 5.21). As observed in Cohort 1, the protein index curve has a less steep 
gradient towards the highly abundant proteins compared to non-depleted plasma again 
confirming depletion of highly abundant proteins. The dynamic range plot was ordered by 
control sample protein abundance and therefore proteins identified in the sepsis group that 
did not follow this trend were highlighted (Figure 5.22). Proteins that were more abundant 
in the sepsis group include haptoglobin, C-reactive protein, myoglobin, serum amyloid A-1 
protein and leucine rich alpha-2 glycoprotein. An increase in the abundance of acute-phase 
proteins (haptoglobin, C-reactive protein and serum amyloid A-1 protein) in the sepsis 
group is expected. Leucine rich alpha-2 glycoprotein is expressed by granulocytes 
undergoing differentiation259 and various studies have shown that expression levels in 
serum increase in bacterial infection and in inflammatory diseases260-262. Raised levels of 
myoglobin have been detected in patients with rhadbomyolysis, the breakdown in muscle 




muscle breakdown and a recent study identified raised serum myoglobin as a predictive 
marker for increased sepsis severity263. As in Cohort 1, the most variability in protein 
abundance between the control and sepsis groups was observed at the upper and lower 
ends of the dynamic range plot (Figure 5.22). Variability of protein abundances within the 
sepsis groups compared to the control group was also highest in these portions of the plot 
as evident by the larger error bars (Figure 5.22).  
The dataset was subjected to principal component analysis to assess the level of separation 
between control and sepsis plasma (Figure 5.23.).  Clear discrimination was observed 
between control (blue dots) and sepsis (purple dots) plasma with the samples clustering 
into distinct groups. The control samples formed two separate clusters within the group. To 
further assess the separation of samples based on differences in protein expression, protein 
abundance values were log10-transformed and analysed by hierarchical clustering (Figure 
5.24). Two distinct clusters of sepsis plasma and three distinct clusters of control plasma 










Figure 5.20 | Summary of alignment and normalisation scores of patient samples. 
Top: Progenesis alignment scores. Sepsis sample 545 was selected as the alignment 
reference file. Control sample 56 failed to align. The other samples achieved an alignment 
scores of 69.6% or greater.   Bottom: Progenesis normalisation scores were in the accepted 
range excluding sepsis sample 41 that had a normalisation score of over 6.5. Control sample 







































































































































































































































































































































Figure 5.21 | Dynamic range of control and sepsis plasma proteome. 
The mean normalised abundance value of each protein expressed in the control and sepsis plasma was calculated using Progenesis QI relative quantification 
using non-conflicting peptides. Ordered by control abundance values. Error bars represent standard error. Blue points correspond to control plasma and red 
points correspond to sepsis plasma. Most abundant and least abundant proteins highlighted in black boxes and examine further in Figure 5.22. Sepsis outlier 





Figure 5.22 | Upper and lower dynamic range of control and sepsis plasma proteome. 
Ordered by control abundance values.  Top: Top 25 most abundant proteins. Bottom: 50 










Figure 5.23 | PCA clustering of protein abundance values calculated in Progenesis QI. 










Figure 5.24 | Heatmap and hierarchical clustering of log10-transformed protein abundance data for comparative proteome analysis of patient cohort 2.  
Normalised protein abundance values taken from Progenesis QI and log10- transformed. Samples clustered on protein abundance with high abundant 




To investigate differentially expressed proteins between control and sepsis plasma, the 
dataset was filtered further; a P value of <0.05 and a q value of <0.05 cut-off was applied. A 
total of 107 proteins were differentially expressed between the two groups with a fold 
change greater than 1.5. Twenty proteins were quantified as having the highest mean 
abundances in the control group and 87 proteins quantified as having the highest mean 
abundance in the sepsis group (Table 5.6). Functional annotation of the sepsis protein 
dataset was performed using the PANTHER classifications system264 and DAVID265,266 (Figure 
5.25). Analysis of the biological processes associated with the identified proteins using 
PANTHER (Figure 5.25 A) highlighted 11 biological process categories with 144 process hits 
in total. Cellular process was the largest category with 43 proteins associated with this 
process. Further analysis of this category identified proteins strongly associated with cell 
communication, in particular signal transduction. As expected, cell signalling and 
communication is an important feature of the immune system in order to recruit and 
activate the appropriate effectors cells267. Interestingly, proteins associated with 
developmental processes were enriched in the sepsis plasma dataset. As the sepsis patients 
are neonates and children, identification of developmental proteins would be expected and 
as patient demographic is unknown for control patients it would suggest that sepsis 
patients are overall younger. Response to stimulus and immune system processes were also 
enriched categories as expected in response to sepsis. 
KEGG pathway analysis using DAVID identified 5 KEGG terms with statistical significance 
(Bonferroni <0.05). The most enriched pathway was the complement and coagulation 
cascade (Bonferroni 1.37E-13). It is well known that sepsis activates the complement and 
coagulation cascade268 and is thought to be responsible for the severe complications of 
disseminated intravascular coagulation that results in blood clot formation269. Gene 
ontology analysis of enriched biological processes using DAVID identified 16 GO terms with 
statistical significance. Enriched terms include acute-phase response, innate immune 
response and regulation of complement activation (Bonferroni of 3.27E-14, 0.001261 and 
2.53E-04 respectively) signifying and confirming the systemic inflammatory and immune 









Table 5.6 | Summary of differentially expressed proteins in Cohort 2. 
Total of 107 proteins identified with a minimum of 2 peptides per protein, a protein score ≥ 20, a P value of <0.05, a q value of <0.05 cut-off and a fold 














P02741 C-reactive protein 7 386.48 6.95E-09 1.39E-06 66.04 Sepsis 
P0DJI9 Serum amyloid A-2 protein 2 374.35 2.62E-05 0.000464 42.82 Sepsis 
P13611 Versican core protein  3 113.36 0.01016299 0.018992 30.56 Sepsis 
P05107 Integrin beta-2 2 92.04 0.00410268 0.01038 23.89 Sepsis 
P13646 Keratin, type I cytoskeletal 13 3 521.56 0.00039827 0.002156 21.28 Control 
P16581 E-selectin  2 51.4 0.00096943 0.004212 18.42 Sepsis 
Q9HAV0 Guanine nucleotide-binding protein subunit beta-4 2 64.52 0.01913902 0.028979 16.72 Sepsis 
P0DJI8 Serum amyloid A-1 protein  3 727.95 1.94E-06 7.76E-05 12.37 Sepsis 
Q14314 Fibroleukin  2 98.37 5.99E-06 0.000171 11.10 Sepsis 
Q16394 Exostosin-1  2 41.72 0.00285504 0.00808 10.90 Sepsis 
P26022 Pentraxin-related protein PTX3  7 440.16 0.00100148 0.004259 10.71 Sepsis 
P11166 
Solute carrier family 2, facilitated glucose transporter 
member 1  3 91.79 0.02455532 0.03432 10.05 Sepsis 
P15291 Beta-1,4-galactosyltransferase 1 2 87.25 1.55E-05 0.000386 9.66 Sepsis 
Q9NZ08 Endoplasmic reticulum aminopeptidase 1  2 58.14 0.00503163 0.012253 7.64 Sepsis 
Q01638 Interleukin-1 receptor-like 1  2 82.95 0.00771611 0.015422 7.17 Sepsis 
P18428 Lipopolysaccharide-binding protein 11 725.12 7.63E-08 6.45E-06 7.13 Sepsis 
P61981 14-3-3 protein gamma 3 171.18 0.00020034 0.001437 6.81 Control 









Leukocyte immunoglobulin-like receptor subfamily A 
member 3  5 226.5 4.71E-06 0.000157 6.72 Sepsis 
P80188 Neutrophil gelatinase-associated lipocalin 5 197.94 0.00218279 0.007123 6.54 Sepsis 
P02458 Collagen alpha-1(II) chain  2 75.35 0.00607307 0.013338 6.48 Control 
P01011 Alpha-1-antichymotrypsin  26 2509.16 9.68E-08 6.45E-06 6.41 Sepsis 
P00738 Haptoglobin 15 2281.35 8.77E-05 0.000877 5.81 Sepsis 
Q12841 Follistatin-related protein 1  2 61.79 7.48E-05 0.000831 5.73 Sepsis 
P02452 Collagen alpha-1(I) chain  10 594.98 0.00024787 0.001501 5.72 Control 
P05451 Lithostathine-1-alpha  2 176.74 0.00382926 0.009939 5.71 Sepsis 
P04075 Fructose-bisphosphate aldolase A  8 471.39 0.00127576 0.005 5.53 Control 
P08123 Collagen alpha-2(I) chain  6 354.01 0.00734987 0.015144 4.92 Control 
P02750 Leucine-rich alpha-2-glycoprotein  15 1214.56 3.42E-07 1.71E-05 4.87 Sepsis 
Q7Z7G0 Target of Nesh-SH3 2 65.6 0.0024793 0.007508 4.74 Sepsis 
P04066 Tissue alpha-L-fucosidase  2 94.52 0.00990651 0.018925 4.72 Sepsis 
P13796 Plastin-2 17 703.55 1.87E-05 0.000414 4.62 Sepsis 
P02763 Alpha-1-acid glycoprotein 1  7 849.4 8.11E-05 0.000853 4.58 Sepsis 
Q15323 Keratin, type I cuticular Ha1  3 701.15 0.04106734 0.048282 4.51 Control 
P07988 Pulmonary surfactant-associated protein B  4 157.44 0.00359662 0.009458 4.33 Sepsis 
P07858 Cathepsin B  4 149.21 0.00896988 0.017576 4.33 Sepsis 
P24821 Tenascin  16 724.62 0.00010548 0.000917 4.32 Sepsis 
P02671 Fibrinogen alpha chain  43 3484.99 0.00440118 0.010996 4.03 Sepsis 
P01009 Alpha-1-antitrypsin 35 2700.63 0.00038585 0.002156 4.00 Sepsis 
P04259 Keratin, type II cytoskeletal 6B  2 866.8 0.00697573 0.014676 3.96 Control 
Q96IY4 Carboxypeptidase B2  12 528.1 7.13E-05 0.000831 3.89 Control 
Q9BTY2 Plasma alpha-L-fucosidase  4 104.7 0.01491552 0.023903 3.85 Sepsis 








P33908 Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA 7 285.97 3.84E-05 0.000511 3.60 Sepsis 
Q86VB7 Scavenger receptor cysteine-rich type 1 protein M130 8 248.03 0.00296502 0.008231 3.60 Sepsis 
P35527 Keratin, type I cytoskeletal 9  28 1919.65 0.00042287 0.002179 3.58 Control 
P12109 Collagen alpha-1(VI) chain  3 109.5 0.01397177 0.022889 3.58 Sepsis 
P14625 Endoplasmin 3 173.23 0.002281 0.007123 3.55 Sepsis 
P05362 Intercellular adhesion molecule 1 3 146.4 3.12E-05 0.00048 3.37 Sepsis 
Q9UK55 Protein Z-dependent protease inhibitor 9 438.55 0.00018637 0.001433 3.29 Sepsis 
P15153 Ras-related C3 botulinum toxin substrate 2 2 52.04 0.00021973 0.001464 3.29 Sepsis 
P01860 Ig gamma-3 chain C region  4 610.9 0.0187447 0.028599 3.25 Control 
Q13822 
Ectonucleotide pyrophosphatase/phosphodiesterase family 
member 2  6 273 0.00257191 0.007559 3.18 Sepsis 
P07451 Carbonic anhydrase 3  9 335.97 0.00039915 0.002156 3.10 Sepsis 
P02679 Fibrinogen gamma chain  30 2632.55 0.00569326 0.013079 3.08 Sepsis 
O00391 Sulfhydryl oxidase 1  12 578.25 2.20E-05 0.000439 3.03 Sepsis 
P35443 Thrombospondin-4 10 727.86 0.01140923 0.020252 3.00 Sepsis 
P12259 Coagulation factor V 27 1149.84 0.02400255 0.033784 2.96 Sepsis 
P01019 Angiotensinogen  16 1573.09 0.00086327 0.003834 2.83 Sepsis 
P26038 Moesin 4 138.73 0.00239502 0.007364 2.80 Sepsis 
P07339 Cathepsin D 5 278.47 0.00170099 0.006071 2.73 Sepsis 
Q92820 Gamma-glutamyl hydrolase  3 91.34 0.00638033 0.013861 2.73 Sepsis 
P02675 Fibrinogen beta chain 32 3635.65 0.02290774 0.033177 2.73 Sepsis 
P10451 Osteopontin 4 203.67 0.00264403 0.007659 2.72 Sepsis 
P04275 von Willebrand factor 77 4355.68 0.00207616 0.007033 2.67 Sepsis 
P20742 Pregnancy zone protein 6 1024.14 0.02887027 0.037227 2.64 Sepsis 
P14543 Nidogen-1 8 322.88 0.00254078 0.007559 2.63 Sepsis 








P36222 Chitinase-3-like protein 1  3 92.74 0.00168644 0.006071 2.60 Control 
P12111 Collagen alpha-3(VI) chain  8 346.22 0.01165302 0.020252 2.60 Sepsis 
P19652 Alpha-1-acid glycoprotein 2  6 713.1 0.00117004 0.004772 2.57 Sepsis 
P54108 Cysteine-rich secretory protein 3  3 103.74 0.00064637 0.003151 2.54 Sepsis 
P08571 Monocyte differentiation antigen CD14 8 623.24 0.00011237 0.000936 2.53 Sepsis 
P04004 Vitronectin  17 1141.87 0.00083412 0.003789 2.48 Sepsis 
Q9Y5Y7 Lymphatic vessel endothelial hyaluronic acid receptor 1  5 222.91 0.00020847 0.001437 2.45 Sepsis 
P13727 Bone marrow proteoglycan 2 54.95 0.01026255 0.018992 2.38 Sepsis 
P19320 Vascular cell adhesion protein 1  8 302.94 0.000709 0.003374 2.36 Sepsis 
P01033 Metalloproteinase inhibitor 1  5 219.2 0.01206942 0.020622 2.25 Sepsis 
Q92954 Proteoglycan 4  11 523.16 0.00023382 0.001501 2.22 Sepsis 
P55058 Phospholipid transfer protein  8 494.81 0.03585503 0.044236 2.21 Sepsis 
P49747 Cartilage oligomeric matrix protein 15 872.88 0.00224811 0.007123 2.19 Sepsis 
P02788 Lactotransferrin  9 325.9 0.0065201 0.014012 2.14 Control 
P00746 Complement factor D  3 118.32 0.00766272 0.015422 2.11 Sepsis 
P80748 Ig lambda chain V-III region LOI  2 154.81 0.01945139 0.02923 2.04 Control 
O75636 Ficolin-3 7 492.95 0.00046716 0.002334 2.01 Sepsis 
P07359 Platelet glycoprotein Ib alpha chain  3 118.01 0.00224516 0.007123 1.99 Sepsis 
P02790 Hemopexin  28 2299.97 0.00143236 0.005505 1.96 Sepsis 
P00739 Haptoglobin-related protein  10 1285.99 0.01387822 0.022889 1.92 Sepsis 
P05154 Plasma serine protease inhibitor  7 317.29 0.02626571 0.035444 1.91 Control 
P15169 Carboxypeptidase N catalytic chain  13 566.17 0.0068095 0.014479 1.85 Sepsis 
Q14624 Inter-alpha-trypsin inhibitor heavy chain H4  44 3769.86 0.00039678 0.002156 1.84 Sepsis 
P02656 Apolipoprotein C-III 4 312.89 0.03991473 0.047485 1.84 Control 
O75882 Attractin  24 1358.53 0.02480577 0.034429 1.76 Control 








P04003 C4b-binding protein alpha chain  24 1459.54 0.0014738 0.005558 1.75 Sepsis 
P49908 Selenoprotein P 6 299.94 6.57E-05 0.000821 1.72 Control 
P05155 Plasma protease C1 inhibitor  21 1594.66 0.00287036 0.00808 1.71 Sepsis 
P00742 Coagulation factor X 10 542.87 0.00176452 0.006187 1.67 Sepsis 
P05109 Protein S100-A8  4 192.89 0.02824177 0.036892 1.67 Sepsis 
P22105 Tenascin-X  10 512.23 0.01056853 0.019148 1.65 Sepsis 
P02748 Complement component C9  24 1728.08 0.01153078 0.020252 1.65 Sepsis 
P07358 Complement component C8 beta chain 21 1373.63 0.00390855 0.010015 1.58 Sepsis 
P00751 Complement factor B  31 2526.62 0.00462938 0.011423 1.55 Sepsis 
P22792 Carboxypeptidase N subunit 2  9 656.69 0.0088291 0.017472 1.54 Sepsis 
P20851 C4b-binding protein beta chain  6 333.84 0.01271469 0.021536 1.52 Sepsis 
Q06033 Inter-alpha-trypsin inhibitor heavy chain H3 20 1181.93 0.00561146 0.013041 1.51 Sepsis 










Figure 5.25| Functional annotation of up-regulated proteins in sepsis. 
(A) Panther Classification – Biological Processes.  87 of the proteins up-regulated in sepsis associated with 144 biological processes (B) KEGG Terms 53 
proteins covering 60.2% of dataset.  (C) GoTerm Enrichment Analysis of Biological Processes. Bonferroni correction < 0.05, represented by red X KEGG and 




To determine the relationship between proteins quantified in both Cohort 1 and Cohort 2, 
the log 10 transformed mean protein abundance values for control and sepsis groups were 
compared (Figure 5.26). In total, 227 proteins were quantified in both studies and used to 
assess the relationship between cohorts. A strong positive linear correlation was observed 
between cohorts 1 and 2 for both sepsis and control proteins. A correlation R2 value of 0.81 
and 0.83 for the control and sepsis groups was achieved. This result suggests that the mean 
relative protein abundance values calculated for the two cohorts are in strong agreement 
demonstrating that the despite the independent studies analysing different samples, 
relative protein abundance values are similar. 
The proteins identified and quantified as differentially expressed in both cohorts using 
Progenesis were also compared to determine characteristic proteome changes in sepsis 
(Table 5.7). A total of 25 proteins that met the q value filter of <0.05 in both studies were 
identified. Three proteins were identified as down-regulated in control plasma and the 







Figure 5.26 | Relationship of the average protein abundances between cohort 1 and 
cohort 2 measured using Progensis QI. 
Top: Average protein abundance values for control sample. Bottom: Average protein 
abundance values for sepsis sample. The data was log10 transformed and linear 
relationship for both the control and sepsis data observed with a R2 value of 0.81 and 0.83 






Table 5.7 | Summary of proteins identified in both patient cohorts. 
Proteins identified with a minimum of 2 peptides per protein, a protein score ≥ 20, a P value of <0.05, a q value of <0.05 cut-off and a fold change >1.5. 
Proteins ordered alphabetically.  
   


















P02763 Alpha-1-acid glycoprotein 1  Sepsis 7 0.003092 0.02358 13.82 7 8.11E-05 0.00085283 4.58 
P19652 Alpha-1-acid glycoprotein 2  Sepsis 8 0.003686 0.026033 12.05 6 0.00117 0.00477243 2.57 
P01011 Alpha-1-antichymotrypsin Sepsis 27 7.17E-06 0.000301 8.98 26 9.68E-08 6.45E-06 6.41 
P01009 Alpha-1-antitrypsin Sepsis 36 0.000551 0.010272 29.09 35 0.000386 0.00215613 4.00 
P01019 Angiotensinogen Sepsis 16 0.002433 0.020414 3.29 16 0.000863 0.00383417 2.83 
Q96IY4 Carboxypeptidase B2  Control 8 0.010787 0.044308 2.66 12 7.13E-05 0.00083057 3.89 
P22792 Carboxypeptidase N subunit 2  Sepsis 12 0.014271 0.049889 2.17 9 0.008829 0.01747154 1.54 
P12259 Coagulation factor V Sepsis 20 0.009814 0.043336 2.29 27 0.024003 0.03378355 2.96 
P08123 Collagen alpha-2(I) chain Control 5 0.004593 0.027523 5.34 6 0.00735 0.01514413 4.92 
P02741 C-reactive protein Sepsis 7 7.42E-08 1.24E-05 112.60 7 6.95E-09 1.39E-06 66.04 
P00738 Haptoglobin  Sepsis 16 0.010482 0.044308 22.16 15 8.77E-05 0.0008769 5.81 
P05362 Intercellular adhesion molecule 1 Sepsis 5 0.00035 0.007334 6.06 3 3.12E-05 0.00048021 3.37 
Q01638 Interleukin-1 receptor-like 1 Sepsis 3 0.000659 0.011051 72.64 2 0.007716 0.01542178 7.17 
P35527 Keratin, type I cytoskeletal 9  Control 19 0.014256 0.049889 2.52 28 0.000423 0.00217935 3.58 
P02750 Leucine-rich alpha-2-glycoprotein Sepsis 15 0.002195 0.020414 5.42 15 3.42E-07 1.71E-05 4.87 
Q8N6C8 
Leukocyte immunoglobulin-like 
receptor subfamily A member 3  Sepsis 4 0.000824 
0.011337 





protein Sepsis 11 0.000201 
0.004808 












alpha-mannosidase IA  Sepsis 6 0.000956 
0.011452 





lipocalin Sepsis 4 0.012632 
0.046079 
4.05 5 0.002183 
0.0071233 
6.54 
P55058 Phospholipid transfer protein  Sepsis 5 0.002775 0.02217 3.27 8 0.035855 0.04423555 2.21 
P13796 Plastin-2  Sepsis 18 0.009294 0.043321 4.48 17 1.87E-05 0.00041418 4.62 
Q9UK55 
Protein Z-dependent protease 
inhibitor  Sepsis 4 0.007034 
0.036883 
2.95 9 0.000186 
0.00143264 
3.29 
P0DJI9 Serum amyloid A-2 protein Sepsis 2 0.00018 0.004808 75.40 2 2.62E-05 0.00046393 42.82 
O00391 Sulfhydryl oxidase 1 Sepsis 7 0.001819 0.019075 2.79 12 2.20E-05 0.00043905 3.03 






Five proteins were selected as candidates for phage display Affimer production. The 
selection criteria was that: 
 The proteins were identified with a minimum of 2 peptides per protein and a 
protein score of ≥ 20. 
 The proteins were identified as differentially expressed based on a P value of <0.05, 
a q value of <0.05 cut-off and a fold change >1.5. 
 The proteins had the highest median abundance in the sepsis plasma. 
 A recombinant protein was commercially available for the phage display screens. 
The five proteins were C-reactive protein (CRP), Protein S100 A8/A9, cathepsin B, 
neutrophil gelatinase associated protein (NGAL) and interleukin-1 receptor-like 1 (Table 
5.8). All five proteins selected met this criterion. Two proteins selected in cohort 1 were not 
included in the new panel; glutathione S-transferase A5 and calcitonin. Glutathione S-
transferase A5 was not identified in cohort 2 and although calcitonin was identified in 
cohort 2, it had the highest mean abundance in control plasma. In addition to protein S100-
A9, protein S100-A8 was also selected as a protein target. The proteins associates as a 
heterodimer and therefore phage display production can be targeted to the heterodimer. 
The normalised protein abundance plots for the candidate proteins are displayed Figure 
5.27. To assess whether there was a significant statistical difference between the control 
and sepsis plasma groups, a t-test was performed (P < 0.05). A significant difference 
between the control and sepsis plasma was observed for all proteins (Figure 5.27).As the 
loading of each sample was adjusted so that similar BPI values were obtained, the 
normalised abundance values of the five selected proteins were adjusted to account for this 
(Figure 5.28). Although the difference between sepsis and control groups is less, the 
proteins selected still have a higher abundance in the sepsis group. To assess whether there 
was still a significant statistical difference between the control and sepsis plasma groups, a 
t-test was performed (P < 0.05). A significant difference between the control and sepsis 
plasma was observed for all proteins expect protein S100-A8 (Figure 5.28).  
To determine the suitability of the five candidate proteins as biomarkers for the diagnosis 
of sepsis, receiver operating characteristic (ROC) curves were evaluated and the area under 




indicating that the protein has high sensitivity and specificity for discriminating the two 
groups of patients (control vs. sepsis). AUC values for intertelukin-1 receptor-like 1, 
cathepsin B, protein S100 A8 and neutrophil gelatinase-associated lipocalin were 0.84, 0.85, 
0.63 and 0.85, respectively. The analysis would suggest that protein S100 A8 is a poor 
marker to discriminate between the two groups of patients, whereas intertelukin-1 
receptor-like 1, cathepsin B and neutrophil gelatinase-associated lipocalins are relative 
sensitive and specific to the sepsis patients. Although the ROC curve analysis would suggest 
that the five proteins are relatively suitable as diagnostic biomarkers for sepsis, the proteins 
may merely be indicative of infection and less specific to sepsis. To assess this further, it 
would be beneficial to increase the patient cohort size and to include additional subclasses 
of patients with localised infection that has not yet spread to the blood stream. 
The protein abundances in this study were calculated using label-free relative 
quantification. This approach is common practice for the analysis of complex samples for 
biomarker discovery and has resulted in the identification of several biomarkers270,271. The 
method is advantageous as there is no need for sample labelling and numerous clinical 
samples can be included in the study design providing increased statistical power. Label-
free relative protein quantification requires the use of mass spectrometers with high 
resolving power and high mass accuracy meaning hybrid mass spectrometers are the 
instruments of choice. In this study, the Thermo Scientific QExactive HF mass spectrometer 
was used272.  In addition, it is important that the stability of the instrument is monitored 
over the course of the study as during data processing, the raw LC-MS/MS data is 
compared. In this study, instrument performance was periodically assessed by the analysis 
of a standard E.coli digest.  
To investigate the candidate proteins involvement in sepsis, the current literature on each 
protein was reviewed.  
CRP: CRP is a well-established non-specific marker of an acute-phase response. 
Inflammatory cytokines induce CRP production in the liver and its key function is thought to 
induce phagocytosis through interacting with Fc receptors on phagocytic cells to remove 
apoptotic and necrotic cells273,274. The levels of CRP rise significantly higher than other acute 
phase proteins in response to inflammation which has meant the protein has been 
routinely used to confirm the presence of infection. In both cohorts, this was observed as 
CRP expression levels had the highest fold change between sepsis and control plasma. 




infectious and non-infectious causes of localised pain and the screening of neonates for 
bacterial infection275,276.  
Cathepsin B: Cathepsin B is a cysteine protease involved in intracellular proteolysis277. 
Multiple studies report that cathepsin B over-expression is strongly associated with 
numerous cancer types including oral squamous cell carcinoma and hepatocellular 
carcinoma. However its association with sepsis is limited. In a study on patients with severe 
septic shock, cathepsin B activity measured in plasma, was elevated278. In another study 
analysing muscle protein degradation, cathepsin B activity was measured in muscle extracts 
from patients with sepsis and was 200 % higher than in controls279. Studies involving rats 
have also showed this association of increased cathepsin B activity and sepsis280,281. 
Inhibition of cathepsin B activity has also shown to reduce CSF leukocyte count and severity 
of pneumococci meningitis282 . Therefore, the potential involvement of cathepsin B in 
immune response may indicate its suitability as a marker of sepsis.  
Protein S100 A8/A9: Protein S100 A8 and protein S100 A9 belong to the S100 protein 
family. Together, they form a non-covalent heterodimer. The role of protein S100 A8 and 
A9 in infection and immune response is well known and they are considered important to 
maintain homeostasis of the immune system; the proteins are expressed by neutrophils, 
and macrophages and monocytes in damaged tissues. Conflicting studies report S100 A8 
and S100 A9 as having roles in both pro-inflammatory283 and anti-inflammatory role in 
sepsis284. An investigation into mice models with endotoxin-induced lethal shock and sepsis 
demonstrated that the S100A8/A9 complex is involved in increasing the activation of 
phagocytes in sepsis285.  In addition, a patent was filed in 2009 describing a method to 
measure the S100A8/A9 heterodimer in plasma as a prognostic marker for patients with 
severe sepsis 286.  
Neutrophil gelatinase-associated lipocalin (NGAL): NGAL belongs to the lipocalin protein 
family and plays a role are preventing bacterial growth. Multiple studies report the 
involvement of NGAL as a marker of sepsis in plasma and urine249,271,287,288. In a proteomics 
analysis on patients with early septic shock elevated levels of NGAL were observed 
compared with control patients249. However, a reduction in NGAL in sepsis patients was 
linked with patient non-survival suggesting that elevated NGAL could be used as a 
prognostic marker. Another study on 120 paediatric patients with suspected sepsis 




a useful diagnostic marker of sepsis. However in contrast to the previously discussed study, 
a significantly elevated level of NGAL was considered to correlate with patient death. 
Interleukin-1 receptor-like 1: Interleukin-1 receptor-like 1, also known as suppression of 
tumourgenecity 2 (ST2) is a member of the IL-1 receptor family and is expressed on many 
cells of the immune system including lymphocytes, natural killer T cells and monocytes. In 
tissue damage, the ligand for Il1RL1, IL-33, is released from endothelial and epithelial cells 
and binds with IL1RL1 inducing numerous immune cell types to release pro-inflammatory 
and anti-inflammatory mediators. Numerous studies have identified IL1RL1 as a potential 
biomarker of sepsis with elevated levels measured in patient’s serum290,291. One study 
reported that elevated IL1RL1 levels, measured using a commercial ELISA kit, in sepsis 
patients was shown to correlate with patient mortality292.  
As previously discussed, the application of a single sepsis biomarker is not suitable for 
disease diagnosis due to the lack of specificity of individual protein markers258. The five 
proteins identified in this study have been previously implicated in sepsis or play a role in 
immune response. Therefore, the combined analysis of these candidate proteins may 








Table 5.8 | Summary of proteins selected for phage display Affimer production. 
 In cohort 1, protein S100-A8 and cathepsin B and in cohort 2, protein S100-A9 were identified with 2 or more peptides per protein and a protein score of 
>20 however they did not pass the q value cut–off score. Note: The phage display will target Protein S100 A8/A9 as a heterodimer. 
 
 

















P02741 C-reactive protein Sepsis 7 7.42E-08 1.24E-05 112.60 7 6.95E-09 1.39E-06 66.04 
P05109 Protein S100-A8  Sepsis 4 0.016102 0.050978 2.91 4 0.02824177 0.036892 1.67 
P06702 Protein S100-A9  Sepsis 4 0.008537 0.04213 4.22 2 0.822054 0.0553 1.31 
P07858 Cathepsin B  Sepsis 5 0.046641 0.083577 13.829 4 0.00896988 0.017576 4.33 
P80188 
Neutrophil gelatinase-
associated lipocalin Sepsis 4 0.012632 
0.046079 
4.05 5 0.002183 
0.0071233 
6.54 















Figure 5.27 | Log 2 normalised abundance plots for the five candidate proteins for Cohort 2 
CRP, protein s100-A8, cathepsin B interleukin-1 receptor-like 1 and neutrophil gelatinase-associated lipocalin abundance plots. Plots display the log 2 
normalised abundances of the normalised protein abundance values. Black plots are control samples and red plots are sepsis samples. Statistical analysis (t-









Figure 5.28 | Log 2 normalised abundance plots for the five candidate proteins for Cohort 2 adjusted for sample loading. 
CRP, protein S100-A8, cathepsin B, interleukin-1 receptor-like 1 and neutrophil gelatinase-associated lipocalin abundance plots. Plots display the log 2 
normalised abundances of the normalised protein abundance values adjusted for sample loading. Black plots are control samples and red plots are sepsis 









Figure 5.29 | ROC curves for five candidate proteins for Cohort 2. 
ROC curve analysis for the normalised protein abundance values adjusted for sample loading of CRP, S100-A8, cathepsin B, interleukin-1 receptor-like 1 and 
neutrophil gelatinase-associated lipocalins measured in Cohort 2 to assess suitability of the proteins as biomarkers for sepsis diagnosis. The AUC and 




5.3.5 Characterisation of Phage Display Adhirons 
After selection of the panel of target proteins implicated in sepsis, Adhiron reagents were 
generated. The Adhirons were produced by Thomas Taylor and Christian Tiede in the 
BioScreening Technology Group at the University of Leeds following the standard 
protocol111. Recombinant protein for the selected proteins was purchased for the phage 
display screenings. Initially, five Adhiron binders for each protein were selected at random 
based on validation ELISA data to confirm target binding. The selected Adhiron binders 
were sub-cloned into plasmids for the addition of a cysteine residue required for Adhiron 
immobilisation. However, a portion of these Adhirons did not express and therefore a total 
of 21 Adhirons were received (Table 5.9).  
The Adhiron sequences were aligned using CLC Sequence Viewer and a phylogenetic tree 
created to compare divergence in sequences (Figure 5.30). The variable loop regions of the 
Adhiron protein scaffold are evident, located at residue positions 39 to 48 and 72 to 82 for 
loop 1 and loop 2, respectively. A total of 20 unique Adhiron sequences were generated; 
NGAL 10 and NGAL 78 had identical sequences.  In total, 11 Adhirons did not contain 
peptide insertions in the loop 2 region of the scaffold. As with the pepsinogen Adhirons, 
there is a greater distribution of the hydrophobic amino acid residues in the loop regions. 
Phylogenetic analysis interestingly revealed that the Affimers were sub-divided based on 
the target protein, suggesting the Affimers produced for a single target share similar 
properties. 
To confirm the protein product of Adhiron expression and purification, ESI-MS analysis was 
performed of the intact Adhiron proteins as detailed in Chapter 2.21. As the Adhirons were 
purified into a buffer that did not contain reducing agent, the Adhrions were first incubated 
with DTT to obtain the monomer form of the protein. Prior to ESI-MS analysis, an additional 
clean-up step was carried out using a C4 trap to remove the glycerol and salts from the 
Adhirons samples. For each Adhiron, the predominant species within each mass spectrum 
corresponded to the theoretical mass of the monomer form of the protein minus the 
initiating methionine (Figure 5.31 – 5.35, Table 5.10). Due to the N-terminal sequence, 
cleavage of the initiating methionine is expected 293.  
The results confirm the correct protein product had expressed for all Adhirons and had 
been purified without contaminants. To confirm that the Adhirons bind their intended 
target protein, future work should ensure that the Adhrions are validated in an affinity 




would be suitable validate target binding using recombinant proteins. Following this, the 
next step would be to confirm that the Adhirons bind endogenous target protein in plasma.  
 
 
Table 5.9 | Phage Display Adhirons. 
Concentration of the 21 Adhirons received from the BioScreening Technology Group at the 
University of Leeds. 








NGAL 10 1.6 
NGAL 39 1.1 
NGAL 42 0.8 
NGAL 78 1.6 






ST 15 0.5 
ST 3 0.7 
ST 45 0.3 
ST 55 0.5 
ST 59 1.2 
CRP 
CRP 16 1.3 
CRP 21 1.3 
CRP 22 1.4 
CRP 30 1.3 












Figure 5.30 | Amino acid multiple sequence alignment and phylogenetic tree of Phage Display Adhirons. 
Protein sequences were aligned and visualised using CLC Sequence Viewer. Residues were coloured using default Rasmol colours. Eleven Adhirons do not 









Figure 5.31 | ESI–MS analysis of Phage Display Adhirons targeting Interleukin-1 receptor-like 1. 
Adhirons were prepared using a C4 trap to remove glycerol and salts. Samples were incubated with DTT and diluted to 1 pmol/µL in 3% acetonitrile, 0.1% 
formic acid. 2 µL of each sample was loaded onto a C4 desalting trapping column. Samples were analysed by ESI-MS on the Waters G2 mass spectrometer. 
Multiply charged protein envelope was deconvoluted using Waters MAXENT 1 algorithm to determine average mass of intact proteins. Observed masses of 









Figure 5.32 | ESI–MS analysis of Phage Display Adhirons targeting CRP. 
Adhirons were prepared using a C4 trap to remove glycerol and salts. Samples were incubated with DTT and diluted to 1 pmol/µL in 3% acetonitrile, 0.1% 
formic acid. 2 µL of each sample was loaded onto a C4 desalting trapping column. Samples were analysed by ESI-MS on the Waters G2 mass spectrometer. 
Multiply charged protein envelope was deconvoluted using Waters MAXENT 1 algorithm to determine average mass of intact proteins. Observed masses of 





Figure 5.33 | ESI–MS analysis of Phage Display Adhirons targeting Cathepsin B. 
Adhirons were prepared using a C4 trap to remove glycerol and salts. Samples were 
incubated with DTT and diluted to 1 pmol/µL in 3% acetonitrile, 0.1% formic acid. 2 µL of 
each sample was loaded onto a C4 desalting trapping column. Samples were analysed by 
ESI-MS on the Waters G2 mass spectrometer. Multiply charged protein envelope was 
deconvoluted using Waters MAXENT 1 algorithm to determine average mass of intact 
proteins. Observed masses of Adhirons correspond to their theoretical masses minus the 





Figure 5.34 | ESI–MS analysis of Phage Display Adhirons targeting neutrophil gelatinase-
associated lipocalin. 
Adhirons were prepared using a C4 trap to remove glycerol and salts. Samples were 
incubated with DTT and diluted to 1 pmol/µL in 3% acetonitrile, 0.1% formic acid. 2 µL of 
each sample was loaded onto a C4 desalting trapping column. Samples were analysed by 
ESI-MS on the Waters G2 mass spectrometer. Multiply charged protein envelope was 
deconvoluted using Waters MAXENT 1 algorithm to determine average mass of intact 
proteins. Observed masses of Adhirons correspond to their theoretical masses minus the 






Figure 5.35 | ESI–MS analysis of Phage Display Adhirons targeting protein S100  A8/A9. 
Adhirons were prepared using a C4 trap to remove glycerol and salts. Samples were 
incubated with DTT and diluted to 1 pmol/µL in 3% acetonitrile, 0.1% formic acid. 2 µL of 
each sample was loaded onto a C4 desalting trapping column. Samples were analysed by 
ESI-MS on the Waters G2 mass spectrometer. Multiply charged protein envelope was 
deconvoluted using Waters MAXENT 1 algorithm to determine average mass of intact 
proteins. Observed masses of Adhirons correspond to their theoretical masses minus the 






Table 5.10 | Comparison between theoretical and observed intact mass analysis of Phage 
Display Adhrions. 
 Theoretical mass (Da) calculated minus the initiating methionine.  







C20 12373.9 12374.1 -0.2 
C2 11687.1 11687.2 -0.1 
C3 11807.2 11807.4 -0.2 





NGAL 10 11691.0 11691.3 -0.3 
NGAL 39 12601.9 12602.2 -0.3 
NGAL 42 12597.0 12597.2 -0.2 
NGAL 78 11691.1 11691.3 -.02 
Protein S100 
A8/A9 
S7 11820.2 11820.4 -0.2 
S20 11776.9 11777.3 -0.4 




ST 15 12411.1 12411.1 0 
ST 3 12449.0 12449.1 -0.1 
ST 45 12454.9 12455.3 -0.4 
ST 55 12454.0 12454.2 -0.2 
ST 59 12380.8 12381.1 -0.3 
CRP 
CRP 16 11655.9 11656.3 -0.4 
CRP 21 12293.5 12293.8 -0.3 
CRP 22 11535.8 11536.0 -0.2 
CRP 30 11569.8 11570.1 -0.3 






The primary aim of this chapter was to identify a panel of proteins implicated in sepsis in 
order to guide phage display production of Affimers. Comparative proteomic analysis of 
two patient cohorts using LC-MS/MS identified differentially expressed proteins and a panel 
of five candidate protein markers of sepsis were selected. The proteins selected met strict 
data filters to obtain a high level of confidence in candidate selection. In addition, candidate 
proteins displayed the same direction of change in expression in both cohorts and 
recombinant forms of the proteins were available. This was an essential criteria of protein 
selection due to the phage display process requiring recombinant protein. Overall, proteins 
identified as up-regulated in sepsis plasma were implicated in inflammation and 
characteristic of an acute immune response. The proteins identified in this analysis were in 
agreement with previously published data.  
As discussed, a major challenge of plasma proteomics is the large dynamic range and in 
particular, the highly abundant protein, albumin. Two key methods to reduce sample 
complexity included sample fractionation and depletion strategies. Routinely, complex 
protein samples are digested into peptides and subjected to pre-fractionation prior to LC-
MS/MS analysis (2D LC-MS/MS) to add an additional dimension to peptide separation78. 
However, this technique was not employed in this study due to the increase in the number 
of samples requiring analysis and additional data analysis steps needed. In this analysis, an 
antibody-based depletion strategy was employed successfully to remove abundant plasma 
proteins. Proteins that would typically go un-detected were identified in this study 
demonstrating the necessity for depletion strategies prior to MS analysis to improve 
proteome coverage.  
The mass spectrometer used in this study for the discovery proteomics was a hybrid 
instrument with a quadrupole-Orbitrap mass analyser and is the ideal instrument for the 
analysis of complex proteomes due to the high scanning speed, mass accuracy and 
resolution272. The fragmentation spectra produced is of high quality and enables the correct 
assignment of product ions for accurate peptide sequencing. However, despite the 
application of protein depletion methodologies and high quality instrumentation, mass 
spectrometers still display a bias towards the most abundant peptide ions within a sample 
due to the selection of the top n ions selected for fragmentation. Therefore, low abundance 




applies protein quantification prior to identification increases low abundance protein 
identification across all samples.   
Although the overall aim of the chapter was met, there were limitations in the study. Two 
samples from cohort 2 were excluded from protein quantification as they did not meet the 
alignment and normalisation cut-off in Progenesis QI. Low numbers of protein 
identifications due to insufficient depletion of highly abundant proteins was suggested as a 
reason for this. Variability of the depletion spin columns to remove highly abundant 
proteins was not assessed in this analysis. Ideally, variability in the depletion method 
should be analysed. If variability in protein depletion is high, a large negative effect on 
protein quantification and identification of differentially expressed proteins could be 
observed. In addition, increasing the number of samples analysed in this study would 
generate a more robust dataset.  Furthermore, patient samples were not analysed in 
triplicate. To gain greater confidence in protein identifications and abundance values it 
would desirable to analyse each patient sample in triplicate, although it should be noted 
that the data has undergone very stringent filtering to generate reliable protein abundance 
values. Obviously, factors such as cost, through-put and availability of patient samples limit 
repeated sample analysis.  
The key outcome of this proteomic study of sepsis plasma is the production of Affimers to 
the five proteins identified as having increased expressed in sepsis patients. Intact mass 
analysis of the Affimers suggested expression and purification of the correct protein 
product with the addition of a cysteine residue necessary for immobilisation. Future work 
should include validation of the Adhirons to confirm they bind both the recombinant and 
endogenous form of the protein targets they were generated against with high affinity and 
specificity. 
The work in this chapter forms part of a collaborative project to use Affimer reagents in a 
multiplexed ELISA format. Following extensive optimisation and development of the 
multiplexed ELISA, the ultimate goal is to develop a miniaturised POCT device for sepsis 
diagnosis and detection. The POCT device will allow rapid detection of sepsis which will lead 
to earlier therapeutic intervention improving patient prognosis. While extensive validation 
is necessary to confirm the candidate proteins are suitable for use as a diagnostic panel for 






Chapter 6: Darcin as an Antibody Alternative Protein Scaffold 
6.1 Introduction 
Lipocalins are small, secreted proteins that encompass a large family of proteins across 
many different species173. Sequence homology between the different lipocalins is extremely 
low however certain members of the protein family, known as prototypic lipocalins, have 
high homology in their secondary structure172. A primary property of proteins in this family 
is molecular recognition including ligand binding, complex formation and receptor 
binding173. Furthermore, the proteins have a compact, rigid structure attributed to the β-
barrel core of the proteins173. These features make lipocalins ideal proteins for engineering 
as protein scaffolds. Their development as such has been described in numerous studies 
and has resulted in the commercialisation of lipocalin based alternative affinity 
reagents107,171,172. Despite many lipocalin proteins undergoing development as protein 
scaffolds, the protein group known as major urinary proteins (MUPs) are yet to be studied 
for development as potential protein scaffolds. MUPs are produced in the urine of rodents 
typically mice and rats and play a role in chemical communication294. As the MUPs are 
deposited in the urine and left for communication with other rodents, it is vital that the 
MUPs are highly stable. A particular MUP, darcin, has demonstrated enhanced stability 
compared to the other MUPs (Figure 6.1). A study examining the effects of high urea 
concentration (8M) on darcin has shown that the protein undergoes little denaturation, 
demonstrating the robust nature of darcin197.  Additionally, darcin displays abnormally high 
mobility on SDS-PAGE 295, a characteristic that can be explained by its compact structure 
preserved by disulfide bonds enabling the protein to pass through the gel more freely.  This 
feature of high stability and its robust nature suggests that darcin is suitable for 
development as a protein scaffold. 
The work in Chapter 4 demonstrated that the pepsinogen Adhiron was able to tolerate 
lysine to arginine mutations to produce a non-digestible scaffold, when Lys-C was the 
protease. Therefore, it was proposed whether darcin could tolerate similar mutations 
without compromising the stability of the protein. A non-digestible scaffold would be 
advantageous for affinity purification MS applications. Furthermore, it was also investigated 





Figure 6.1 | 3D tertiary structure of darcin. 
Ribbon diagram of the 3D tertiary structure of darcin, a mouse MUP. β-sheets highlighted in 
yellow form the central β-barrel and highlighted in red are the α-helices. Structure 







6.2 Aims and Objectives 
The work in this chapter will focus on the preliminary development of darcin, as an 
alternative affinity reagent protein scaffold. The key objectives were to: 
- Express and purify recombinant darcin. 
- Express and purify a mutant darcin lacking a disulfide bond. 
- Analyse the role of the disulfide bond in protein stability. 
- Compare non-specific binding of proteins to the mutant darcin lacking a disulfide 
bond and darcin. 
- Design darcin variants with other features required for protein scaffolds. 
 
6.3 Results and Discussion 
6.3.1 Design of darcin lacking a disulfide bond 
While all MUPs have a single disulfide bond which may explain their high stability296, it may 
be a detrimental feature when designing a protein scaffold. Previous work has shown that a 
recombinant form of darcin expresses at high levels and forms with a disulfide bond 
producing a fully folded protein197,297. However, modifying the protein to make it more 
suitable to function as a protein scaffold, for example with the addition of variable loop 
regions, may affect protein expression and folding. Therefore to ensure production of a 
reliable, fully folded, consistent protein scaffold it may be advantageous that the scaffold 
lacks the disulfide bond. In addition, engineered removal of the disulfide bond may increase 
protein flexibility, a potentially useful feature when developing a protein scaffold as 
accessibility to potential variable interaction sites may increase. However, it is necessary to 
evaluate whether darcin lacking a disulfide bond results in the loss of high stability. 
To assess the role of the disulfide bond in protein stability a darcin mutant, termed darcin 
[C78S, C171S] v 1.0, was engineered so that the two cysteine residues at positions 64 and 171 
were replaced for serine residues, preventing disulfide bond formation (Figure 6.2). The 
amino acid serine was chosen as the preferred residue substitution for cysteine as it has the 













Figure 6.2 | Amino acid sequence alignment of darcin and darcin [C78S, C171S] v 1.0.  
Protein sequences were aligned and visualised using CLC Viewer. Amino acid residues were coloured using the default Rasmol colours. Difference in two 
amino acid residues; cysteine residues at positions 78 and 171 have substitutions for serine residues. Theoretical molecular weight of darcin and darcin 




6.3.2. Expression of darcin and darcin [C78S, C171S] v 1.0 
Darcin and darcin [C78S, C171S] v 1.0 were expressed following standard protocol in Chapter 
2.1. Both genes were codon optimised for enhanced expression in E.coli and cloned into a 
pET28b + plasmid. A glycerol stock of BL21 (λDE3)  E.coli cells containing a pET28b plasmid 
for darcin had been previously generated and was used to streak a kanamycin containing 
agar plate and grown overnight. The darcin [C78S, C171S] v 1.0 plasmid was transformed into 
BL21 E.coli cells following the transformation protocol. Due to the antibiotic resistance 
gene to kanamycin within the plasmid, only transformed cells containing the plasmid were 
selectively grown. A single colony for both darcin and darcin [C78S, C171S] v 1.0 were 
selected from the overnight agar plate cultures and used to inoculate a small overnight LB 
culture. The overnight broth was used to make glycerol stocks of darcin [C78S, C171S] v 1.0. 
For larger scale protein production, the overnight cultures were used to inoculate 200 mL 
of LB broth containing kanamycin following the protein expression protocol. The culture 
growth rate and protein expression post IPTG induction was monitored by removal of 
culture solution at time points during the trial induction and analysed by SDS-PAGE. Pre- 
and post – induction protein expression gels for darcin and darcin [C78S, C171S] v 1.0 and 
growth curves were analysed to assess for protein expression (Figure 6.3).  
For the darcin construct, after IPTG induction, a protein band was visible on SDS-PAGE at 
approximately 20 kDa, which was not present before induction (Figure 6.3). This is the 
approximate expected mobility for darcin. For darcin [C78S, C171S] v 1.0, after IPTG 
induction, doublet protein bands were visible on SDS-PAGE at approximately 20 kDa and 16 
kDa, both of which were not present prior to induction (Figure 6.3). Again, 20 kDa is the 
approximate molecular weight for darcin [C78S, C171S] v 1.0, however the lower molecular 
weight band suggests that either a truncated form of the protein was expressed or that the 
band is a degradation product of the full length protein. To determine the products of 
protein expression, an in-gel digestion was carried out on the three protein bands discussed 
above as described in Chapter 2.16 (Figure 6.4) and the peptides analysed by MALDI MS. 
Peptides corresponding to darcin were identified for all three protein bands suggesting 
protein expression. However, due to low sequence coverage it was not possible to confirm 
expression of the full length proteins. Although the results suggest that darcin and darcin 
[C78S, C171S] v 1.0 have expressed, it was still unclear why darcin [C78S, C171S] v 1.0 expressed 
as a doublet band. Therefore, to further evaluate the products of protein expression, the 








Figure 6.3 I E.coli culture and expression of darcin [C78S, C171S] v 1.0 and darcin. 
SDS-PAGE analysis of pre-induction and post-induction timepoints and growth curves for 
darcin and Darcin [C78S, C171S] v 1.0 expression. Protein expression was induced with IPTG at 
an OD = 600 nm and protein left to accumulate for 16 hours. Arrows represent protein 
bands appearing after IPTG induction. A doublet band is visible at approximately 20 kDa 
and 16 kDa for darcin [C78S, C171S] v 1.0 and a single band at approximately 20 kDa for 










Figure 6.4 | MALDI spectra of in-gel digest of the products of darcin and darcin [C78S, C171S] v 1.0 protein expression.  




Prior to purification, the cells were lysed by sonication. Following centrifugation, the 
soluble fraction and insoluble inclusion body were analysed by SDS-PAGE to determine the 
location of the protein; both darcin and darcin [C78S, C171S] were expressed in the soluble 
fraction of the lysate (Figure 6.5). The proteins were purified using the immobilised metal 
affinity chromatography protocol using the AKTA start and fractions analysed by SDS-PAGE 
(Figure 6.5). Darcin eluted in fractions 4 to 7 and was present at high levels, whereas darcin 
[C78S, C171S] v 1.0 eluted predominantly in fractions 5 to 7.  Although both doublet bands of 
darcin [C78S, C171S] v 1.0 contained peptides for this protein by in-gel digestion and MALDI 
analysis, the lower molecular weight band did not bind to the purification column and was 
present in the flow through fraction. This further supports the idea that degradation of 
darcin [C78S, C171S] v 1.0 has occurred, with this portion of the protein lacking the His-tag. 
Elution fraction 6 for darcin [C78S, C171S] v 1.0 and elution fraction 5 and 6 for darcin were 
dialysed into 25 mM ammonium bicarbonate and the protein concentration determined by 
Coomassie plus protein assay. 
To confirm full length protein expression and the absence of contaminant proteins 
following purification, darcin and darcin [C78S, C171S] v 1.0 were analysed by intact mass 
spectrometry following the method in Chapter 2.21 (Figure 6. 6). The predominant species 
within the mass spectrum for darcin has a mass of 20403.29 Da which corresponded to the 
theoretical mass of darcin with the loss of the N-terminal initiating methionine and the 
presence of a disulfide bond (- 2 Da). An additional species, with a mass of 20581 Da was 
also observed which corresponds to a modification of + 178 Da. Work by Geoghegan et al 
first reported the observation of a + 178 Da and a + 258 Da mass adduct to recombinant 
proteins expressed in E.coli containing N-terminal His-tags298. Thus, the modification of + 
178 Da was suspected as gluconoylation. Although the modification results in a 
heterogeneous population of the protein, it is thought that it does not affect protein folding 
due to its location on the His-tag portion of the protein. The predominant species within 
the mass spectrum for darcin [C78S, C171S] v 1.0 has a mass of 20373.30 Da which 
corresponds to the theoretical mass of the protein with the loss of the initiating N-terminal 






Figure 6.5 | Expression analysis and purification of darcin and darcin [C78S, C171S] v 1.0.  
Top and bottom left: Cell pellet generated from cultures were lysed by sonication and 
centrifuged. The supernatant (SF) was collected and the remaining cell pellet washed by re-
suspension. Sample was centrifuged at supernatant collected (W1). The cell pellet (inclusion 
body (IB)) was re-suspended for analysis. Darcin and darcin [C78S, C171S] v 1.0. 
predominantly expresses as soluble protein. Top and bottom right: His-tag proteins were 
purified using GE Healthcare NiNTA affinity columns on the AKTA start using a gradient 
elution of 0 % buffer B (elution buffer) to 100 % buffer B over 20 minutes. Arrows at 
approx. 20 kDa represent protein eluting from column. 10 µl of each fraction was ran on 15 





Figure. 6.6 | Deconvoluted ESI-MS analysis of darcin and darcin [C78S, C171S] v 1.0.  
Protein samples were diluted to 1 pmol/µL in 3% acetonitrile, 0.1% formic acid. 2 µL of each 
sample was loaded onto a C4 desalting trapping column. Samples were analysed by ESI-MS 
on the Waters G2 mass spectrometer. Multiply charged protein envelope was 
deconvoluted using Waters MAXENT 1 algorithm to determine average mass of intact 
proteins. Observed masses of 20403 Da and 20581 Da for darcin corresponds to the loss of 
the initiating methionine and modification of gluconoylation respectively. Masses take into 
account disulfide bond (-2 Da). Observed mass for darcin [C78S, C171S] v 1.0 of 20373 Da and 
20550 Da corresponds with the loss of the initiating methionine and modification of 




6.3.3 Expression of darcin [C78S, C171S] v 2.0 
The expression level of darcin [C78S, C171S] v 1.0 was considerably lower than that of darcin 
protein expression, as well as the obvious issues with truncation of some of the protein 
product of darcin [C78S, C171S] v 1.0. This could be explained due to two amino acid 
substitutions introduced into the darcin sequence resulting in two cysteine residues 
substituted for serine residues. As it was hoped that a cysteine to serine substitution would 
have minimal effect on protein expression, this result was disappointing.   
Therefore, to deduce the cause of the altered expression level of the proteins, the DNA and 
protein sequences of darcin and darcin [C78S, C171S] v 1.0 were analysed further (Figure 6.7). 
Despite the protein sequences of darcin and darcin [C78S, C171S] v 1.0 differing in only two 
amino acid residues, at a DNA level, the sequences differed by 67 base residues. This could 
explain the low expression levels and truncation of darcin [C78S, C171S] v 1.0 compared to 
darcin. Codon frequency analysis was performed and revealed the gene was suitability 
optimised for expression in E.coli, so it was unexpected that darcin [C78S, C171S] v 1.0 did not 
express in a similar way to darcin. To assess this hypothesis, a second darcin mutant 
construct was designed, termed darcin [C78S, C171S] v 2.0. In this version the DNA sequence 
was identical to that of the original darcin construct, apart from the six DNA bases coding 











Figure 6.7 | DNA sequence alignment of darcin and darcin [C78S, C171S] v 1.0.  
Protein sequences were aligned and visualised using CLC Viewer. Amino acid residues were coloured using the default Rasmol colours. Despite the amino 




The plasmid for darcin [C78S, C171S] v 2.0 was transformed into BL21 (λDE3) E.coli cells and 
expressed as described previously. Time points of the culture solution were taken during 
expression and analysed by SDS-PAGE. After IPTG induction a single protein band at the 
approximate molecular weight for darcin [C78S, C171S] v 2.0 (20 kDa) was visible, suggesting 
expression of the full length protein (Figure 6.8). When comparing protein expression levels 
between darcin [C78S, C171S] v 1.0 and darcin [C78S, C171S] v 2.0, increased protein expression 
levels were observed for darcin [C78S, C171S] v 2.0. This result demonstrates that, for this 
particular protein, keeping the original gene optimisation is the ideal strategy for yielding 
high protein expression when creating a variant with minor modifications to a pre-existing 
gene.  
The darcin [C78S, C171S] v 2.0 cell pellet was sonicated and centrifuged. The protein was 
expressed in the soluble fraction, determined by SDS-PAGE analysis of the soluble fraction 
and insoluble inclusion body (Figure 6.9). Darcin [C78S, C171S] v 2.0 was purified as described 
in Chapter 2.3 and eluted in fractions 5 to 8. Elution fractions 6 and 7 were dialysed against 
25 mM ammonium bicarbonate and the protein concentration determined using the 
Coomassie plus protein assay. Expression levels of darcin [C78S, C171S] v 2.0 were 
comparable to darcin. To confirm full length protein expression, darcin [C78S, C171S] v 2.0 
was analysed by intact mass spectrometry as described in Chapter 2.21 (Figure 6.9). The 
main species within the mass spectrum had a mass of 20373 Da corresponding to the 
theoretical mass of darcin [C78S, C171S] v 2.0 minus the initiating N-terminal methionine. An 
additional species, with a mass of 20551 Da was also observed which corresponds to a 
modification of + 178 Da. This is the same modification observed with darcin corresponding 







Figure 6.8 | E.coli culture and expression of darcin [C78S, C171S] v 1.0 and darcin [C78S, 
C171S] v 2.0.  
SDS-PAGE analysis of pre-induction and post-induction timepoints and growth curves for 
darcin [C78S, C171S] v 1.0 and darcin [C78S, C171S] v 2.0 expression. Protein expression was 
induced with IPTG at an OD = 600 nm and protein left to accumulate for 16 hours. Arrows 
represent protein bands appearing after IPTG induction. A doublet band is visible at 
approximately 20 kDa and 16 kDa for darcin [C78S, C171S] v 1.0 and a single band at 
approximately 20 kDa for darcin [C78S, C171S] v 2.0. Samples ran on a 15 % gel and visualised 







Figure 6.9 | Expression, purification and ESI-MS analysis of darcin [C78S, C171S] v 2.0. 
Top: Cell pellet generated from culture was lysed by sonication and centrifuged. The 
supernatant (SF) was collected and the remaining cell pellet washed by re-suspension. 
Sample was centrifuged at supernatant collected (W1). The cell pellet (inclusion body (IB)) 
was re-suspended for analysis. Darcin [C78S, C171S] v 2.0. predominantly expresses as soluble 
protein. His-tag darcin [C78S, C171S] v 2.0. was purified using GE Healthcare Ni-NTA affinity 
columns on the AKTA start. Arrows at approx. 20 kDa represent protein eluting from 
column. Bottom: Protein samples were diluted to 1 pmol/µL in 3% acetonitrile, 0.1% formic 
acid. 2 µL of protein was loaded onto a C4 desalting trapping column and analysed by ESI-
MS on the Waters G2 mass spectrometer. Multiply charged protein envelope was 
deconvoluted using Waters MAXENT 1 algorithm to determine average mass of intact 
proteins. Observed masses of 20373 Da and 20551 Da correspond to the loss of the 




6.3.4 Role of the disulfide bond in stability of darcin 
To explore whether the disulfide bond in darcin helped to provide the high stability, a 
proteolysis study was undertaken to examine the rate of degradation of darcin and darcin 
[C78S, C171S ] v 2.0, the variant lacking the disulfide bond. It was hypothesised that darcin 
[C78S, C171S] v 2.0 would be more susceptible to degradation than darcin and therefore 
undergo proteolysis at a quicker rate. A total of 200 µg of both proteins were separately 
incubated with 1.25 µg trypsin at 37 oC for 3 hours. Samples were taken periodically to 
assess the rate of proteolysis by SDS-PAGE and MS. Proteolysis was stopped by the addition 
of TCA and neutralised with ammonium bicarbonate for SDS-PAGE analysis (Figure 6.10) or 
by formic acid for analysis by mass spectrometry (Figure 6.11). A control sample of each 
protein was also incubated at 37 oC for 3 hours to confirm that the trypsin was responsible 
for degradation and not the temperature. SDS-PAGE analysis revealed that after a 3 hour 
incubation with trypsin, darcin does not undergo complete proteolysis. Lower molecular 
weight species become visible during the time-course with a consistent intermediate 
species forming after 10 minutes at approximately 14 kDa. The protein band for full length 
darcin disappeared after 60 minutes. Intact mass spectrometry analysis of proteolysis time-
point supports this result as a stable fragment species at 17973 Da becomes the main 
species from 15 minutes onwards with the full length darcin signal disappearing after 45 
minutes. Conversely, darcin [C78S, C171S] v 2.0 undergoes complete and rapid proteolysis 
after 3 hour incubation with trypsin indicated by smearing on SDS-PAGE, with partial 
proteolysis occurring within the first 2 minutes of the time-course. Intact mass analysis of 
the time-course fractions supports this result with no species detectable after 5 minutes 
due to extensive proteolysis of the starting material (Figure 6.11). Analysis of control gels 
reveal that a temperature of 37oC does not cause either protein to degrade after 3 hour 
incubation (Figure 6.10). 
These findings suggest that removal of the disulfide bond in darcin to form darcin [C78S, 
C171S] v 2.0 reduces the protein stability and resistance to proteolysis. The disulfide bond 
allows the three dimensional structure of the protein to remain stable and compact. 
Removal of the bond causes the protein structure to unfold more readily, increasing the 
number of potential proteolytic sites available to interact with the protease enzyme, thus 
increasing the rate of degradation. As stability is a highly desired feature of a protein 
scaffold, the results suggest that darcin [C78S, C171S] v 2.0 is unsuitable for development 
whereas the usual disulfide bond containing darcin may be a more suitable candidate for 







Figure 6.10 | SDS-PAGE analysis of darcin and darcin [C78S, C171S] v 2.0 proteolysis time-
course.  
Recombinant darcin and darcin [C78S, C171S] v 2.0 were incubated at 37 
oC for 3 hours. 
Aliquots of sample were taken throughout the time-course for analysis. Top gel: Control gel 
of protein incubated without trypsin indicates darcin and darcin [C78S, C171S] v 2.0 remain 
intact at 37 oC. Bottom gel: Protein incubated with trypsin. Darcin [C78S, C171S] v 2.0 
undergoes rapid and complete proteolysis represented by smearing on gel. Darcin forms a 
stable proteolytic fragment at 3 hours and is resistant to complete proteolysis. Samples ran 








Figure 6.11 | ESI–MS analysis of darcin and darcin [C78S, C171S] v 2.0 proteolysis time-
course. 
Recombinant darcin and darcin [C78S, C171S] v 2.0 were incubated at 37 
oC for 3 hours. 
Aliquots of sample were taken throughout the time-course for analysis. Proteolysis was 
halted by the addition of TCA (5 % final concentration). No detectable species were 
measurable for darcin [C78S, C171S] v 2.0 at 5 minutes onwards indicating rapid proteolysis. 
Darcin withstood complete proteolysis with an intermediate stable species forming. 1510.5 
Da initially removed corresponding to the His-tag (GSSHHHHHHIEGR) followed by a further 




6.3.5 Assessment of non-specific background in darcin affinity purification assay 
As previously discussed, a protein scaffold should be biologically neutral, meaning that it 
has low or no binding affinity for proteins when in a complex biological matrix and that it 
exhibits no biological activity. Therefore, to explore protein interactions with darcin, an 
affinity purification assay using darcin in place on an affinity reagent was performed as 
described in Chapter 2.12. To assess whether removal of the disulfide bond in darcin alters 
protein interactions and affinity of matrix proteins to darcin, darcin [C78S, C171S] v 2.0 was 
also analysed in the assay.  
Darcin and darcin [C78S, C171S] v 2.0 were immobilised onto Ni-NTA magnetic agarose beads 
via the His-tag. The bead-darcin complexes were incubated with either yeast lysate or 
human plasma, separated from the biological background using a magnetic rack and then 
washed to remove non-specific background. To identify proteins that bind to the Ni-NTA 
beads, a bead control with no darcin or darcin [C78S, C171S] v 2.0 was exposed to either yeast 
lysate or human plasma and analysed as described above. The samples were divided into 
two for SDS-PAGE or LC-MS/MS analysis. 
SDS-PAGE analysis revealed that with either darcin or darcin [C78S, C171S] v 2.0 bound to the 
beads, the amount of non-specific proteins from both human plasma (Figure 6.12) and 
yeast lysate (Figure 6.13) observed is less than beads only exposed to biological matrix. This 
was more evident with the human plasma than the yeast. It is likely that both darcin and 
darcin [C78S, C171S] v 2.0 block the available interaction sites on the bead surface preventing 
additional proteins binding. Additionally, the beads had selective binding properties, 
displaying preferences to certain proteins. This is evident by the notable differences 
observed between the plasma only lane and lanes where the beads have been incubated 
with plasma; these lanes do not look like the plasma lane. Beads incubated with yeast 
lysate also appear to share this selective binding property. Non-specific binding of both 





Figure 6.12 | SDS-PAGE analysis of darcin and darcin [C78S, C171S] v 2.0 background 
analysis of plasma. 
Beads incubated with sample buffer and loaded directly onto the gel. Top: Control gel with 
beads only, beads & darcin and beads and darcin [C78S, C171S] v 2.0. Bottom: Beads & 
plasma, beads, darcin & plasma and beads darcin [C78S, C171S] v 2.0 and plasma. All samples 
analysed in triplicate as indicated by A, B and C. Samples were ran on 15 % gels and 





Figure 6.13 | SDS-PAGE analysis of darcin and darcin [C78S, C171S] v 2.0 background 
analysis of yeast lysate. 
Beads incubated with sample buffer and loaded directly onto the gel. Top: Control gel with 
beads only, beads & darcin and beads and darcin [C78S, C171S] v 2.0. Bottom: Beads & yeast, 
beads, darcin & yeast and beads darcin [C78S, C171S] v 2.0 and yeast. All samples analysed in 
triplicate as indicated by A, B and C. Samples were ran on 15 % gels and visualised with 





To prepare samples for LC-MS/MS analysis, an on-bead digest was carried out as described 
in Chapter 2.17. Peptides were analysed by the Thermo Scientific QExactive HF mass 
spectrometer on a 30 minute gradient. The raw data was processed using Proteome 
Discoverer and the generated mgf file searched in MASCOT against a database contain the 
two darcin sequences (sequences in Figure 6.2) and either a human or yeast database for 
the plasma or yeast lysate samples respectively. A 1% FDR filter was applied and proteins 
had to be identified by two or more peptides. As samples were analysed in triplicate, the 
average number of protein identified was reported for each condition (Figure 6.14). Label-
free quantification data was not obtained for this experiment as it was a preliminary 
investigation into the non-specific binding. As observed with SDS-PAGE results, the plasma 
only and yeast only beads achieved the highest number of protein identifications. Due to 
the inherent ‘stickiness’ of the agarose beads, this is expected216. Furthermore, as the 
beads had no darcin or darcin [C78S, C171S] v 2.0 coated on them prior to exposure to 
biological sample, binding sites on the bead surface and the nickel sites would be available 
to interact with plasma and yeast proteins. More proteins were identified in the beads 
exposed to both human plasma and yeast lysate that had darcin [C78S, C171S] v 2.0 
compared to darcin suggesting that the increased flexibility in the structure of darcin [C78S, 
C171S] v 2.0 increases the amount of non-specific binding to the protein. In the beads only, 
darcin only and darcin [C78S, C171S] v 2.0 only samples, an average of 4, 3 and 3 proteins 
were identified, respectively. Other than darcin and darcin [C78S, C171S] v 2.0, the proteins 
identified were keratins. Despite precautions and care taken during the affinity purification 
and sample digest steps, keratin contamination is extremely common and nearly 
unavoidable during proteomic analysis. A separate search of the yeast data against a 
human database did reveal keratin identification. Darcin and darcin [C78S, C171S] v 2.0 was 
identified in all digests where it had been pre-bound to the beads however, due to the high 
sequence homology between darcin and darcin [C78S, C171S] v 2.0, the two proteins could 








Figure 6.14 | Average number of protein identifications in background binding analysis 
comparison. 
Top: Human plasma samples. Bottom: Yeast lysate samples.  Error bars represent standard 






To further investigate the non-specific proteins binding to darcin and darcin [C78S, C171S] v 
2.0, the proteins identified in the different conditions were compared. Proteins identified in 
at least two of the replicates were included in the analysis. The MASCOT score and number 
of peptides identified per protein were reported for the plasma background binding (Table 
6.1) and yeast background binding (Table 6.2) analysis. In total, 22 and 83 unique proteins 
were identified in the plasma and yeast lysate background experiment respectively.  
Histidine-rich glycoprotein was identified in all samples where plasma was added. As 
indicated by the name, histidine-rich glycoprotein contains a large number of histidine 
residues. As the magnetic nickel beads using in the affinity purification bind proteins 
through the his-tag, it is likely that histidine-rich glycoprotein binds to the beads. 
Apolipoprotein C-III and apolipoprotein E are the only two proteins identified in the darcin 
& plasma and darcin [C78S, C171S] v 2.0 & plasma that were not identified in the plasma only 
sample. This may suggest that these two proteins bind non-specifically to both darcin and 
darcin [C78S, C171S] v 2.0 instead of to the magnetic beads. Apolipoprotein D and Ig kappa 
chain C region are the only two proteins identified in solely darcin [C78S, C171S] v 2.0 & 
plasma samples. This again suggests that the more flexible structure of darcin [C78S, C171S] v 
2.0 results in more non-specific binding of plasma proteins. Most proteins identified in the 
plasma only control are also identified in both the darcin & plasma and darcin [C78S, C171S] v 
2.0 & plasma samples. This suggests there is a common subset of proteins that bind non-
specifically to the Ni-NTA magnetic agarose beads. Of these proteins identified, most have 
been previously identified as contaminates of affinity purifications299. When analysing the 
yeast data, the same pattern was observed with most proteins identified in the yeast only 
samples also identified in the darcin & yeast and darcin [C78S, C171S] v 2.0 & yeast samples. 
Significantly more proteins were identified in the yeast background binding analysis 
compared to the human plasma experiments. Although the same amount of protein was 
used in both studies, the dynamic range of a yeast lysate is lower than human plasma19 
which could explain the lower number of protein identifications in the human plasma 
background binding analysis. A large number of ribosomal proteins (46) were identified in 
the yeast samples but as they form complexes, this was expected300. Darcin was identified 
in both the bead only samples for the yeast and plasma experiments, despite not being 
incubated with beads. Therefore, it was probably identified because of carryover from the 
previous sample analysed in the mass spectrometer, despite blank samples being ran in-









Table 6.1 | Summary of the MASCOT score and number of peptides observed for proteins identified in plasma background binding analysis. 












Table 6.2 | Summary of the MASCOT score and number of peptides observed for proteins identified in yeast lysate background binding analysis. 





















6.3.6 Engineered darcin 
Although it has been determined that darcin is extremely stable and that the disulfide bond 
is vital in preserving this stability, it is necessary that a protein scaffold possesses additional 
features to make them suitable for use147, as discussed in Chapter 1. Therefore the design 
of various engineered darcin proteins will be discussed. 
Variable loop regions 
The ability to engineer variable loop regions into the protein to facilitate binding is a key 
feature of a protein scaffold.  Therefore, to identify regions of the protein suitable for 
variable peptide loop insertions, the 3D structure of darcin was visualised and examined 
using PyMol. The protein structure was loaded into PyMol from the Protein Data Bank 
archive and represented as both a ribbon and mesh structure. The mesh view was more 
informative as it provides a view of the reach of the proteins interactions. Areas of the 
protein that had ‘natural’ loop regions and clefts were first considered for selection. Figure 
6.15 presents the 3D structure of darcin and highlights the two regions of the protein 
hypothesised for loop selection. The two proposed loop regions naturally form loops in 
darcin and therefore could be suitable for further engineering. Loop 1 consists of residues 
46 - 49 and loop 2 consists of residues 73-77, separated by 24 residues. To evaluate the 
suitability of the selected loops regions further, a multiple sequence alignment analysis of 
the MUP proteins was performed (Figure 6.16). The MUP proteins have high sequence 
homology and therefore by analysing whether the proposed loop regions are conserved 
across the MUPs may provide insight into the role of the selected regions. The protein 
sequence of loop 1 is fairly consistent across all MUP whereas the sequence of loop 2 is 
more variable. The high variability of loop 2 may suggest that this portion of the protein 




















Figure 6.15 | 3D structure of darcin with proposed loops. 
Orange region represents loop 1. Purple region represents loop 2. Yellow residues 





Figure 6.16 | Multiple amino acid sequence alignment of MUPs. 
Sequences were aligned using Clustal X301, a tool for multiple sequence alignment and 
visualised in Jalview302. Amino acid residues were coloured using the default Clustal X 
colours and highlights differences in residues. High sequence homology observed between 






As with the ‘non-digestible’ pepsinogen Adhiron, a darcin mutant that can withstand 
proteolysis would be beneficial for use in affinity purifications. As discussed in Chapter 3, a 
major problem with affinity purifications and co-immunoprecipitations is the large signal in 
mass spectrometry assays from the tryptic peptides of the reagent involved in the 
purification and enrichment. The signals of peptides of interest from enriched or purified 
proteins are usually too low to detect. Generating a ‘non-digestible’ affinity reagent would 
therefore be beneficial, allowing the reagent to be separated from peptides prior to MS 
analysis. A mutant darcin was designed that had all lysine residues substituted to arginine 
residues. Therefore, when the mutant darcin and its payload are digested using the 
proteases Lys-C, that cleaves at lysine residues, darcin will remain intact and its protein 
payload will undergo proteolysis, assuming the proteins contain lysine residues. Although 
trypsin is the standard protease used in proteomics, numerous other enzymes are used, for 
example in de novo sequencing protocols. A lysine to arginine substitution is considered the 
most favourable, as discussed previously in Chapter 4. 
 
Cleavable His-tag darcin 
The addition of a His-tag to recombinant darcin is necessary for simple protein purification 
from other proteins and cellular components. In addition, for use as a protein scaffold, the 
His-tag is beneficial for affinity purifications for protein immobilisation. However, the His-
tag may affect the stability, conformation and activity of darcin. The His-tag is also fairly 
long and flexible which could interfere with the interaction sites. His-tag cleavage is easy to 
achieve using proteases. Therefore a mutant darcin was designed containing a protease 
cleavage site. The tobacco etch virus (TEV) protease recognises the amino acid sequence 
ENLYFQ↓G (cleavage site annotated with ↓) and was chosen due to its high specificity. To 
save time, both mutations of the lysine to arginine substitutions and TEV cleavage sites 
were combined into one modified protein, termed darcin [KtoR], as shown below. The red 
portion represents the His-tag, blue portion represents the TEV cleavage site, green 
residues represent arginine substitutions and the orange and purple portions represent 








6.3.7 Confirmation of darcin [KtoR] expression 
It was decided that a darcin variant with a cleavable His-tag and with a resistance to Lys-C 
proteolysis would be the first variant to express. To generate a plasmid for protein 
expression, the desired sequence was sent to Eurofins Scientific, a biotechnology company 
that provides genomic services. The typical workflow for plasmid generation first requires 
the optimised DNA sequence for the desired protein to be inserted into a vector. This 
vector is usually a cloning vector as they allow for the easy insertion of DNA fragments. To 
generate a protein product the vector requires promoter regions which requires an 
expression vector. However, a full length clone in an E.coli expression vector could not be 
generated and instead a cloning vector was supplied. To overcome this and as part of a 
collaboration, the wheat germ cell-free protein expression system was proposed for darcin 
[KtoR] protein expression. Victoria Harman from the Centre for Proteome Research, 
alongside collaborators at Ehime University in Japan carried out the work to express and 
purify the protein303. Due to requirements of the other proteins expressed in the workflow, 
darcin [KtoR] was expressed as heavy labelled. 
To identify the product of protein expression and purification, an in-solution digest was 
carried out following the standard protocol as described in Chapter 2.17. However, it was 
suspected that the protein concentration was fairly low so the amount of trypsin added 
was adjusted. Peptides were analysed on the Thermo Scientific QExactive mass 
spectrometer on a 30 minute gradient and the raw data processed using Proteome 
Discoverer. The resulting mgf file was searched in mascot against a darcin database with 
the additional constant modification of [13C6][
15N4] arginine due to the heavy expression. 
Based on MS/MS identifications, 50 % protein coverage was achieved (Figure 6.17). 
Extracted ion chromatograms of precursor ions were able to increase protein coverage to 
89.6% (Figure 6.17). A large number of peptides were identified with missed cleavage sites. 
Previous work has demonstrated that darcin is difficult to digest fully due to the protein 
structure being fairly resistant to reduction and thus remains tightly folded. The high 
number of missed cleavage sites could also suggest that darcin [KtoR] is also fairly robust. 
The region of the protein with the TEV cleavage site was identified with a peptide with high 
quality MS/MS spectra and there was sufficient coverage of the other mutated residues to 










Figure 6.17 | Tryptic peptide map of darcin [KtoR]. 
 89.6% sequence coverage achieved. Top: BPI chromatogram with the main peaks labelled 
with the corresponding peptide number. Middle: Peptide map of darcin [KtoR] generated 
using Peptide Mapper234. Blue peptides identified in mass spectrum with no missed cleaves, 
whereas red peptides were identified with one missed cleavage site. Bottom: Darcin [KtoR] 






In total, three darcin constructs have been designed to further develop darcin as putative 
protein scaffold. A mutant darcin, termed darcin [KtoR] combining two of the three designs 
has been expressed successfully using cell-free methodology. Due to time constraints, it 
was not possible to investigate the effects on the stability and structure of darcin [KtoR] 
compared to darcin. Future work should confirm that the protein cannot be digested using 
Lys-C and that the his-tag can be cleaved from the protein using the TEV protease. If these 
mutations introduced into the protein do not have a detrimental effect on the stability of 
the protein then future work should also establish whether the introduction of loop regions 
into the protein sequence alter the stability of the protein.    
6.4 Conclusion 
The main aim of this work was to establish whether darcin was suitable for development as 
a protein scaffold. The robust nature and highly stable structure of darcin is an ideal feature 
of a protein scaffold. The preliminary developmental work has demonstrated that darcin is 
suitable and amenable for modifications. This work has confirmed that the disulfide bond is 
vital in providing the protein with stability. Although a darcin protein scaffold lacking a 
disulfide bond may express with greater ease and may provide more flexibility for the 
variable loop regions, all future designs should include the cysteine residues for disulfide 
bond formation. In an affinity purification application, darcin exhibits low levels of non-
specific binding of plasma and yeast proteins. Despite this, the challenge with all affinity 
purification mass spectrometry workflows, of non-specific binding of proteins to the solid 
support and the overriding signal of the affinity reagent still exist. The successful expression 
of a darcin variant without lysine residues should address the issue of the signal of the 
protein scaffold by the application of the protease, Lys-C. Due to time restrictions, further 
work characterising darcin [KtoR] was not carried out however assessing the stability of the 
new variant is vital in determining its suitability as a scaffold. 
Future work should investigate whether darcin can tolerate the insertion of peptide 
fragments into the proposed loop regions of the protein. Furthermore, the addition of a 
single cysteine at either the N- or C-terminus of the protein would be useful for covalent 
immobilisation and also allow for labelling, increasing the functionality of the scaffold. With 
further development and implementation of the discussed improvements, the work 




Chapter 7: General Discussion and Conclusions 
7.1 Summary 
The aim of this thesis was to characterise next generation affinity reagents, with a focus on 
Affimer technology. The primary aims, described in each chapter were: 
 Develop an affinity purification workflow for naïve Affimer target identification by 
MS. 
 Characterise Affimers that target human pepsinogen. 
 Identify differentially expressed proteins in sepsis plasma using LC-MS/MS as 
candidates for Affimer generation. 
 Investigate whether darcin was suitable for development as a novel protein 
scaffold. 
In each chapter, the underlying rationale was to develop approaches that address and 
overcome proteome complexity and the associated analytical challenges. Whilst this goal 
was partly achieved, because of the challenging nature of affinity purifications, alternative 
strategies to Affimer-based proteomics were employed for complex proteome analysis.  
 
This thesis presents novel approaches to improve on current affinity purification methods 
and reagents. A novel proof-of-concept strategy to remove the affinity reagent from the 
affinity purification following enzymatic digestion was developed by generating both an 
Affimer and Adhiron that was resistant to Lys-C proteolysis. An affinity purification mass 
spectrometry method to identify Affimer array protein binders was developed as a novel 
strategy to identify differentially expressed proteins. Finally, a proteomic analysis of plasma 
was undertaken that identified an original panel of five proteins implicated in sepsis for 
Affimer development. 
 
The work presented in the first chapter highlights the many approaches available for the 
immobilisation of Affimers for affinity purifications. Furthermore, the challenges of affinity 
purification method development, particularly when using low affinity binding reagents are 
also presented. A method for covalent immobilisation of Affimers through a free cysteine 
was developed and used successfully for the enrichment of both recombinant IgG and 




phage display. However, the affinity purifications using naïve Affimers selected from the 
Affimer arrays were unsuccessful in enriching for interacting proteins.  
Despite failing to identify binding partners of naïve Affimers, knowledge of the common 
non-specific background was obtained. A frequently reported problem of affinity 
purification assays coupled with mass spectrometry is determining a ‘true’ interaction from 
non-specific background215. Although numerous immobilisation chemistries and solid 
supports were investigated, background contamination of non-specific proteins continued 
to be problematic. Higher stringency washes could be applied to reduce background 
contamination however this could compromise low affinity interactions. These findings 
could be useful for future reference by adding to the previously identified non-specific 
contaminant protein repertoire, helping in the identification of ‘true’ affinity purification 
interactions.  
Although for differential expression analysis, the naïve Affimer array overcomes the 
limitations of typical bottom-up LC-MS/MS as the method displays no bias towards the 
most abundant species, the methodology presents additional challenges for subsequent 
target identification. When the Affimers are immobilised on the array, changes in the 
protein conformation may occur that may differ when bound to the His-tag or SulfoLink® 
resin. This may explain the lack of Affimer target identification due to the inability to bind 
protein targets, although it has previously been established that Affimers are able to retain 
their recognition function when immobilised onto a solid surface. It is more likely that 
target identification was not possible due to the weak binding affinities of the naïve 
Affimers, an inherent feature of combinatorial peptides that do not undergo multiple 
rounds of panning to enrich for high affinity binders. 
An approach to overcome the challenges of affinity purifications was considered and 
involves direct interrogation of the array using MALDI-MS, however due to the small 
amount of Affimer immobilised onto the array, the limit of detection of the instrument 
would not have been low enough for detection of the Affimer let alone the protein targets.  
It would be interesting to investigate whether, with increased amounts of Affimer 
immobilised on the array, direct interrogation of the array using MALDI-MS would allow 
protein detection. MALDI does not produce highly charged species during ionisation, and 
therefore limitations in the mass range of the mass analyser mean that high molecular 
proteins would not be detected. Therefore, proteolysis of the Affimer-target complex 




Affimer production can be untargeted with unknown binding partners such as with the 
naïve Affimers or targeted to interact with specific proteins using phage display 
technology111,192. In Chapter 4, Affimers were produced to target the human protein 
pepsinogen to address the limitations and availability of existing affinity reagents. The 
challenges of affinity purifications were again highlighted with pepsinogen interacting with 
the SulfoLink® resin preventing the confirmation of enrichment with the pepsinogen 
Adhirons. 
To overcome this issue, other methods to assess binding could be employed such as 
isothermal titration calorimetry (ITC), surface plasmon resonance (SPR) and size-exclusion 
multi-angled light scattering (SEC-MALS). This would provide information regarding on the 
strength of binding, something that is not feasible with an affinity purification assay, 
allowing for the selection of the highest affinity binder. Gaining an insight into the specific 
sites of binding of an Affimer with its protein targets would be extremely beneficial and 
increase the applications of Affimers. For example, if the Affimers bound to two different 
epitopes on the target proteins surface, the Affimers could be used for simultaneous 
immobilisation and detection completely removing the need for antibodies in a sandwich 
ELISA formats. A limitation to these methods are that extremely pure proteins are needed 
for analysis and therefore recombinant or purified endogenous protein is require to 
explore protein interactions. Whilst this is possible for proteins with known binding targets 
such as those produced by phage display, analysis of the naïve Affimers could not be 
performed using this technique without earlier target identification. It would be interesting 
to investigate native MS of the Adhiron-pepsinogen complex to determine if binding is 
observed in the gas phase.  
The preliminary work in Chapters 4 and 6 developing non-digestible protein scaffolds 
through specific engineering has great potential for future applications in affinity 
purification MS. It is common that the signal from the affinity reagents themselves 
suppress the detection and identification of any protein interactors. A non-digestible 
protein scaffold would eliminate this issue by allowing a pre-digestion step using Lys-C to 
remove captured proteins followed by the selective removal of the undigested protein 
scaffold using either precipitation techniques or a molecular weight cut-off. Unfortunately, 
this method would not eliminate non-specifically bound proteins from analysis. 
Alternatively, if the variable loops in the binding region were unknown, then the protein 




Although the challenges of Affimer affinity purification failed to allow the identification of 
naive Affimer targets, an alternative approach was proposed. LC-MS/MS is a 
complementary approach to Affimer arrays for the differential proteomic analysis of 
complex proteomes. Therefore, a comparative proteomics analysis using LC-MS/MS was 
implemented for the identification of proteins differentially expressed in sepsis for directed 
Affimer generation. Following depletion of highly abundant proteins using antibody spin 
columns, samples were digested and analysed by LC-MS/MS. Label-free relative 
quantification revealed a consistent set of proteins differentially expressed in two separate 
cohorts. Five proteins (CRP, protein S100 A8/A9, cathepsin B, interleukin-1 receptor-like 1 
and neutrophil gelatinase-associated lipocalin) were nominated as targets for phage display 
Affimer production. The work in thesis characterised the phage display Affimers and on-
going work is aiming to identify the Affimers that have the highest affinity for their protein 
targets. 
To further enhance this study, several analyses could be carried out. Firstly, validation of 
the Affimers generated to the five proteins selected from the comparative study could be 
undertaken to confirm binding of the recombinant target proteins in a complex mixture.  
This could be carried out using the SulfoLink® resin affinity purification method optimised 
in this study. As the Affimers were produced using phage display, it is expected that the 
Affimer have high binding affinities and therefore will enrich for target. Furthermore, it 
would be interesting to assess whether enrichment of the five proteins from the plasma 
samples analysed in the comparative study could be achieved using the Adhirons 
generated.  
Although Affimers were originally intended to be used from start to finish in the biomarker 
pipeline from discovery, validation and clinical detection, they still have value despite 
proving to be inadequate for biomarker discovery. The five proteins identified from the 
comparative proteomics analysis of sepsis plasma will be used for an on-going study to 
develop and identify protein biomarkers of sepsis. The Affimers will be validated using 
multiplexed ELISA technology to determine if they have improved sensitivity and specificity 
to the currently available antibodies. 
The final Chapter in this thesis investigated the suitability of darcin as a proteins scaffold. 
To gain a greater insight into the potential of darcin as a protein scaffold, studies examining 




been selected, if time had allowed for the expression and stability studies of a darcin 
scaffold with variable loops, this would have been valuable addition to the chapter. 
7.2 Key conclusions 
 Affinity purification method development using Affimers is challenging, particularly 
when using naïve Affimers and when coupled with MS for target identification.  
 The selective mutation of Affimers to prevent Lys-C proteolysis may be an 
appropriate method to overcome challenges of affinity purifications. 
 Differential proteomic analysis of sepsis plasma using LC-MS/MS identified a panel 
of five protein markers of sepsis; CRP, neutrophil-gelatinase associated protein, 
Protein S100 A8/A9, interleukin-1 receptor-like 1, cathepsin B. 
 Preliminary investigations of darcin as a novel protein scaffold are promising. 
7.3 Future perspectives 
Whilst Affimer technology is promising, the findings in this thesis suggest significant further 
development of Affimer reagents is needed for them to compete with antibody reagents, 
particularly for capture and enrichment applications. The high levels of non-specific 
background, low binding affinities and low specificity would need addressing before the 
reagents have any real future potential. In other areas of research, Affimers have shown 
promise112 however it is unlikely that the scientific community will choose a well 
characterised antibody reagent over a novel Affimer. A shift in attitudes amongst the 
research community will be necessary for the wide-spread and favoured use of antibody 
alternative affinity reagents over antibodies. It should be noted however, that Affimer 
technology was not developed to replace antibodies, instead to complement the current 
affinity reagent toolbox available. The revolutionary and fundamental role of antibodies is 
invaluable in biological research and will undoubtedly remain the key affinity tool in the 
future. The development of Affimers to protein targets with no affinity reagents currently 
available may be the ideal application for Affimers. The beneficial features such as speed of 
production, high stability and extensive potential targets suggest that, with further 
development, Affimers do have a potential future as renewable affinity reagents in the 
biological research. 
The study of complex proteomes requires the use of enrichment and fractionation 
strategies in order to overcome the associated dynamic range and complexity challenges. 




thereby reducing complexity issues. This therefore means that enrichment is highly reliant 
on high quality binding reagents that target the specific protein of interest.  
The concept of developing an anti-proteome, in which affinity reagents are available that 
target a complete proteome, is in principle possible. However, this is only realised if an 
anti-proteome does not take into account the different proteoforms generated from a 
single gene. The development of an anti-proteome for the human proteome has made 
significant progress due to the huge collaborative effort of various consortia and projects 
including as The Human Protein Atlas Project304, ProteomeBinders305, AffinityProteome306, 
and The Renewable Protein Binder Working Group306. The latest release of Antibodypeida, 
a database containing validated antibodies against human proteins, currently contains 
reviews for antibodies that target proteins for 19142 gene products corresponding to 94 % 
of all human genes307,308. However, whilst this is impressive coverage, the dynamic and 
variable expression of proteins means that full proteome coverage is still a long way from 
completion. With the estimated number of highly transient PTMs at 200309, this may be 
very difficult to achieve. It is doubtful that affinity reagents that target every proteoform 
will ever exist. 
A concern of achieving a complete anti-proteome relates to the availability of target 
proteins necessary for binder production and validation. Furthermore, to be confident in 
the quality and specificity of the binder, additional validation is needed for the intended 
application of the binder, increasing the amount of target protein required. Whilst 
sequencing of the human genome has theoretically made it possible to generate 
recombinant proteins to any protein target, certain proteins such as membrane proteins 
are notoriously difficult to express310. Therefore, if recombinant proteins are not available, 
binder generation is not possible. Fortunately, full length proteins are not always needed 
for affinity reagents generation as peptides, partial protein domains and protein epitope 
signature tag (PrEST)311 can be used. In addition, cell-free methods can be employed for 
recombinant protein production that readily expresses typically temperamental proteins312. 
Furthermore, whilst an anti-proteome may be a possibility for the human proteome, it is 
unlikely that an anti-proteome will be developed for other species. The huge cost and time 
implications associated with binder production do not yet warrant the benefits or demand 
for anti-proteomes for other organisms or species. However, if improvements to the speed, 
cost and amount of target protein needed for affinity reagent production were made then, 




Whilst MS methods may be improving in terms of their sensitivity and achieving greater 
proteome coverage, it is important to note that accuracy and confidence in protein 
identifications and quantification may still not be satisfactory. Therefore, the availability of 
affinity reagents for the targeting of every protein within a proteome is still needed despite 
these advancements in MS technology. The scale and challenges of developing a ‘binder’ 
for an entire proteome, although daunting, will ultimately lead to advancements in both 
basic and translation research. Particularly, the development of affinity reagents that target 
the complete human proteome will enhance clinical research and investigations improving 
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